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Abstract  
Introduction:  
 
Uterine fibroids are common benign tumours in women. The effect they have 
can range from pressure symptoms and heavy menstrual bleeding to denying a 
woman a successful pregnancy. Despite the overall benign classification of 
fibroid, it is undeniable that the reduced quality of life these tumours cause may 
exceed the effect that some early stage gynecological cancers have on a 
suffering woman. There has been extensive research into treatments for fibroids 
however this has only resulted in a handful of worthy advances which are not 
proportionate to the impact these “benign” tumours have on a suffering woman. 
The mechanism for how fibroids affect the endometrium and cause heavy 
menstrual bleeding is understudied. Some of this research has pointed towards 
vascular endothelial growth factor and cyclooxygenase as potential mediators 
that change the perceived heaviness –amount and length- of a menstrual period 
in a woman with fibroids.  
Uterine artery embolisation (UAE) has emerged as a lesser invasive option and an 
alternative to surgery. The reported high technical success of the procedure 
independent of BMI and the short hospital stay and quick recovery has made it 
an attractive treatment modality. However, the mechanism of how it works is 
still not understood. Women with large variation in uterine size and fibroid 
number and size are undergoing this procedure without the full knowledge of 
how they will individually respond.  
This thesis aims to explore the mechanism of how UAE works by looking at the 
change in expression of VEGF, COX-2 & Ki67 and also the change in 
microvascular density of the endometrium post UAE. Our aim was to investigate 
how women with different sized fibroid uteri would respond to UAE and if DWI 
MRI had any advantages above standard MRI in predicting the outcome of UAE. 
 
 
 Methods: 
In this thesis we describe the use of endometrial biopsies taken from women 
with fibroids and HMB before and after the UAE procedure. The expression of the 
markers mentioned above was measured using mainly immunohistochemistry. 
Standard MRI imaging & newly emerging DWMRI was used extensively in this 
thesis to evaluate the response to UAE.  
Results:    
The study found an overall trend of increased VEGF expression and increased 
microvascular density in the endometrium post-UAE. Proliferation of the 
endometrium as assessed by Ki67 expression in both the proliferative stage and 
early secretory stages of the endometrium seemed to increase post UAE. 
However there was also an overall trend of decreased expression of COX-2 post 
UAE.  Due to low sample numbers, statistical analysis was not performed in some 
group comparisons. 
We found around 95% of the patients had a reduction in their uterine & dominant 
fibroid size post UAE. Mean fibroid volume reduction ranged between 38-70% 
according to dominant fibroid location while a fibroid uterus reduced in volume 
by an average of 38%. Age of the patient, number of fibroids and the location of 
the fibroid all play a small role in determining the response to UAE. The 
complication rate of UAE is low however re-intervention rate and the need for 
additional treatment appear to rise with time.  
Diffusion weighted MRI (DWMRI) is an understudied imaging technique. In this 
thesis a pilot study demonstrated that it may have a role to play in both 
predicting and assessing the response to UAE. The Apparent Diffusion Coefficient 
(ADC) values were unchanged immediately after and 6 months post UAE, 
indicating that normal uterine tissue –unlike fibroids-is unaffected by the 
ischemia-like conditions following UAE. 
Using the pictorial blood loss assessment chart score (PBAC) the study 
demonstrated a significant reduction in menstrual blood loss. However, the 
score did not relate to the size of the uterus or size and location of the fibroids 
pre-UAE. It also did not significantly correlate to the change in volume of the 
above or the endometrial markers studied.  
Conclusion: 
It appears that the endometrial markers studied play a role in explaining the 
mechanism of how UAE affects the endometrium and how symptom improvement 
is achieved. Standard MRI and DWMRI both play an important role in assessing 
response to UAE. 
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PACS Picture archiving and communication system 
PBAC Pictorial Blood loss Assessment Chart 
PG Prostaglandin 
PR Progesterone receptors  
R&D Research & Development 
RNA Ribonucleic acid 
SPRMs Selective progesterone receptor modulators  
Tx Acid Tranexamic acid 
UAE Uterine artery embolisation 
VEGF Vascular endothelial growth factor 
VEGF-A Vascular endothelial growth factor-A 
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1.1 The human uterus 
The human uterus is an inverted pear shaped fibromuscular organ that is located 
in the pelvis in a non-pregnant state. It occupies both the pelvis and abdomen 
when in a pregnant state and is then known as the gravid uterus. It is composed 
mainly of a thick, smooth muscular outer layer known as the myometrium and a 
thin inner layer lined by endometrial cells known as the endometrium. This in 
turn surrounds the uterine cavity. There is also a further thin outer layer known 
as the serosa which completely covers the uterus posteriorly and only partially 
anteriorly. The cavity of the uterus has one opening inferiorly that leads to the 
uterine cervix. However, superiorly it has two openings, one on either side that 
lead into each fallopian tube known as the ostia. The cells in the myometrium 
can undergo both hypertrophic and hyperplastic changes during a woman’s 
reproductive life. This leads to a change in the size of the uterus that is mostly 
noticeable at puberty and throughout pregnancy (gravid state). The endometrial 
layer is a dynamic layer that undergoes cyclical changes on a near monthly basis. 
These changes involve shedding (menstruation), regeneration and remodelling in 
preparation for conception. These changes occur throughout the monthly 
menstrual cycle and are influenced by the ovarian sex steroid hormones and are 
often referred to as phases. They coincide with changes that occur in the ovaries 
known as the ovarian cycle (fig 1-1).  
The first day of the menstrual cycle is the day of menstrual shedding which 
signals the end of one cycle and the start of another. The menstrual phase 
usually lasts 5 days (+/-2) where both oestradiol and progesterone are at the 
lowest level. Following this phase, there is a rise in the level of oestradiol 
leading to the proliferative phase. In this phase the endometrium grows and 
thickens (proliferates). Ovulation occurs mid-cycle (usually day 14) and 
progesterone is then produced from the corpus luteum and the cycle moves into 
the secretory phase. In this phase the dominant sex steroid is progesterone 
which in association with oestradiol prepares the endometrium and renders it 
suitable for implantation of the fertilised ovum and the start of a pregnancy. In 
the vast majority of times implantation does not occur. This leads to a drop in 
the progesterone level secondary to corpus luteal regression and menstruation 
occurs.   
22 
 
1.2 The endometrium 
1.2.1 Endometrial structure and the menstrual cycle 
The endometrium consists of two layers or zones. The first layer is the 
superficial functioning zone that is shed during each menstruation. The second 
layer is known as the deep basilar zone that is not shed and from which the 
endometrium regenerates. The endometrium undergoes three phases, the 
proliferative phase, the secretory phase and the menstrual phase, which is 
collectively called the menstrual cycle (Fig 1-1).  
1.2.1.1 Proliferative phase 
It is the stage of the menstrual cycle in which the ovarian follicles prime 
themselves for ovulation. It is also known as the pre-ovulatory phase of the 
menstrual cycle. In this phase the rebuilding process of the endometrium starts. 
The functional zone is shed during menses leaving the basilar zone exposed. The 
surface epithelial cells regenerate and the epithelial glands gradually elongate 
and curve. The stroma is dense, containing spindle shaped cells and stromal 
oedema tends to regress through the proliferative phase. These proliferative 
changes are more prominent in the functionalis layer than the basalis layer. The 
biologic rationale for the environmental variation in proliferative indices may lie 
in the different physiologic functions of the functionalis layer versus the basalis 
layer. Where the functionalis layer is the site of blastocyst implantation, the 
basalis layer provides the origin for regeneration of the endometrium. Although 
oestradiol (E2) is the prominent sex hormone in the pre-ovulatory period, many 
authors demonstrated that both intracellular oestrogen receptor (ER) and 
progesterone receptor (PR) concentrations are at their highest during this period 
of the menstrual cycle [1-3]. This is in keeping with the hypothesis that PR 
synthesis is mainly induced by E2 in the target cells via the E2-receptor complex 
mechanism. Therefore, the presence of PR in the proliferative phase is a good 
indicator of endometrial E2 sensitivity.  
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1.2.1.2 Secretory phase 
Once ovulation occurs, the oestrogen-primed endometrium undergoes changes 
under the influence of progesterone. Progesterone inhibits the proliferative 
activity of the endometrium and induces a complex secretory activity that starts 
with the polarization of glycogen at a subnuclear location followed by its 
transport via microfilaments to the apical region of the cell. Secretory granules 
are formed when the Golgi apparatus packages the glycogen and various other 
substances. These granules are then expelled into the glandular lumen. This 
period is known as the secretory phase and the daily changes are specific to 
post-ovulatory endometrium. These changes are used in dating the endometrium 
as the structural changes are apparent on routine examination and can indicate 
whether ovulation has or hasn’t taken place. In an average cycle the secretory 
phase duration is constant whereas the length of the follicular phase is variable.  
This phase of the endometrium is further subdivided into three stages; early, 
mid and late secretory. 
1.2.1.2.1 Early	secretory	stage	
This stage represents 1-4 days post-ovulation (day 15-18 of the cycle). During 
this stage the epithelial gland cells acquire subnuclear glycogen vacuoles and 
the nuclei lose their pseudostratification configuration. The glands exhibit a 
regular tortuosity and are clearly oriented from the base to the surface of the 
endometrium.  
1.2.1.2.2 Mid-Secretory	stage	
This stage represents 5-8 days post-ovulation (day 19-23 of the cycle). During 
this stage there is maximum intra-glandular secretion which coincides with 
blastocyst implantation. There is maximal stromal oedema secondary to 
transudation of plasma from endometrial blood vessels. The spiral arterioles 
become more prominent due to thickening of their walls, coiling and 
endometrial proliferation.  
1.2.1.2.3 Late	secretory	stage	
This stage represents around 9 days post ovulation and lasts until menstruation 
(day 24 of the cycle to the menstrual phase of the next cycle). Peri-vascular pre- 
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decidulalization takes place which consists of cytonuclear enlargement with 
mitotic activity and the formation of a pericellualr laminin-rich basement 
membrane particularly of the epithelial cells [4]. The spiral arterioles are 
surrounded by predecidual stroma and there is stromal regression and loss of 
endometrial height.  
1.2.1.3 Menstrual phase   
In the absence of conception, there is progesterone withdrawal. This is 
secondary to human chorionic gonadotrophin (HCG) not being produced by the 
newly formed placenta and therefore the corpus luteum is unable to sustain 
itself. The gland secretion is exhausted and involution of the epithelial glands 
and stromal collapse ensues leading to shedding of the functionalis layer. The 
menstrual tissue that is expelled vaginally is the result of the enzymatic auto-
digestion and prostaglandin related ischemic necrosis of non-gestational 
oestrogen/progesterone primed endometrium [5]. The remaining basalis layer 
and the deep functionalis layer of the endometrium begin the regeneration 
process at day three of this phase. 
 
Figure 1-1: The menstrual cycle 
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1.2.2 The endometrial blood supply 
The uterus is supplied by two main vessels known as the uterine arteries. These 
usually arise from the anterior division of the internal iliac artery that is a 
branch of the common iliac artery that arises from the bifurcation of the aorta 
at the level of the fourth lumbar vertebrae (L4). The blood supply of the 
endometrium comes from branches of the circumferentially oriented arcuate 
arteries in the myometrium that are derived from the uterine arteries. These 
branches form straight arteries which supply the basalis layer and spiral arteries 
which supply the functionalis layer. The spiral shaped arteries are unique to 
menstruating species [6]. As discussed earlier these blood vessels undergo 
cyclical changes as part of preparing the endometrium for pregnancy and like in 
the heart are ‘end arterioles’. 
Endometrial angiogenesis is likely to occur through a process of elongation and 
expansion of pre-existing blood vessels [7]. Unlike most vascular beds that keep 
a persistent structure throughout life, the endometrial blood vessels grow and 
regress during the menstrual cycle and are therefore thought to be controlled by 
the circulating oestrogen and progesterone [8]. The growth of these vessels must 
then be mediated by the presence of oestrogen receptors (ER) and progesterone 
receptors (PR) in the endothelium of these vessels. However, there are 
conflicting reports on the expression of ER and PR in human endometrial 
endothelium both in vivo and in vitro [9, 10]. It may be that there is an indirect 
effect of these hormones on the blood vessels. One study showed that this may 
be mediated by certain components of the basement membrane such as heparan 
sulfate proteoglycan (HSPG). The disappearance of HSPG from the vascular 
basement membranes may play a role in the vascular remodelling process during 
the menstrual phase [11]. Progesterone withdrawal seems to induce significant 
elevations in fibronectin. There is a correlation between the repair of the 
endometrium and the expression of fibronectin and its receptors after 
menstruation [12].   
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1.3 Steroid hormones and their receptors in the 
endometrium 
Oestrogen and progesterone play a significant role in the cyclical endometrial 
changes that occur throughout the menstrual cycle. The variation in the 
concentration of these ovarian sex steroid hormones control these changes [13]. 
The appropriate response to increasing and decreasing hormone concentration 
requires dedicated receptors. The transcriptional effects of oestradiol and 
progesterone involve classical nuclear receptors (ER and PR). These, together 
with androgen receptors and glucocorticoid receptors belong to the nuclear 
receptors subfamily 3 group shuttling between the cytoplasm and the nucleus. 
PR and ER have also been shown to mediate rapid activation of non-genomic 
signalling pathways independent of their transcriptional activity and alternative 
membrane receptors may be involved in this [14]. 
1.4 Vascular Endothelial growth Factor (VEGF)  
It is an important angiogenic cytokine with a critical role in tumour angiogenesis 
[15]. Under low oxygen conditions the endothelial cells produce vascular 
endothelial growth factor (VEGF) as it has a role in enhancing the mitosis of 
endothelial cells as well as their permeability. It exerts its effect by binding to 
two types of tyrosine kinase receptors on the endothelial cells [16]. The first is 
known as VGEF receptor 1, which is responsible of the organization of 
endothelial cells in vessels and the second being VGEF receptor 2, which induces 
endothelial cell migration and proliferation. Both receptors are upregulated in a 
hypoxic environment (further details in section 3.1) 
 
1.5 Prostaglandins & Cyclooxygenase 
Prostaglandins (PGs) are lipid autocoids derived from arachidonic acid. They 
sustain homeostatic functions and mediate pathogenic mechanisms, including 
the inflammatory response. They modulate biological functions in several 
systems in the body including the cardiovascular, gastrointestinal, genitourinary, 
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endocrine, central nervous system, immune, respiratory and reproductive 
systems. PGs were first observed in 1930 by two gynaecologists Kurzrok and Leib 
while studying the effect of the seminal fluid on the human uterus. It was noted 
then that they reduced blood pressure and caused smooth muscle contraction. 
At that time it was thought that they were produced by the prostate and hence 
the name prostanoids. They were successfully extracted and purified in 1957 and 
were later subdivided alphabetically according to the substituent groups on their 
cyclopentane ring.  
PGs are formed when arachidonic acid (AA), a 20-carbon unsaturated fatty acid, 
is released from the plasma membrane by phospholipases. PG production (figure 
1.3) depends on the activity of PGG/H synthases, colloquially known as 
cyclooxygenases (COXs), bi-functional enzymes that contain both COX and 
peroxidase activity and that exist as distinct isoforms referred to as COX-1 and 
COX-2 [17]. PGH2 is produced by both COX isoforms, and it is the common 
substrate for a series of specific isomerase and synthase enzymes that produce 
PGE2, PGI2, PGD2, PGF2α, and TXA2. COX-1 couples preferentially, but not 
exclusively, with thromboxane synthase, PGF synthase, and the cytosol (c) PGE 
synthase (PGES) isozymes [18].  
The biological action of prostaglandin is mediated through their receptors, which 
are designated by the letter P and a prefix D, E, F, I and T, and have the form 
DP, EP, FP, IP and TP referring to PGD, PGE, PGF, PGI and TXA2 respectively.  
PGE2 exerts its effect through four subtype receptors, EP1, EP2, EP3 and EP4.  
These receptors are G-protein coupled receptors using alternate and sometimes 
opposing intracellular pathways.  These receptors are represented with a 
separate encoded gene, with extra splice variant for EP3,FP and TP which are 
different in their C-terminal [19]. 
In addition to the prostanoids that act principally via plasma membrane-derived 
G-protein-coupled receptors, several COX products can activate nuclear 
receptors of specific classes, and stimulate the common nuclear receptor 
pathway [20]. It was found that these nuclear-acting prostanoid ligands inhibit 
the IkappaB kinase activity and thereby block the NF-kappaB transcription factor 
pathway and raise the possibility that the COX pathway may induce anti-
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angiogenic effects by nuclear-acting prostanoids [21]. Therefore, a number of 
COX-2-selective inhibitors are developed to control the anti-inflammatory and 
anti-neoplastic activities of the COX-2 isoenzyme. Inhibition of the COX 
isoenzyme activity and/or expression may be the basis of future development of 
anti-inflammatory and anti-neoplastic drugs [22].  
Towards the end of the menstrual cycle COX-2 expression is upregulated in 
parallel with the withdrawal of progesterone and shedding of the functionalis 
layer of the endometrium with subsequent synthesis of PGE2 [23, 24]. Excessive 
expression of COX-2 and PGE2 synthesis in the endometrium has been recognised 
in women suffering from heavy menstrual bleeding and their signalling pathways 
are potential therapeutic targets [25]. (Further details in section 3.2) 
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1.6 Endometrial angiogenesis 
Angiogenesis is the process by which new microvessels develop from existing 
blood vessels.  Normal physiological angiogenesis occurs during foetal growth 
and development. It rarely occurs in adults except in wound healing and in the 
female reproductive tract. In the female of reproductive age, angiogenesis 
occurs in the corpus luteum and the endometrium during the menstrual cycle 
[26]. Such a process is of utmost importance in the development and 
differentiation of the human endometrium which is necessary for implantation 
and maintenance of pregnancy [27]. Pathological angiogenesis occurs in 
conditions such as malignancy, chronic inflammatory disorders, diabetic 
retinopathy, endometriosis and in fibroid tumours [28]. 
The demand for vessel growth and regression in human endometrium differs 
spatially and temporally during the sequence of events that occur during the 
menstrual cycle. Spatially angiogenesis occurs in different regions of the 
endometrium according to the stage of the menstrual cycle. When menstruation 
is ongoing angiogenesis occurs in the superficial part of the remaining basalis 
layer. During the rapid endometrial growth of the proliferative phase it occurs 
throughout the functionalis layer under the influence of oestrogen. While during 
the secretory phase the growth of spiral arterioles also occurs in the functionalis 
layer, whereas the capillary plexus which is supplied by the arterioles develops 
just below the luminal epithelial surface. Vasoconstriction of the distal segments 
of the spiral arteries occurs in response to progesterone withdrawal. A few days 
later this is followed by diffuse necrosis, inflammation and vascular thrombosis 
resulting in endometrial shedding and menstruation. 
Studies have demonstrated the importance of smooth muscle cells together with 
endothelial cells in the process of developing new blood vessels and the 
signalling that occurs between them during development [29, 30]. It is thought 
that proliferation of smooth muscle cells is intrinsically central to angiogenesis 
(figure 1-5).  
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Figure 1-2: The mechanism of angiogenesis 
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1.7 The mechanism of normal menstruation 
Menstruation in principle is the event of shedding of the superficial (functionalis) 
layer of the endometrium. A series of sequential events occur before, during and 
after this important event that occurs in a women of reproductive age on a near 
monthly basis. Inflammatory pathways play a role in the female reproductive 
health and regulate the menstrual cycle. Alterations in these pathways 
contribute to the pathologies of the female reproductive system [31]. Sex 
steroids influence endometrial growth, differentiation and function, and are also 
implicated in endometrium pathology [32]. 
Menstruation is a result of the profound tissue remodelling that occurs each 
month in reproductive-aged women. Regular, pulsatile secretion of 
gonadotrophin releasing hormone (GnRH) from the hypothalamus is the primary 
event that drives the mechanism of menstruation. In response to this secretion, 
the pituitary gland releases follicular stimulating hormone (FSH) and luteinizing 
hormone (LH). FSH is the principal regulator of follicular growth and maturation. 
It initiates follicular growth and the secretion of oestrogens.  Ovulation is caused 
by a peak level of LH, but it is dependent on progesterone levels. LH promotes 
the formation of the corpus luteum and stimulates the production of oestrogen, 
progesterone and inhibin which in turn form a negative feedback loop on the 
hypothalamus (figure 1.6). 
Synthesis of progesterone by the corpus luteum precedes the negative feedback 
of progesterone at the hypothalamic level. While at the endometrial level (the 
functionalis layer) the number of sex steroid receptors increases during the 
proliferative phase and decreases during the secretory phase.  
In the absence of pregnancy, the corpus luteum collapses leading to a sharp 
decline in the ovarian steroids hormones. This is turn triggers compound events 
within the functionalis layer of endometrium leading to endometrium break 
down. 
In 1978 JE Markee transplanted a fragment of human endometrium into the 
anterior chamber (iris) of rhesus monkey’s eyes and his direct observations 
provided the initial understanding of the mechanism of menstruation [33]. The 
development of the implanted graft involved progressive episodes including, 
increased coiling of spiral arterioles, vascular stasis, alternation of 
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vasoconstriction and vasodilatation episodes and perivascular bleeding. Marked 
regression of the developed grafts was noted after oestrogen and progesterone 
withdrawal.  
The expression of prostaglandins in many compartments of the endometrium 
varies across the menstrual cycle and tends to increase during menstruation. For 
instance, prostaglandin F2 αlpha (PGF2 α) causes vasoconstriction of blood vessels 
and leads to reduction in the blood flow to the endometrium [34]. PGF2α is 
upregulated during the mid-secretory phase but still has high expression during 
menstruation. On the other hand, prostaglandin E2 (PGE2) is responsible for 
vasodilatation and is mainly increased during menstruation with a lower 
concentration than PGF2α [35].  
Upregulation of prostaglandin is associated with increased expression of locally 
acting mediators such as interleukins, angiogenic factors and protease enzymes. 
These mediators play a role in releasing and activating cytokines which in turn 
allows leukocyte infiltration of the endometrium [36]. 
Due to the above processes, it is fair to describe the mechanism of menstruation 
as an inflammatory process under the control of ovarian sex steroid hormones 
[31]. 
 
Figure 1-3: The Hypothalamic-Pituitary axis 
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1.8 Heavy Menstrual Bleeding 
Heavy menstrual bleeding (HMB), formally known as menorrhagia is defined as 
excessive menstrual blood loss that interferes with a woman’s physical, 
emotional and social quality of life [37]. HMB is considered to be one of the most 
significant causes of ill health in women. In the UK one in 20 women of 
reproductive age consults their general practitioner each year because of heavy 
menstrual bleeding. It accounts for 20% of gynaecology outpatient referrals 
making it is the most common condition that requires referral to a gynaecologist 
[38, 39]. In a Scottish postal survey about self-reported symptoms of heavy 
periods, 30% of women who were asked reported heavy menstrual loss and a 
further 5% reported very heavy menstrual loss. [38]. 
 
In 1966 Hallberg et al measured the haemoglobin level in menstruating women. 
He found that the average volume of menstrual blood loss per cycle was 40 ml.  
When the blood loss was more than 60ml, the incidence of anaemia increased 
[40]. Clinically, around 50% of women complaining of HMB who have a normal 
uterus, have objectively measured blood loss of 80ml or less [41]. Different 
methods have been studied to quantify menstrual blood loss and this will be 
discussed in some depth later in chapter 6. 
 
It is generally accepted that menstruation is associated with an element of pain. 
This is usually described as cramps, backache and pelvic pain. A UK-wide 
national audit concluded that 54% of pre-menopausal women reported pain. This 
was higher in the presence of uterine fibroids and endometriosis. However, 
severe pain seems to be one of the main symptoms that accompanies HMB and is 
generally reported in up to 15% of women[42]. 
 
HMB should be recognised as having a major impact on a woman’s quality of life, 
and interventions should be aimed at improving it and not just focusing on 
reducing menstrual blood loss alone.    
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1.8.1 Mechanisms leading to HMB in the normal uterus 
Idiopathic HMB also called dysfunctional uterine bleeding (DUB) is defined as 
HMB in the absence of microscopic and/or macroscopic uterine pathology or 
pregnancy [43]. The vast majority of women with DUB will have normal 
endometrium and a minority of young women will have a hereditary coagulation 
abnormality such as Von Willebrand [44]. Progesterone inhibits plasminogen 
activators (PA) which is reflected by reciprocal upregulation in the output of the 
PA inhibitor PAI-1 [45]. High levels of circulating PAI-1 are associated with a 
number of thrombotic diseases, however, PAI-1 deficiency can have the opposite 
effect and lead to HMB [46]. 
Twin studies found a hereditary link between menstrual blood loss in 
monozygotic twins (genetically similar) but failed to find such a link in dizygotic 
twins (genetically different). This may suggest a genetic component to HMB [47]. 
The upregulation of COX enzymes expression and prostaglandin receptors 
enhances the production of vasodilatatory factors. This in turn leads to a 
downregulation in the expression of anti-angiogenic factors such as 
thrombospondin, angiostatin and endostatin which are potent vasoconstrictors.  
The increase in these vasodilatatory factors may further enhance menstrual 
bleeding and vascular dysfunction by further upregulating the COX–PG 
biosynthetic pathway via a positive feedback loop, and promote an autocrine–
paracrine regulation of growth factors specific for vascular function such as 
VEGF [48, 49].  
 
The increased expression of prostanoids in the endometrium of women with HMB 
has been targeted by cyclooxygenase enzyme inhibitors (COX-inhibitors) [50]. 
Prevention of PG synthesis is the mechanism of action of non-steroidal anti-
inflammatory drugs (NSAIDs) such as mefenamic acid. Mefenamic acid works by 
reducing PG synthesis and suppressing PGE2 binding to its receptors. This can 
reduce the number of days of bleeding and reduce menstrual blood loss by up to 
35% [51].  
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All the above mechanisms play a role in altering the endometrial 
microenvironment in women suffering from HMB and most treatment 
methodologies have been aimed at correcting these. 
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1.9 Uterine Fibroids 
1.9.1 The history of Uterine Fibroids 
Uterine fibroids are benign tumours that develop predominantly in a woman’s 
uterus.  They also called myomas, leiomyomas, fibromyomas and fibroid 
tumours. However there has been a case of a fibroid developing in a male with a 
rudimentary uterus due to persistent müllerian duct syndrome [52].  The first 
mention of uterine fibroids was in Greek literature. Hippocrates (460-375 B.C) 
referred to them as uterine stones. Fibroids were later referred to as 
“scleromas” during the second century of the Christian period. Medieval texts 
refer to some women expelling eggs from their vagina in parturition which 
probably represented what is known today as fibroid expulsion. These women 
were accused of possessing evil spirits [53]. In 1854 Rudolph Virchow, a German 
pathologist, demonstrated that fibroids were composed from smooth muscle 
cells and later introduced the word myoma [54]. The modern term “fibroid” was 
introduced in 1860 by Karl von Rokitansky and in 1863 by his assistant Julius 
Klob. 
1.9.2 The prevalence of uterine fibroids 
Uterine fibroids are the most common benign tumours affecting women and are 
asymptomatic in 50% of women [55]. They may be single or multiple and their 
size varies from a maximum diameter of a few millimetres to up to 30 cm. They 
are highly prevalent and studies have shown that by the time women reach 50 
years of age, nearly 70% of white women and more than 80% of black women will 
have had at least one fibroid although the majority will be asymptomatic [56]. 
Fibroids are the fifth leading cause of hospitalisations for gynaecologic 
conditions unrelated to pregnancy in women aged 15–44 years and the primary 
indication for hysterectomy among women of all ages in the United States. 
Around 30% of women presenting with heavy menstrual bleeding (HMB) will be 
found to have fibroids [57]. A recent study estimated annual direct costs 
(surgery, hospital admissions, outpatient visits, and medications) in the United 
States is over four billion dollars [58]. There is no similar UK wide cost 
estimation study, however, it is thought that surgical treatment of fibroids costs 
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the NHS around £62.5 million per year based on the 2012-2013 payments by 
results tariff [59].  
 
Fibroids are a mixture of smooth muscle cells and fibroblasts, leading to hard, 
round, whorled tumours in the myometrium. The pathophysiology of fibroids 
remains unknown, although, it is hypothesised that each fibroid is derived from a 
mutation in a single smooth muscle cell [60]. It has been well established that 
oestrogen and progesterone are involved in the proliferation and maintenance of 
uterine fibroids and the majority of medical treatments currently available work 
by inhibiting  sex steroids production or action [61]. It has also been shown that 
fibroids have a familial predisposition and that the frequency of newly diagnosed 
fibroids among first degree female relatives of women with fibroids is 2.2 times 
higher than in a non-familial group [62]. 
 
Case-control analysis has shown that the risk of developing fibroids was reduced 
with increased number of pregnancies and increased duration of oral 
contraceptive use. This suggests that unopposed oestrogen plays a central role in 
fibroid development and stimulation of growth [63]. The risk factors for 
developing fibroids are summarised in table 1-1. 
 
Table 1-1: Factors that affect  the risk of developing uterine fibroids 
 
a-Age: Incidence increases with age during reproductive years [64] 
b-Race: Incidence is higher in Black and Latina women than in white 
women[56] 
c-Heredity: Risk is higher in women with first degree relatives who have 
fibroids [60] 
d-Early menarche (before age of 11) [65] 
e-Pregnancy: Full term pregnancy is related to lower rates of fibroids [66] also 
parous women experience lower rates of fibroids compared to nulliparous [57] 
f-Hormonal contraception: OCP and progestin-only injectable contraceptives 
offers a protective effect against development of fibroids [57, 67] 
g-Hormonal replacement therapy (HRT): while menopause reduces the risk of 
developing fibroids, the use of HRT increases it [67] 
h-Obesity: Weight gain, central distribution of body fat are risk factors for 
fibroids [68] 
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1.9.3 Fibroid symptoms 
The location of a uterine fibroid may impact on symptoms and quality of life but 
has no association with the size. Fibroids can cause menstrual problems, 
infertility or pressure symptoms which are usually associated with large fibroids 
compressing adjacent structures. When these symptoms impact on the quality of 
life of women, they usually require treatment. The symptoms women with 
uterine fibroids present with are summarised in table 1-2. [69] 
 
Table 1-2: Symptoms which may be associated with uterine fibroids 
1-Heavy menstrual bleeding (main symptom) 
2-Sub-fertility/infertility 
3-Dyspareunia 
4-Pressure symptoms: 
a-Pelvic pressure or discomfort  
b-Abdominal distension/distortion 
c-Urinary tract problems such as frequency, urgency, urinary incontinence 
and hydronephrosis 
d-Lumbo-sacral spine: back pain & pelvic pain 
5-Symptoms in pregnancy: miscarriage, pain, bleeding & placental abruption 
[70] 
6-Severe pelvic pain secondary to fibroid torsion or ischemia secondary to 
fibroid degeneration [71] 
 
 
1.9.4 Fibroid location 
Fibroids can present in different locations. (Fig 1-4) 
a-Intramural fibroids that grow within uterine muscle.  
b-Submucosal fibroids that bulge into the uterine cavity.  
c-Subserosal fibroids that project to the outside of the uterus.  
d- Pedunculated that hang from a stalk inside or outside the uterus 
e-Cervical (less common)  
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1.9.5 Fibroids and menstrual disorders 
Heavy Menstrual Bleeding (HMB) is one of the main symptoms that fibroids can 
cause which has a major impact on a woman’s quality of life. 
The location of the fibroid in the uterus may have an impact on the clinical 
manifestations, for example submucosal fibroids seem to be associated with 
higher risk of developing anaemia secondary to HMB [72]. Although Sulaiman et 
al reported menstrual blood loss of more than 80ml in all women who had 
submucosal fibroids. He admitted in his study that menstrual blood loss does not 
correlate to the fibroid location [73]. Another study found that only 25% of 
patients with submucosal fibroids have HMB. Regardless of the location, uterine 
fibroids may have paracrine molecular effects on the adjacent endometrium that 
are extensive enough to cause HMB [74]. 
 
The exact mechanism by which fibroids cause HMB is still unknown and several 
theories have tried to explain this. One theory was that HMB associated with 
fibroids was a result of ovarian hormone imbalance [75]. However, this was 
refuted as no ovarian sex steroid difference has been found between women 
with fibroids and those without [76]. 
 
Increase in the endometrial surface area secondary to the presence of fibroids 
may explain HMB in some instances. Chimbira et al demonstrated that as the 
Figure 1-4: Fibroid locations 
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uterus enlarges the surface area of the uterine cavity increases proportionately 
[77]. This larger surface area may also reduce the efficiency of uterine 
contractibility. Compression of fibroids on the venous plexus of the adjacent 
tissue leads to venous congestion of the myometrium and the endometrium 
which may lead to abnormal menstrual bleeding or HMB [69]. 
 
Fibroid tissue and normal myometrium are different. There is an increase in 
some matrix metalloproteinase, VEGF, transforming growth factor-b (TGF- β) as 
well as plasminogen activators and inhibitors in fibroid tissue. 
TGF- β from fibroids adjacent to the endometrium may affect the endometrial 
stromal cells and lead to reduced production of plasminogen activator inhibitor 
(PAI), antithrombin III and thrombomodulin, which play a role in the local 
endometrial haemostasis [78, 79].  
 
Dysregulation of angiogenic and regulatory growth factors may further 
contribute to heavy menstrual bleeding in women with uterine fibroids.  
One of the causes of abnormal uterine bleeding may be the over-expression of 
growth factors or their receptors compared to that of the adjacent normal 
endometrium [79]. 
 
It has also been demonstrated that VEGF undergoes differential expression in the 
three components of human endometrium at various phases throughout the 
normal menstrual cycle. This suggests that VEGF has a functional role in the 
cyclical changes and remodelling process of the endometrium and any treatment 
for HMB in fibroids should theoretically alter the expression of VEGF [80].  
 
 
1.9.6 Fibroids and fertility 
It is difficult to say whether fibroids cause infertility and whether treating them 
improves it. Each should be answered individually as it also depends on other 
associated conditions that might impact on the chance of conception. The 
widespread use of ultrasonography has resulted in an increase number of women 
who present with sub-fertility being diagnosed with uterine fibroids. However, 
this may only be a coincidental finding rather than the main cause of infertility. 
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The role of fibroids in sub-fertility has been controversial for many years since 
the evidence is not strong and whether they should be removed, is still uncertain 
[81]. Due to the fact that fibroids are common in women of reproductive age, it 
is of no surprise that women presenting with sub-fertility, who are often older, 
have them. Fibroids may exert a negative effect on fertility even if the cavity is 
normal. This may be due to effects on uterine blood flow, impaired embryo 
implantation or abnormal sperm migration [82]. Despite this, many women with 
relatively large fibroids still achieve pregnancy and some experience no 
difficulty in becoming pregnant.  
 
There have been studies that looked at the impact of fibroids on the success of 
in- vitro fertilisation (IVF) [83]. These studies often do not take into account 
that the mean age of women with fibroids who conceive is higher than the 
general pregnant population and the incidence of all complications increases 
with age.  
 
Fibroids have the potential to cause a number of problems in pregnancy, 
including miscarriage. A systematic review of 23 studies concluded that 
spontaneous miscarriage rates were significantly higher in women with fibroids. 
However, no significant differences in preterm delivery rates were observed. 
This review reported improved ongoing pregnancy and live birth rates from 16 
observational studies of myomectomy for intramural fibroids, but not from the 
four observational studies of myomectomy for submucosal fibroids [83]. It has 
also been shown that fibroids in close proximity to the placenta are more likely 
to be associated with bleeding in early pregnancy and spontaneous miscarriage 
[84]. This irregular bleeding seems to be similar to non-pregnant women with 
submucous fibroids [85]. 
 
The appropriate management for women who have fibroids and wish to retain 
their fertility or are actively trying to conceive is under review and further 
information in this area is very much needed. It is clear that subfertility 
resulting from fibroids is not absolute and many patients will conceive without 
intervention. 
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1.9.7 Diagnosing fibroids 
1.9.7.1 Clinically 
Women may present to their GP with one of the symptoms listed in table 1-2. 
The most common presentation is HMB or pressure symptoms. However, fibroids 
may also be an incidental finding when abdominal examination is performed for 
another reason. The impact on quality of life and other factors that may 
determine treatment options should be explored.  
A clinical diagnosis of a fibroid uterus can often be made by an abdominal and 
pelvic examination. Findings of a firm, enlarged, and irregular shaped pelvic 
mass are characteristic of uterine fibroids although it can sometimes be difficult 
to distinguish a fibroids from an ovarian cyst or a malignant pelvic mass on 
clinical examination alone. Very large fibroids can be palpated abdominally as a 
solid mass extending from the uterus.  
If a woman’s symptoms are thought to be due to fibroids, an early referral to 
secondary care is advised as many of the treatment options offered in General 
Practice (GP) are unlikely to be successful in the presence of fibroids.  
 
 
1.9.7.2 Ultrasound: 
Pelvic ultrasound (trans-abdominally and trans-vaginally) is the most common 
initial investigation of a pelvic mass and can often be organised by the GP. It is a 
non-invasive, cheap, rapid and accurate investigation. Following referral to 
secondary care, a hysteroscopy may be carried out to assess the uterine cavity 
and whether any fibroids impinge on it.  In a small study of 71 patients 
comparing trans-vaginal ultrasound versus hysteroscopy in diagnosing uterine 
fibroids, this showed ultrasound to have a sensitivity of 100% and specificity of 
94% to predict the presence of fibroids in the uterus [86]. However its main 
limitation is the inability to distinguish between sub-mucosal fibroids and 
endometrial polyps necessitating a relatively invasive hysteroscopy to reach the 
diagnosis (fig 1-5). Transvaginal ultrasonography and outpatient hysteroscopy 
should be considered complimentary investigations and not alternatives when 
planning operative hysteroscopy [87]. 
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1.9.7.3 Magnetic Resonance Imaging (MRI): 
MRI is increasingly being performed for the pre-intervention evaluation of 
uterine fibroids and the reasons for organising this are listed in table 1-3. The 
higher soft-tissue resolution of MRI compared with sonography allows more 
accurate determination of uterine and adnexal anatomy and might offer 
additional benefits over ultrasound. It should be considered in all patients prior 
to uterine artery embolisation as it assesses vascularity before and after 
treatment by measuring the contrast uptake of individual fibroids (fig 1-6). 
Further studies into myometrial and endometrial perfusion after uterine sparing 
surgery are needed to assess the specific effects on fertility and ovarian function 
this may well be by using dynamic contrast enhanced MRI (DCE-MRI) [26,27]. 
Diffusion weighted imaging (DWI) is a well-established MRI sequence that is used 
in cerebral imaging and its application to other parts of the body is relatively 
new.  It is now being used as a part of the imaging protocols for pelvic 
malignancies and fibroids. In this thesis we will assess if using DWI offered any 
additional information over a standard MRI pelvis when imaging uterine fibroids.  
 
 
 
 
 
Figure 1-5: Fibroid visualised on hysteroscopy (left) and polyp visualised 
on hysteroscopy (right) 
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Table 1-3: Advantages of pelvic MRI over pelvic ultrasound 
1-Better soft tissue resolution 
2-Easier to diagnose adenomyosis  
3-Easier to visualise ovaries 
4-More accurate measurements of fibroids and uterine volume 
5-Assess suitability for uterine artery embolisation   
 
 
 
1.9.7.4 Computerised tomography (CT): 
CT scan is not the routine investigation of choice for the characterization of 
uterine fibroids. They are often found incidentally on CT scans that are 
requested for other various reasons such as those performed as part of a 
chest/abdomen and pelvis screening scan. Fibroids that are degenerating appear 
complex and contain areas of fluid attenuation. Calcification is seen in 
approximately 4% of fibroids and is typically dense and amorphous [88]. 
However, calcification can also be confined to the periphery of the fibroid when 
it is thought to be secondary to thrombosed veins from previous red 
degeneration. On contrast-enhanced scans, fibroids usually show low attenuation 
relative to the myometrium although, occasionally, they may be of the same or 
of higher attenuation. If the fibroid has undergone acute torsion, there may be 
enhancement of the rim of the fibroid due to obstructed peripheral veins but 
there will be no enhancement centrally. Fibroids can occasionally grow to 
massive sizes and present with symptoms secondary to mass effect, such as 
hydronephrosis.  
Figure 1-6: MRI of uterine fibroid showing contrast enhancement pre-UAE (left) and 
no contrast enhancement post-UAE (right) 
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1.9.7.5 Fibroids and malignancy: Leiomyosarcomas (LMS):  
Fibroids are benign tumours while leiomyosarcomas are rare malignancies that 
may be difficult to distinguish clinically from fibroids. They can only be reliably 
diagnosed by histopathology. They can cause a great deal of concern since many 
women with fibroids either have no treatment or conservative options that 
preserve the uterus. Such treatment modalities do not lead to removal of the 
fibroids and therefore no histopathological diagnosis can be made. The incidence 
of leiomyosarcomas is low and it was thought that they represent only 1% of all 
uterine malignancies [89]. 
Leiomyomas (fibroids) do not generally develop into leiomyosarcomas [90]. One 
study reported leiomyosarcomas in 0.5% of hysterectomies for fibroids [91]. 
However a more recent review of 64 prospective studies found this rate to be 
less at 0.12% [92]. They usually present in women aged between 47 and 56 years 
of age but more commonly in post-menopausal women. Their symptoms can 
overlap with fibroids making the diagnosis difficult. Rapidly growing and painful 
fibroids, fibroids growing after menopause or growing despite GnRH use should 
raise suspicion. In a study by Parker et al the total incidence of uterine sarcoma 
among women operated on for having rapidly growing fibroids was 0.27% [93].  
 
Dynamic contrast enhanced MRI using Gadolinium increases the likelihood of 
diagnosing leiomyosarcomas [94] and clinical applications of diffusion weighted 
MRI (discussed in chapter 5) may prove to be an effective and simple way of pre-
operatively differentiating between benign and malignant disease of the uterus 
and hence early diagnosis of leiomyosarcomas [95].   
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1.9.8 Treatment of fibroids: 
A historical perspective: 
Ephraim McDowell in 1809 in Danville, USA performed the first laparotomy to 
treat a uterine fibroid. This was performed on Abraham Lincoln’s 56 year-old 
cousin. Although the initial surgery was performed to relieve abdominal 
distension thought to be secondary to constipation, an ovarian cyst was removed 
which on later analysis was found to be a pedunculated fibroid [96]. The first 
successful myomectomy was performed in 1840 by Jean Zuléma Amussat in 
Paris. Myomectomy as a procedure was later abandoned due to the high 
mortality rate secondary to blood loss. It was later reintroduced in 1922 when 
Victor Bonney invented the myomectomy clamp which significantly reduced 
blood loss. He reported 403 myomectomy cases with low mortality rate [97].  
 
Although hysterectomy is still widely offered as a treatment for uterine fibroids, 
there are different treatment options that should be first explored in order that 
women are able to give informed consent. 
A combination of presenting clinical symptoms, fibroid size and location and the 
patient’s desire to retain fertility all influence the choice of the therapeutic 
modality that can be offered and will be accepted by a woman today [98].  
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1.9.9 Nonsurgical Treatment of uterine fibroids 
These treatments are aimed at symptom relief by reducing HMB and do not cure 
fibroids.  
 
1.9.9.1 Tranexamic acid (Tx acid) 
Tranexamic acid is a synthetic anti-fibrinolytic agent that is well tolerated 
orally. It provides a non-hormonal treatment for patients with excessive 
haemorrhage during the menstrual period [99]. It is used in many clinical 
situations in which the inhibition of fibrinolysis has shown to be of benefit in 
managing excessive bleeding. It is still unclear what the mechanism is for using 
Tx acid in treating HMB secondary to fibroids.  
The anti-fibrinolytic effect can also cause complications such as thrombosis and 
embolism but the majority of studies haven’t reported such adverse effects and 
tend to limit its reported side effects to mild headaches, allergy and discomfort 
[100]. 
A systemic review of the current evidence has shown that oral Tx acid may 
reduce menorrhagia in patients with fibroids. However, the review did not 
stratify fibroids by size or location [101].  
The safety and efficacy of the modified release variant has been proven in 
women with fibroids when compared to placebo [99]. When given intravenously 
it has a role in decreasing peri-operative blood loss at myomectomy [102]. It is 
also being studied for potential use in postpartum haemorrhage [103]. 
 
 
 
1.9.9.2 Mefenamic Acid  
Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that is 
commonly used for dysmenorrhoea. It leads to a modest reduction in HMB in 
women without fibroids although it is less effective than tranexamic acid [104]. 
One small study indicated that Mefenamic acid reduced blood loss in women 
with anovulatory dysfunctional uterine bleeding and fibroids[41].  However, 
there have been no large trials to date to show the benefits of NSAIDs in women 
with fibroids.  
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1.9.9.3 Levonorgestrel-releasing intrauterine system (LNG-IUS) 
Levonorgestrel is a second generation progestin which is used as an active 
ingredient in some hormonal contraceptives. Chemically it is a gonane progestin 
derived from 19-nortestosterone. It is a hormonally active levorotatory 
enantiomer of the racemic mixture norgestrel and hence its name levonorgestrel 
[105].   
The LNG-IUS is marketed under the trade name MIRENA™. It was developed by 
Luukkainen and first released in 1976 by manufacturer Bayer AG and used for 
contraception [106]. It provided a safe and highly effective form of 
contraception for up to 5 years.  Its main role was to mitigate the increased 
menstrual bleeding associated with copper and inert IUDs. 
It has a range of non-contraceptive uses including treatment of heavy menstrual 
bleeding with/without fibroids, endometriosis, endometrial hyperplasia and can 
be used in combination with oestrogen for hormone replacement therapy in non-
hysterectomised women to avoid endometrial hyperplasia.  
Levonorgestrel-releasing intrauterine system consists of a T-shaped polyethylene 
frame with a steroid reservoir around the vertical stem. The reservoir consists of 
a white or nearly white cylinder, made of levonorgestrel, containing a total of 
52 mg levonorgestrel. The reservoir is covered by a semi-opaque silicone 
(polydimethylsiloxane) membrane. The T-body is 32 mm in both the horizontal 
and vertical directions. The polyethylene of the T-body is compounded with 
barium sulfate, which makes it radiopaque. A monofilament brown polyethylene 
removal thread is attached to a loop at the end of the vertical stem of the T-
body.  
 
Following intrauterine insertion of the LNG-IUS, the initial release rate of 
levonorgestrel is 20µgm per day. This provides a stable plasma levonorgestrel 
concentration which, after the first few weeks, stabilizes between 150 to 200 
pg/mL in women of fertile age. It releases levonorgestrel locally into the 
endometrium, causing endometrial atrophy by suppressing endometrium 
proliferation, while minimising systemic doses and side-effects. The thin 
atrophic endometrium is characterised by fragile blood vessels and are sub-
optimal for implantation.  An ultrasound scan to rule out significant uterine 
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cavity distortion is usually carried out prior to insertion. A follow up 6 weeks 
after insertion is carried out to check for expulsion. The overall incidence of 
spontaneous LNG-IUS expulsion is 9.6% over a three year period. This is increased 
to 15.8% in the presence of fibroids [107]. 
 
The LNG-IUS itself does not affect the size of the fibroids and doesn’t lead to 
shrinkage. A prospective, comparative study of the efficacy of LNG-IUS in the 
presence of fibroids demonstrated a marked reduction in mean blood loss (MBL) 
in both women who had idiopathic HMB and those who had HMB related to small 
fibroids less than 50ml in volume. However, there was no significant reduction in 
fibroid volume after a 2 year follow-up period compared to baseline [108]. This 
was echoed by another prospective cohort study comparing HMB and uterine 
volume in women with uterine fibroids using LNG-IUS and a control group using 
LNG-IUS for contraception. This showed that LNG-IUS significantly reduced 
uterine volume in both groups but there was no significant reduction in the 
volume of the fibroids themselves [109].  
 
 
1.9.9.4 Gonadotrophin-releasing hormone (GnRH) agonists 
Gonadotropin-releasing hormone (GnRH), also known as luteinising-hormone 
releasing hormone (LHRH) is a trophic peptide hormone responsible for the 
release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from 
the anterior pituitary gland (fig 1-6). GnRH is synthesised and released from 
GnRH neurons within the pre-optic anterior hypothalamus. It is the target of 
various regulatory mechanisms of the hypothalamic-pituitary-gonadal axis and is 
inhibited by increased oestrogen levels in the body. The pulsatile secretion 
pattern of GnRH affects the synthesis and release of LH and FSH. A high GnRH 
pulse frequency is more effective in releasing LH than FSH [110]. However, low 
pulse frequency supports FSH synthesis and release but is not as effective in 
increasing LH concentration. On the other hand, high GnRH pulse frequency 
inhibits FSH synthesis and release [111] .  
 
GnRH agonists are derived from native GnRH by substitution of a D-amino acid 
for the native L-amino acid at position 6 in the decapeptide. This substitution 
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yields the agonist resistant to degradation and increases its half-life and the 
time of receptor occupancy [112].  
 A constant intravenous infusion of GnRH or administration (subcutaneous/ 
intramuscular/ intranasal) of GnRH agonists causes an initial agonistic action 
known as the flare phenomenon [113]. This is then followed by down-regulation 
of receptor concentrations, which desensitizes the pituitary to continued 
stimulation. The flare phenomenon is caused by the release of the gonadotropins 
which are already produced and stored in the pituitary. It is greatest in the early 
follicular phase when GnRH and oestradiol have combined to create a large 
reserve pool of gonadotropins. Within 3 to 4 weeks, it induces a 
hypogonadotropic-hypogonadal anovulation state, a situation simulating WHO 
Group-1 anovulation [114]. This is referred to as “switching off” the ovaries 
temporarily and can be used for the treatment of uterine leiomyomas [115].   
 
Randomised, controlled trials have demonstrated that the use of GnRH agonists 
for 3 to 4 months prior to fibroid surgery reduces both uterine & fibroid volume. 
However, this effect is only present during therapy and withdrawal of GnRH 
treatment results in fibroids returning to their original size within a short period 
of time [116].  
GnRH agonists are beneficial in correcting pre-operative iron deficiency anaemia 
reducing intra-operative blood loss & operating time and decreasing hospital 
stay. When uterine size is such that a mid-line incision is planned, this can be 
avoided in many women with the use of GnRH agonists [117]. There are, 
however, doubts as to their benefits prior to myomectomy [118]. A Cochrane 
review found that they are not cost-effective [117]. One double-blind placebo 
controlled randomised trial did not support pre-operative GnRH agonist therapy 
for hysteroscopic resection of fibroids as no benefit in such treatment was 
identified [119].  Add-back therapy should be initiated at the same time as the 
treatment with a GnRH agonist if use for more than 6 months is anticipated. This 
reduces the hypo-estrogenic side effects such as vasomotor symptoms and loss of 
bone mineral density and mostly preserves agonist efficacy [120]. 
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1.9.9.5 Selective progesterone receptor modulators (SPRM): 
SPRMs are a relatively new class of synthetic ligands with tissue-selective effects 
of mixed agonist and antagonist activity. The first member of this class was 
mifepristone which has unique antagonist properties.  Its use currently is 
predominantly in termination of pregnancy [121]. The anti-progesterone 
properties of mifepristone have also been utilised for the treatment of fibroids 
and have been shown to be effective in reducing fibroid size and improving the 
quality of life at low doses[122]. Research has shown that progesterone 
augments fibroid proliferation, raising the possibility that selective progesterone 
receptor modulators (SPRM) could inhibit fibroid growth [123]. This research has 
culminated in the emergence of ulipristal acetate (UPA) for the treatment of 
fibroid related symptoms.  
 
Three randomised controlled trials on UPA have now been published using 
varying doses and duration of use HMB [124-126]. Comparison has been made 
with GnRH agonist and also of 2-three month courses with and without a 
progestagen. These showed that it had some preoperative benefit of shrinking 
fibroids sized between 3cm to 10cm and was very successful in relieving HMB. 
UPA induced amenorrhea in women with fibroids and controlled menstrual 
bleeding, however, irregular bleeding occurred in those with sub-mucous fibroids 
[85, 124].  
 
Unlike GnRH agonists, UPA does not induce bone loss and climacteric side effects 
as endogenous oestrogen secretion is maintained [127]. The potential long term 
effects of UPA on the endometrium are under study. An unusual histological 
pattern, “non-physiologic” endometrial change has occurred in the majority of 
women treated with UPA. These changes are thought to be benign as there is no 
increase in proliferation and no increase in hyperplasia [128]. It should only be 
used for treating HMB, if it is thought to be caused by fibroids [125]. Common 
side effects for its use are headaches, nasopharyngitis and abdominal pain. The 
issue of endometrial effects of these compounds remains to be resolved, 
however, other promising applications, including long-term contraception, 
treatment for endometriosis, endometrial cancer, Cushing's disease and 
Alzheimer disease are currently in development [129].  
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There has been a recent publication of a case series of 18 pregnancies following 
UPA treatment of uterine fibroids. The initial results are promising with a 71% 
pregnancy rate and a subsequent two thirds of these resulting in a live baby 
[130]. Further research is needed before recommending UPA to all women with 
fibroids contemplating pregnancy. 
 
1.9.9.6 Other Medical Treatments 
Other medical treatments can be used although frequently, they are less 
effective in the presence of fibroids.  Treatments that inhibit ovulation and/or 
decrease oestrogen levels such as the oral contraceptive pill, norethisterone 
acetate and depot medroxyprogesterone may be valuable. Aromatase inhibitors 
in premenopausal women and have been shown to reduce the size of uterine 
fibroids, improve symptoms and are generally well tolerated [131]. 
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1.9.10 Radiological Treatments 
1.9.10.1 Uterine Artery Embolisation (UAE) 
UAE as a treatment for symptomatic uterine fibroids was first described in 1995 
[132]. Prior to this it was used for massive obstetric haemorrhage. It is indicated 
for symptomatic fibroids and is an alternative to myomectomy since it allows 
conservation of the uterus and also only involves a short hospital stay. UAE is a 
minimally invasive treatment option for uterine fibroids performed by an 
appropriately trained interventional radiologist. A catheter is inserted through 
the femoral artery in the groin under local anaesthetic and directed towards the 
uterine arteries using fluoroscopy (Fig 1-7). The uterine artery is blocked on 
each side using an appropriate embolic agent.  The objective of UAE is to 
completely infarct all the fibroid tissue while preserving the uterus, ovaries and 
surrounding pelvic structures. The most common problem associated with UAE is 
post procedure pain which can usually be controlled by opiates (appendix 4). 
Expulsion of a necrotic fibroid, chronic vaginal discharge and premature ovarian 
failure are less common effects of UAE.  
 
A recently published Cochrane review summarized the results of five RCTs 
comparing UAE versus surgery (hysterectomy/myomectomy). Two of these 
studies included a 5-year follow-up. Satisfaction with treatment was the primary 
outcome measure and the pooled results showed no short-term or long-term 
differences in satisfaction rates between the UAE and the surgery group [133]. 
Major complications were rare and no reported difference was found between 
the two groups. However, there were more minor complications in the UAE 
group [133]. 
 
The evidence is still lacking regarding fertility after UAE. It has been derived 
from small studies since, up until recently, the intention to conceive was 
considered a contraindication to the procedure by some gynaecologists and 
radiologists. Patients were actively excluded from several UAE studies on that 
basis [134]. Pregnancies in women who have had UAE have been carefully 
followed up and some reports have suggested an increase in complications of 
pregnancy.  
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UAE is also associated with degradation of ovarian function which is mainly seen 
in women > 45 years old with little evidence of an impact in women < 40 years 
of age [135]. 
It is not fully understood how uterine artery embolisation works in women with 
HMB. Some women achieve a significant reduction in their fibroid size and 
uterine size but continue to suffer from HMB. Other women have minimal 
reduction in fibroid and uterine size but have good symptom relief.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.9.10.2 Magnetic Resonance-Guided High Intensity Focused Ultrasound                      
(MRgHIFUS) 
MRgHIFUS is a relatively new technique that was first performed in 2002 [136] . 
It is a thermo-ablative technique that uses focused high-energy ultrasound 
(HiFU) to cause coagulative necrosis at a precise focal point within the body. 
The focal point is the point where ultrasound waves converge and the distance 
between the transducer and the focal point can be altered.  The location and 
extent of treatment can be monitored accurately with real-time magnetic 
resonance imaging (MRI) and MRI thermal mapping [137, 138]. MRI provides a 
three-dimensional view of the targeted fibroid tissue allowing precise focusing 
and delivery of the ultrasound energy. Immediate post-procedure MRI of the 
treated area aids in determining success.  
Figure 1-7 Fluoroscopy pre-UAE (left) showing the uterine artery coiling and post-
UAE (right) showing stasis of contrast material and blood flow 
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In the short term MRgHIFUS has proven to be a safe and effective non-invasive 
method of managing symptomatic fibroids [139]. The disadvantage is that the 
treatment time is long and relatively few patients are eligible, since only those 
with fibroids located immediately beneath the anterior abdominal wall and 
without scars in the region of interest are suitable. [140]  
MRgHIFUS can be performed on an outpatient basis and is associated with short 
recovery time. In women with future childbearing plans and a single uterine 
fibroid, it can be an effective treatment alternative. Despite a high rate of 
intervention following treatment, MRgHIFUS benefits from being a non-invasive 
and uterine-sparing treatment modality [141]. Obstetric outcomes following 
MRgHIFUS are encouraging but further research is required especially to compare 
the outcome with more established procedures such as UAE and myomectomy 
[142].  
 
 
1.9.10.3 Other ablation procedures: The Vizabalate and Sonata System 
This system includes a high resolution, ultra-compact sonography probe at the 
tip of a radiofrequency ablation device. It is designed to be introduced into the 
uterine cavity similar to a hysteroscope. It can image and treat submucosal 
fibroids using a SMART (Setting Margins Ablation in Real Time) targeting system. 
This system is used to place the ablation probe in the centre of the fibroid and 
selectively apply heat cause fibroid coagulative necrosis. 
 
This approach of using radiofrequency ablation under laparoscopic/hysteroscopic 
guidance to treat symptomatic fibroids was first introduced in 2002 [143]. This 
has led to the development of the study device Acessa™ which carries out 
laparoscopic ultrasound guided radiofrequency volumetric thermal ablation of 
uterine fibroids (RFVTA). It has the benefit of delivering high frequency 
ultrasound directly to the fibroid. RFVTA of uterine fibroids has resulted in 
sustained relief from fibroid symptoms and low repeat intervention rates [144]. 
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1.9.11 Surgical Treatment 
 
1.9.11.1 Hysterectomy 
Hysterectomy is the established treatment of fibroids for women who no longer 
wish to retain their fertility. The first successful selected hysterectomy 
operation was performed in 1813 by Conrad Langenbeck via the vaginal approach 
[145]. Approximately 55,000 hysterectomies are performed each year in the UK 
and over 600,000 in the USA [146, 147]. Around one third of these 
hysterectomies are performed to treat uterine fibroids[147]. 
 
Although hysterectomy is a major surgical procedure, it results in significant 
resolution of symptoms and has a high satisfaction rate. The cost benefit of this 
procedure was accounted for in the REST trial, an RCT of UAE versus surgical 
treatment for fibroids. Although there was initial cost benefit of UAE over 
surgery at 12 months, this was substantially reduced, because of subsequent 
interventions, with UAE and surgery being cost neutral at 5 years. [148] 
 
Hysterectomy is associated with procedure related morbidity and mortality and 
is often the non-preferred option to treating fibroids. Complications can include 
haemorrhage, infection, injury to bladder and/or urethra, bowel injury, blood 
transfusion, increased risk of future prolapse and anaesthetic risks.  
 
Two patient preference studies showed that women with HMB secondary to 
fibroids and other causes tend to prefer alternative treatments that are only 50% 
successful in order to avoid a hysterectomy. Although many will have a 
hysterectomy at a later date [149]. Minimally invasive surgery rates for 
hysterectomy (both laparoscopic and robotic) have increased over time and 
patient experience has been shown to be better than that for open abdominal 
surgery [150]. Perhaps the future will see an even more significant move towards 
minimally invasive approaches for all gynaecology surgery both for benign and 
malignant causes. 
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1.9.11.2 Myomectomy:  
Myomectomy is a fertility sparing option to surgically remove fibroids and 
preserve the uterus. However, it can be associated with life-threatening 
bleeding, risk of hysterectomy, prolonged postoperative stay, post-operative 
adhesion formation and recurrence [98]. Depending on the size and location of 
the fibroid it can be performed as an open procedure, laparoscopically, 
robotically or vaginally using hysteroscopy. Some of these procedures require 
specific skills that are often only available in specialist units. There is no 
difference in morbidity between patients undergoing abdominal myomectomy 
and those undergoing abdominal hysterectomy. 
The data regarding fertility and pregnancy outcomes after myomectomy is 
incomplete and the effect of myomectomy on future pregnancies is 
understudied.  
 1.9.11.2.1 Abdominal	Myomectomy	(laparotomy)		
 
Is defined as removal of a single or multiple uterine fibroids through an 
abdominal incision and conserving the uterus. Abdominal myomectomy was  first 
reported in 1845 and was performed by Dr Washington Atlee Burpee in 
Pennsylvania [151]. Prior to this hysterectomy was the main treatment for 
women who presented with symptomatic uterine fibroids due to the associated 
bleeding thought to occur with myomectomy [152]. As blood transfusion was 
introduced and its safety vastly improved, more successful myomectomies care 
now being achieved.  
It is perceived that women whom opt for myomectomy are doing so to retain 
fertility & improve chances or conception. A recent observational study has 
suggested that abdominal myomectomy might improve reproductive outcomes in 
patients with fibroids. The reproductive performance was especially good with 
younger patients and those that had previous pregnancies prior to myomectomy. 
It was also associated with lower miscarriage rate after pregnancy compared to 
those prior to surgery [153]. However, there is currently insufficient evidence 
from randomised controlled trials to evaluate the role of myomectomy to 
improve fertility [154].  
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 1.9.11.2.2 Laparoscopic	myomectomy		
 
Laparoscopic myomectomy has long been the only minimally invasive treatment 
option for symptomatic fibroids, prior to the introduction of UAE. It can be used 
to remove subserosal and intramural fibroids depending on the size and position 
of the fibroid and the skill of the surgeon [155] .  
 
The rate of conversion of laparoscopy to laparotomy and all major complications 
have been reported to be very low [156]. Pregnancy outcomes are encouraging 
and major complications such as uterine rupture are reported as rare [157].  
Further studies into the strength of uterine scars following laparoscopic 
myomectomy in comparison with open myomectomy should be conducted [158].  
 
It seems reasonable for surgeons to adhere to techniques developed for 
abdominal myomectomy including limited use of electrosurgery and multi-
layered closure of the myometrium. Nevertheless, individual wound healing 
characteristics may predispose to uterine rupture [159]. Laparoscopic 
myomectomy, when performed by an experienced surgeon, can be considered a 
safe technique, with an extremely low failure rate and good pregnancy 
outcomes. The pregnancy rates for women with fibroids, managed by this 
method are similar to those after laparotomy [160].  
 1.9.11.2.3 Hysteroscopic	Myomectomy	
 
A hysteroscope is a form of gynaecological endoscope that carries optical and 
light channels. It is introduced into the uterine cavity covered by a protective 
sheath through the cervix. The sheath provides an inflow and outflow channel 
for insufflating the uterine cavity with either gas or fluid.  
Submucosal fibroids can often be removed by hysteroscopic myomectomy. This 
can be done under general anaesthetic or local anaesthetic as an outpatient 
procedure under the auspices of office gynaecology. It is however dependant on 
the size of the fibroid. Despite the well-known effect of reduction in bleeding 
after removing a submucosal fibroid, there is little evidence from randomised  
studies to support this [155]. 
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The most common perioperative complications associated with hysteroscopic 
myomectomy are haemorrhage, uterine perforation, cervical laceration and fluid 
overload [155]. Intrauterine adhesions (Asherman’s syndrome) can be a delayed 
complication and has a reported incidence of 10% at second look hysteroscopy. It 
seems to be higher when resecting multiple submucosal fibroids and those that 
have an intramural element [161]. Such adhesions can be treated successfully in 
an outpatient hysteroscopy setting [162]. 
 
Hysteroscopic myomectomy of submucosal fibroids seems to increase the odds of 
clinical pregnancy in women with unexplained subfertility. It also appears to 
increase pregnancy rates and decrease miscarriage rates, however, the evidence 
at present is still inconclusive [163]. 
 1.9.11.2.4 	Robotic	surgery	
 
The Food and Drug Administration (FDA) approved the Da Vinci surgical system in 
2005 for gynaecological surgery. The Stanford Research Institute along with the 
defence department developed the Da Vinci system initially so that surgeons 
sitting remotely from the battlefield could perform tele-surgery on wounded 
soldiers.  It comprises of three components (Fig 1-13): 
1-A surgeon's console 
2-A high-definition three-dimensional (3D) vision system 
3-A patient-side cart with robotic arms 
 
The first component is the surgeon console where the surgeon sits away from the 
patient and uses a stereoscopic viewer with hand manipulators and foot pedals 
that allow control of the robot-assisted instruments within the patient. The 
second component is the vision system, which provides the 3-dimensional image 
through a 12-mm endoscope containing stereoscopic cameras and dual optical 
lenses. The third component is the patient-side cart with telerobotic arms and 
endowrist instruments. One of the arms holds the laparoscope while the other 2 
to 3 arms hold the various laparoscopic surgical instruments. The endowrist 
instruments areunique in that they possess a mechanical wrist that replicates 
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the full range of motion of the surgeon’s hand as controlled from the surgeon 
console. The advantages of this robotic technique are smaller incisions, leading 
to lower morbidity, less postoperative pain and shorter hospital stays which are 
similar to any minimally invasive surgery. However, robotics do seem to have an 
edge in highly complicated procedures when extensive dissection and normal 
anatomy re-establishment is required [164]. 
One of the first series of myomectomy using the Da Vinci robot included 35 
patients and was reported in the literature by Advincula et al. [165]. The 
conversion rate from robotic to laparotomy was comparable to that of 
conventional laparoscopic myomectomy. Robotic surgery has also shown less 
intraoperative blood loss, shorter hospital stay and fewer complications when 
compared to abdominal myomectomy. Operative time however is longer when 
compared with conventional laparoscopies [166].  
 
Pregnancy outcomes following robotic assisted myomectomies have been studied 
and were found to be similar to open surgery [167]. This new promising field is 
undergoing significant research and development at present. 
 
  
Figure 1-8 Robotic surgery layout showing centre console and patient 
A: Console and first surgeon, B: Robot, C: Open surgery tray, D: Second surgeon & E: 
Scrub nurse 
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1.10 Aim and hypothesis  
Uterine artery embolisation (UAE) is a unique procedure used to treat HMB 
associated with fibroids but its mechanism of action is unknown. The usual result 
of this procedure is a necrotic fibroid that is smaller than pre-UAE mass and 
symptom resolution. The blood supply to the fibroid is completely occluded and 
this is evident by lack of contrast enhancement in an affected fibroid despite the 
rest of the uterus appearing to be unaffected. Taking a biopsy from the 
endometrium is usually tolerated well by women. By obtaining such biopsies 
both before and after UAE means that differences in the expression of various 
endometrial markers can be studied. Women undergoing UAE usually have an MRI 
before and after treatment. The high quality imaging of the fibroid uterus with 
MRI allows an objective and reproducible comparison of the different 
components of a fibroid uterus before and after applying treatment this 
treatment method. This thesis is based on the hypothesis that uterine artery 
embolisation alters the expression of certain angiogenic factors such as VEGF 
and down regulates the COX-PG biosynthetic pathway leading to improvement of 
heavy menstrual bleeding. Despite this change, the function of endometrium is 
not affected and no long term damaging to the uterus is visible. 
The two main aims are: 
1-To study the effect of UAE on the endometrium of women with HMB. This was 
done through looking at the changes in the expression of VEGF-A and COX-2 and 
also through assessing the changes in  microvascular density (MVD) and 
endometrial proliferation after UEA.  
2-To look at the morphological changes occurring in the fibroid uterus after UAE 
and whether these changes are governed by the size and location of the 
dominant fibroid. We also looked at other factors that may influence the 
outcome after UAE such as age of the patient at the time of UAE, the size of the 
uterus and whether a single fibroid uterus responds differently to UAE than a 
multi-fibroid uterus. We will explore the success rate by blood loss measurement 
and fibroid shrinkage and the general complications that occur.   
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Chapter 2 
2.  Methods and materials 
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2.1 Subjects 
The study subjects in this thesis were pre-menopausal women who had heavy 
menstrual bleeding secondary to uterine fibroids. These women underwent 
uterine artery embolisation (UAE) as a treatment modality to relieve symptoms 
associated with uterine fibroid.  
Study 1 (Prospective histological study) 
Endometrial biopsy specimens were collected from women that were booked to 
undergo uterine artery embolisation. Each study participant presented with a 
fibroid uterus containing variable numbers, sizes and locations of fibroids (Fig 2-
1).  
All these women presented mainly with the complaint of heavy menstrual 
bleeding (HMB). Uterine fibroids in all participants were diagnosed initially at a 
gynaecology outpatient clinic by pelvic ultrasound after being referred by a 
general practitioner (GP). They were then referred to the tertiary interventional 
radiology clinic at Gartnavel Hospital in Glasgow. The different options of 
treating fibroids were discussed again with each patient & written information 
was provided.  Each patient then underwent a contrast enhanced MRI prior to 
uterine artery embolisation to further evaluate the number, location and size of 
the fibroids. The contrast was used to assess fibroid tissue enhancement thus 
reflecting fibroid viability and suitability for UAE.  
Although 23 patients were initially recruited to participate in this study, four 
patients did not subsequently have a UAE procedure. One of the patients was 
found to have an incidental right ovarian teratoma which required a laparotomy. 
Three patients changed their mind and requested a hysterectomy instead.  
Endometrial sampling was attempted both before and after UAE in 18 of the 
remainder 19 patients as one patient could not tolerate endometrial sampling 
and was therefore excluded from the study. 
Although 36 samples (18 before and 18 after) were obtained, only 26 samples 
from 13 different patients included endometrial tissue that was suitable for 
64 
 
dating and testing. The samples that were not analysed included those with 
chronic endometritis, cervical tissue samples and those that were deemed 
insufficient samples for dating.   
The study protocol had been previously approved by the ethics committee West 
of Scotland REC 5, REC reference number (10/S1001/1) and favorable ethical 
opinion was given on 04/05/2010. A substantial amendment was submitted to 
allow access to the Diffusion weighted MRI images and reports of all the patients 
in this study and to include them in this research. A favorable opinion of the 
amendment was given on 18/03/2015. Participants filled in a questionnaire 
obtaining their demographic and clinical data. All women signed a consent form 
agreeing to participate in the study & to give permission to access their data and 
inform their GP (Appendix 1). They were asked to complete the Pictorial Blood 
loss Assessment Chart (PBAC) for one period prior to UAE and one period 6 
months after UAE. The subjects’ details will be addressed in the results section 
of each chapter. (Appendix 1) 
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Figure 2-1 Flow chart of patients recruited for the endometrial biopsy study 
 
 
 
 
 
 
 
 
Recruited for UAE study     
(23 patients) 
Did not have UAE  
(4 patients) 
Had UAE                    
(19 patients) 
Unable to obtain 
endometrial sample             
(1) 
Obtained endometrial samples         
(18 patients = 36 samples) 
 
Samples dated 
(20) 
Inactive samples 
progesterone effect                         
(6) 
Chronic 
endometritis (2) 
Insufficient or 
cervical 
samples (8) 
Non-usable samples       
(10) 
Samples used                      
(26) 
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Table 2-1: Summary of demographic & endometrial sample details of participants in study 1 
The character 
Pre-UAE group 
(N= 13) 
Age (mean ± STD)* 47.1 ± 3.6 
BMI (mean ± STD)** 32.1 ± 6.4 
Parity (Number of children) 
Nil 
1 
2 
3 
 
N=4 
N=3 
N=5 
N=1 
Length of period pre-UAE: 
5-7 days 
7-10 Days 
>10 days 
 
N=5 
N=5 
N=3 
Number of uterine fibroids in the uterus: 
1 fibroid 
Multi-fibroids 
 
N=2 
N=11 
Location of dominant fibroid: 
Unable to identify 
Submucosal 
Subserosal 
Intramural 
 
N=2 
N=2 
N=1 
N=8 
Stage of endometrial samples obtained: 
Inactive 
menstrual 
Proliferative 
Secretory 
 
N=6 
N=0 
N=10 
N=10 
 
*Age range (37-50) 
**BMI range (22.1 – 40.8) 
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Study 2 (Retrospective MRI study) 
We collected & analysed five years of MRI image data from patients who had 
undergone UAE between 1st of January 2010 and 31st of December 2014 in NHS 
Greater Glasgow and Clyde. It was not possible to retrospectively look at data 
prior to 2010 as the patient’s electronic record system had not been introduced 
to NHS GG&C prior to this.  
The end date for this period (31st December 2014) ensured that data from 18 
months follow up post-UAE would be available for analysis to include in this 
thesis. 
The study population was identified using the Clinical Research Information 
System (CRIS) at Gartnavel Hospital, Glasgow using a search by exam name: 
Embolisation of uterine fibroid, code IUTFDE. Follow up post UAE and re-
admission rates was identified through the Information Services Division (ISD) 
Scotland. Exclusion criteria were applied and this will be discussed further in 
chapter 4. The total number of patients in this group n=133 who had MRI images 
available pre-UAE & 6 months post-UAE. 
 
Caldecott guardian approval was obtained and the local R&D team at the 
Western Infirmary, Glasgow approved the study and individual consent was 
waivered. Using the Research Application System (IRAS) the Proportionate 
Review ethics Sub-Committee reviewed the ethics application and gave a 
favourable opinion (Appendix 3).  
 
Measurements of the uterus and the dominant fibroids were undertaken on the 
MRI images pre & 6 months post-UAE. The volumes were then measured and 
compared. The number of fibroids was counted in each patient and the location 
of the dominant fibroid identified. Further details will be discussed later in this 
chapter (Section 2.5) 
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Table 2-2: Summary of Age distribution and fibroid data for study 2 
 
Character  Group of patients 
N= 133 
Age (Mean  ± STD) 
 
<35 
35-40 
41-45 
46-50 
>50 
44.3 ± 6.1 
 
N=10 
N=20 
N=40 
N=43 
N=21 
Pre-UAE Volume of: 
 
Uterus  (Mean  ± STD) 
 
Dominant fibroid (Mean  ± STD) 
 
 
= 882.28 ± 660.9 cm3 
 
=385 ± 407.2 cm3 
Number of fibroids in the uterus: 
Unable to distinguish 
One 
Two 
Multiple 
 
N=3 
N=40 
N=7 
N=84 
Location of dominant fibroid: 
Unable to identify 
Submucosal 
Subserosal 
Intramural 
Intramural and part submucosal  
 
N=5 
N=9 
N=41 
N=69 
N=9 
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2.2 Histological study  
2.2.1 Collection of biopsy specimens 
2.2.1.1 Uterine biopsy specimen collection 
The Pipelle® endometrium sampler (Williams Medical) was used to obtain 
endometrial biopsies from women who underwent uterine artery embolisation on 
two separate occasions. 
The first endometrial biopsy was taken prior to UAE and a mutually convenient 
appointment was made for the woman to attend the hysteroscopy outpatient 
clinic in Stobhill hospital. However, some women expressed preference to have 
the endometrial sample taken at the time of the UAE procedure and this was 
arranged in ward 56A at Glasgow Royal Infirmary. The second endometrial biopsy 
was taken 6 months after the UAE procedure at the hysteroscopy outpatient 
clinic in Stobhill Hospital. We timed the second biopsy to be taken at the same 
stage of the menstrual cycle as the first sample relying on the patients last 
menstrual period date. 
 
2.2.1.2 Blood samples specimen collection 
Two 5ml blood samples were obtained in a lithium heparin yellow bottle at the 
time of collecting endometrial samples. One sample was processed by 
biochemistry laboratory at Glasgow Royal Infirmary. This was used to obtain 
luteinizing hormone (LH), follicular stimulating hormone (FSH), oestradiol & 
progesterone levels. The second sample was stored for future research.  
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2.2.2 Handling and storage of biopsy specimens 
2.2.2.1 Handling and storage of endometrial biopsies 
The presumed endometrial biopsy that was obtained was divided immediately 
into two parts. The first part was inserted into a histological specimen collection 
pot that contained 4% formaldehyde. This was sent to the central pathology 
department at the Queen Elizabeth University Hospital (formerly the Southern 
General Hospital) in Glasgow were it was processed and embedded in paraffin 
and was reported by a pathologist. The second part was placed directly into RNA 
later solution, Ambion R 0901 RNA Later® (0.5-1 cm of tissue sample in 5-10 ml 
of the solution respectively) and stored in -20Cº freezer (Reproductive and 
Maternal Medicine laboratory, McGregor building, Glasgow Western Infirmary 
Hospital). After two weeks the biopsies were transferred to a cryo-pot by using 
liquid nitrogen and stored in -80 Cº until used. After the transfer of the 
university laboratory from the McGregor building to the New Lister Building, 
liquid nitrogen was not immediately available. Therefore the process of 
transferring the biopsy samples from RNA later to a cryo-pot was changed to 
accommodate this. The cryo-pot was cooled down by leaving in a -80 freezer 
overnight. It was taken out of the -80 freezer and sat on dry ice just prior to 
transferring the biopsy sample from RNA later into it. This ensured that the 
sample would freeze immediately however it is a deviation from the original 
method using liquid nitrogen. Liquid nitrogen became available again later in the 
study.  
On certain occasions it was not possible to split the Pipelle® sample into two 
separate samples as there was minimal tissue. On such occasions the whole 
tissue specimen was sent to the histopathology laboratory and was processed 
into a paraffin block process. RNA was then extracted from the blocks (Section 
3.5.5). 
 
2.2.2.2 Handling and storage of blood samples  
Blood samples were centrifuged at 13000 rpm for 15minutes at 4C°. The serum 
was split into 4 tubes (0.5ml in each tube) and stored in a -80C° freezer. 1 ml 
serum from each sample was sent to the biochemistry department at Glasgow 
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Royal Infirmary where oestradiol, progesterone, luteinizing hormone (LH) and 
follicular stimulating hormone (FSH) assays was carried out using ARCHITECT 
reagent for each assay through the ARCHITECT ί System (Section 3.5).  
 
2.2.3 Blood loss assessment 
We used the Pictorial Blood Loss Assessment Chart (PBAC) to estimate vaginal 
blood loss during a period. This is validated chart and is internationally used  
[168].  
Participants who were awaiting uterine artery embolisation and agreed to join 
the study were sent the PBAC form with instructions on how to use it. They were 
asked to fill the form for one menstrual period prior to the procedure. 
Participants indicated the degree to which the sanitary wear was soiled by 
indicating the number of slightly, moderately and heavily soiled pads and 
tampons that they used. This was then repeated for one other menstrual period, 
6 months after the UAE procedure. Assessment of blood loss using this chart and 
the results of comparing pre & post-UAE results are discussed in chapter 6.  
 
2.2.4 Histological dating  
Histological dating was carried out according to Noyes et. al. criteria to confirm 
the stage of the menstrual cycle by Professor Alistair Williams, University of 
Edinburgh (fig 3-9) [169]. All histological stages were consistent with the 
patients’ last menstrual period (LMP) and the circulating oestradiol and 
progesterone concentrations in venous blood obtained at the time of tissue 
collection. Consistency between these parameters has been approved to be a 
robust method for characterising the stage of the cycle in endometrial samples 
[170]. Some endometrial samples were reported as inactive secondary to an 
exogenous progesterone effect and we will discuss this further in chapter 3. 
Another group of samples were deemed unsuitable for dating. These included 
samples that did not contain endometrial tissue, those that only had scanty 
tissue and those with chronic endometritis. Chronic endometritis samples were 
excluded as there has not been any human study looking at the effect this has on 
the markers we studied. There has however, been one study on gilts 
endometrium that looked at COX-2 expression in acute & chronic endometritis 
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compared to normal endometrium. This suggested COX-2 expression might be 
dependent on the duration of exposure to inflammatory agents [171]. As such 
duration was not known in our study nor is there a known standard range for 
COX-2 expression, we excluded these samples.     
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2.3 Immunohistochemistry (IHC) 
Immunohistochemistry is a powerful investigative tool that can provide 
additional information to the routine morphological assessment of tissues that 
are studied. Immunohistochemical techniques have adapted and been refined 
over time particular when used in fixed tissue. In this study standard IHC 
techniques were used to localise a number of cellular proteins within the 
endometrium of women undergoing UAE. The protocols were optimised for best 
immune-staining and least background staining. 
 
2.3.1 Antibodies 
Antibodies are host proteins found in plasma and extra cellular fluids that serve 
as the first response and comprise one of the principal effectors of the adaptive 
immune system. The body produces antibodies to annul foreign molecules & 
organisms. Since they are soluble, and secreted in large quantities, antibodies 
can be easily obtained & studied. The discovery of the ability of antibodies to 
bind to specific antigens like a lock and key mechanism led to their wide use in 
science disciplines and human healthcare has benefited from their use in 
developing diagnostic tests and therapeutic agents.  
Antibodies are the secreted form of the B-cell receptor. They are also referred 
to as immunoglobulin (Ig) as they contain a common structural domain found in 
many proteins. 
An antibody molecule consists of four polypeptides, two heavy chains and two 
light chains. These polypeptides join to form a Y-shaped molecule.  This 
molecule consists of three equal-sized portions that are connected loosely by a 
tether. 
 
There are five immunoglobulin classes of antibody molecules found in the serum: 
IgG, IgM, IgA, IgE and IgD. The Ig class determines both the type and the 
temporal nature of the immune response. All primary antibodies used in this 
research were of the IgG class. VEGF and COX-2 were polyclonal IgG while CD-34 
was monoclonal.  
Polyclonal antibodies are typically produced by inoculation of a suitable mammal 
with an antigen. The immune system instructs B-lymphocytes to produce IgG 
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immunoglobulins that are specific to that antigen. Larger mammals such as 
mice, rabbits and goats are used as the amount of serum that can be collected is 
greater. The polyclonal IgG is then purified and used. As polyclonal antibodies 
are produced by a variety of cells with each animal species, they can be 
immunochemically different and may react against various epitopes on the 
antigens they target. The epitope is a short amino acid sequence that the 
antibody is able to recognize as a part of the antigen. 
 
 
 
 
Figure 2-2: antibody structure 
 
2.3.2 Paraffin processing of tissue  
All endometrial tissue processing took place in the histopathology laboratory at 
Queen Elizabeth Hospital, Glasgow. This is a standard procedure that is 
performed by technicians in the laboratory.  
The usual fixative for paraffin embedded tissues is 10% neutral buffered formalin 
(NBF). This is equivalent to 4% paraformaldehyde in a buffered solution plus a 
preservative (methanol) which prevents the conversion of formaldehyde to 
formic acid.  Because of the preservative, NBF has a shelf life of months, 
75 
 
whereas 4% PF must be made fresh. Histological specimen pots are usually kept 
in all surgical departments & operating theatres in the NHS including the 
gynaecology department. 
Optimal histology requires adequate fixation, about 48 hrs at room temperature 
for thinly sliced tissues.  Inadequately fixed tissues will become dehydrated 
during tissue processing, resulting in hard and brittle specimens.  Paraffin 
processing is then performed by taking the cassettes through a series of graded 
ethyl alcohol (ETOH) baths to dehydrate the tissues and then into xylene.  Hot 
paraffin is then able to permeate the tissue. Processed tissues can be stored in 
paraffin blocks indefinitely at room temperature.  
Immunostaining fixed specimens can be difficult as formaldehyde fixation may 
prevent recognition of epitopes by the primary antibody.  Frozen sections are 
better. However, this would require repeating the immunostaining protocol after 
each specimen being taken. 
2.3.3 Tissue sectioning and mounting 
Paraffin embedded sample blocks of the study samples were collected from the 
pathology department archive at Glasgow Royal Infirmary and at the new 
pathology department archive at the Queen Elizabeth Hospital after obtaining 
the histopathology laboratory number. Sections were cut using a microtome 
(Leica RM 2135). Blocks to be sectioned were placed face down on an ice block 
for 10min. A fresh microtome blade was used and was replaced every 10 blocks. 
The microtome dial was set at 105µM until the cutting was smooth and then it 
was set at the desired 5µM. The slices were floated on a 37oC water bath and 
then mounted on SuperFrost® glass slides (BDH, Merck House, and Poole). Slides 
were dried completely by vertically draining them at room temperature. The 
slides were then heated overnight in an oven at 45°C to achieve optimum 
section adherence to the glass.  
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2.3.4 Immunohistochemistry  Avidin Biotin Complex (ABC) 
method 
2.3.4.1 Deparaffinising and Rehydration 
Slides must be deparaffinised and rehydrated prior to proceeding with any 
staining protocols. This process will allow antibodies to access the tissues. Poor 
staining of the section can be caused by incomplete removal of paraffin. 
The slides were placed in a rack and were washed twice with Xylene for 3min. 
Then with Xylene1:1 with 100% ethanol for 3min. The slides were then put 
through ethanol baths (95%, 70% & 50%) for 3 minutes each. They were then 
rinsed with tap water and finally rinsed with 0.01 M phosphate buffered saline. 
From this point onwards the slides were kept wet. Drying out would cause non-
specific antibody binding and therefore high background staining. 
  
 
2.3.4.2 Antigen Retrieval  
Most tissue that’s fixed with formalin requires an antigen retrieval step prior to 
immunohistochemistry staining. The reason behind this is that methylene bridges 
form during fixation. These bridges cross-link proteins and can interfere with the 
recognition of epitopes on the antigen by the antibody. 
The two methods of antigen retrieval are Heat-induced epitope retrieval (HIER) 
and proteolytic-induced epitope retrieval (PIER). We used either of these two 
methods to break the methylene bridges and expose the antigenic sites in order 
to allow the antibodies to bind. The temperature, the pH level and the time of 
incubation are all critical factors that must be controlled for optimal antigen 
unmasking without causing damage to the morphology of the section. Sodium 
citrate pH 6.0 or Tris/EDTA pH 8.0 buffers were used for microwaving sections in 
a pressure cooker. 
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2.3.4.3 Staining methods 
An indirect staining method was used for all immunohistochemistry (IHC), were 
an enzyme labelled secondary antibody was directed against the primary 
antibody.  
This allowed for amplification of the primary antibody-antigen complex thereby 
enhancing the target signal. The use of a biotinylated secondary antibody allows 
for subsequent incubation with pre-formed avidin-biotin complexes and can lead 
to further amplification of signal. Once these complexes attach to an enzyme-
substance system, the amplified antibody-antigen complex can be visualised. 
This signal amplification due to the high affinity of avidin to biotin increases the 
sensitivity of staining techniques. This in turn helps to reduce unwanted 
background staining. 
 
2.3.4.4 Controls  
Validation of all IHC protocol was carried out by the inclusion of control tissue 
slides to ensure the primary antibodies worked as expected and specifically on 
their target. The inclusion of positive and negative controls was required. For 
negative controls, the primary antibodies were omitted. However, tissue 
samples which are known to express the protein of interest were used in the 
experiment for positive controls. (Table 2-3). This inclusion is required to ensure 
that the immunostaining achieved is within the expected cellular compartments. 
 
Table 2-3: The used positive control tissues for different antigens in this study 
Antigen Positive control tissue 
VEGF Kidney 
COX2 Colon 
CD34 Colon 
Ki67 Colon 
 
 
78 
 
2.3.4.5 Reducing background immunostaining 
Before using antibodies to detect proteins by immunohistochemistry (IHC), all 
epitopes on the tissue sample should be blocked to prevent the nonspecific 
binding of the antibodies. Otherwise, the antibodies or other detection reagents 
may bind to any epitopes on the sample, independent of specificity. This step is 
essential prior to using antibodies to detect proteins by immunohistochemistry 
(IHC).  
 
The blocking step for IHC is performed after sample preparation is completed 
and immediately prior to incubation with the primary antibody. The general 
protocol is to incubate the fixed, embedded, mounted, cleared and unmasked 
IHC sample with the appropriate blocking buffer for a time period from 30 
minutes to overnight at either ambient temperature or 4ºC based on the 
optimized protocol specific to each antibody and target antigen. Adequate 
washing after the blocking step is critical to remove excess protein which may 
interfere with the detection of the target antigen. 
 
Normal serum was the common blocking reagent as it carries antibodies that 
bind to reactive sites and thus prevents the nonspecific binding of the secondary 
antibodies used in the assay. It is vital to use serum from the species that the 
secondary antibody was generated in rather than that of the primary antibody.  
Serum from the primary antibody species would bind to reactive sites, but the 
serum from the secondary antibody would recognize those non-specifically-
bound antibodies along with the antibodies bound to the target antigen. The 
prevention of peroxidase activity and reduction of background staining is 
achieved by submerging the section in hydrogen peroxide (H2O2).  
 
Standard IHC techniques were performed to localise a number of cellular 
proteins within the human tissue. All protocols were optimised to determine the 
best conditions for maximal immunostaining with minimal background staining.  
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2.3.5 General Immunohistochemistry Protocol 
Tissue section slides of 5µ thickness were placed in a rack and heated in an oven 
at 55°C for 35 minutes. Slides were then dewaxed by washing in xylene (2 x 
10min) baths. They were then rehydrated by washing through graded alcohol 
concentration baths. This was by using 100% ethanol (2 x 5 min), 95% ethanol (2 
x 5 min), 90% ethanol (2 x 5 min) and 70% ethanol (2 x 5 min). They were then 
washed in 0.01M phosphate buffered saline (PBS) pH 7.6 (5min x 1). Endogenous 
peroxidase activity was blocked by exposing the slides to 1.7% H2O2 in Methanol 
(300 ml Methanol + 5 ml H2O2) for 30 minute. The sections were then washed 
with PBS (2×10min).  
 
Antigen retrieval was then performed by placing the buffer solutions in a 
pressure cooker (Lakeland Plastics Ltd.Cumbria, UK) for 15 min at full power to 
come to the boil. The slides were immersed in the buffer solutions and 
microwaved for 8min on full power. This takes into account that after 3 min the 
cooker should be at the required pressure and the slides are then under pressure 
for 5min. The sections were left to cool in the buffer solution for 20 minute. 
Sections were then washed in distilled water (1 x 5min) then again in PBS (1 x 
5min).  
 
The slides were then loaded into racks and placed in the auto-stainer (Leica XL) 
and covered with TBStw (Tris buffered saline/tween 20) buffer pH 7.6. A specific 
programme was setup on the machine for each antibody and was then chosen 
(section 3.5.4). Positive controls were used in every protocol to determine the 
best condition for maximal immunostaining with minimal background staining.  
 
A counter staining protocol was then followed once the staining cycle was over. 
The slides were removed from the racks and counterstaining in Haematoxylin for 
3 minutes and washed under running tap water for 1 minute. Acid alcohol was 
added for 5 seconds and then washed in tap water. This was followed by washing 
in Scott’s tap water for 1 minute followed by a further wash in tap water. The 
slides were dehydrated for 1 minute in 95% Ethanol and then 1 minute in 100% 
ethanol then Xylene (3 x 5 min). Then mounted in DPX.  
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Sections were scanned and uploaded to Digital Slidebox by Roderick Ferrier, 
Laboratory manager & Clare Orange, TMA and Image Analysis Unit Manager at 
Glasgow University pathology department, Queen Elizabeth Hospital. Slide path 
software was used to access the slides and partly used for scoring.  
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Table 2-4 Summary of IHC protocols 
Antigen Primary antibody Secondary antibody Antigen 
retrieval 
Negative 
control 
Species Conc. Incubation Species Conc. Incubation 
VEGF-A Goat 1:200 30min at  
4oC 
Horse-
biotinylated 
1:200 30min RT 0.01M Sodium 
Citrate 
Omit 
Primary 
antibody 
COX-2 Goat 1:500 30min at  
4oC 
Rabbit- 
biotinylated 
1:200 30min RT 0.01M Sodium 
Citrate 
Omit 
Primary 
antibody 
CD34 Mouse 1:150 60 min at 
25oC 
Rabbit-
biotinylated 
1:200 30min RT 0.01M Sodium 
Citrate 
Omit 
Primary 
antibody 
Ki67 Rabbit 1:200 60 min at 
25oC 
Goat- 
biotinylated 
1:200 30min RT 0.01M Sodium 
Citrate 
Omit 
Primary 
antibody 
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2.3.6 Scoring and analysis of immune-reactivity 
Semi-quantitative scoring systems are used to convert subjective perception of 
IHC-marker expression by the observer into quantitative data, which is then used 
for statistical analysis and drawing up conclusions. Without such a method, data 
would be provided with subjective perception and expressed as strong, weak, 
absent [172].  To reduce subjectivity it is recommended to have at least more 
than one observer when interpreting a clinical study [173]. 
The endometrial stromal tissue was scored. The immunostaining intensity of 
epitopes in VEGF and COX-2 antibodies stained sections was assessed in the 
semi-quantitative manner on the 4-point scale: 0= no immunostaining, 1= mild 
immunostaining, 2= moderate immunostaining, 3= intense immunostaining. The 
H-Score was derived by using the following equation: 
% of mild staining x 1 + % of moderate stating x 2 + % of intense staining x 3 
  
All tissue sections were scored by myself and one independent observer who was 
blinded to the patients’ data. Coefficient correlation was accepted at ≥ 0.7. 
The computerised image analysis system (Version 4.0, Digital Image Hub, Leica 
biosystems) was used to assess Ki67 expression & calculate microvascular density 
(MVD) when CD34 antibodies were used. The stained cells measuring algorithm 
was optimised and analysis was performed at 20X. This will be discussed in detail 
in section 3.5.6. 
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2.4 RNA Extraction  
Due to time constraints, RNA extraction was performed by fellow researcher Dr 
Salha Abukhnjr . The extraction method was only observed, however, the 
analysis was performed by the author. 
RNA isolation process was performed in a biosafety cold hood. All work surfaces 
and equipment needed such as pipettes, forceps and homogenizer were cleaned 
using either 75% Ethanol or Zap RNase  
 
2.4.1.1 Isolation of RNA from frozen samples 
Tissue samples were kept frozen on dry ice while weight measurement was 
undertaken. The cold cryo- pot was placed onto the balance and the balance 
was zeroed. The tissue sample was quickly added to the pot and weighed. 
Weight of samples taken was between 50 and 100mg. Large sample pieces were 
ground using a cold mortar, spatula and scrape with occasional addition of liquid 
nitrogen to keep cold. Samples were transferred to a glass tube including Trizol 
solution (1ml of Trizol was added to 50-100mg of tissue sample). Each sample 
was then homogenized using a hand holding homogenizer and separated into 1ml 
aliquots in autoclaved 1.5 Eppendorf tubes.  
The tubes were then incubated in room temperature for 5 minutes to permit 
complete dissociation of nucleoprotein complexes. In order to keep a high RNA 
yield, 0.2ml of chloroform was then added to each 1ml Trizol and the samples 
were shaken vigorously. Tubes were incubated for 3 minutes at room 
temperature before they were centrifuged at 13,000 rpm for 15 minutes at 4 C°.  
The upper aqueous phase transferred to fresh autoclaved tubes and 0.5ml of 
Isopropyl alcohol was added to each 1ml Trizol used in the initial 
homogenization to precipitate RNA from the aqueous phase. A second 
centrifugation was performed at 13,000 rpm for 10 minutes at 4 C°. The tubes 
were then incubated for 10 minutes at room temperature. The isopropyl alcohol 
was decanted and a small white pellet was left in the bottom of the tube. 1ml of 
75% ethanol was added to each tube then vortexed. At this stage some of sample 
was stored in - 80C°and the rest of the protocol continued later. The third 
centrifugation was done at 10,000 for 5 minutes at 4C°. Ethanol was poured off 
and tubes tapped carefully in order not to dislodge the pellet and left to dry for 
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10 minutes at room temperature. Appropriate amounts of DEPC water were 
added to each tube according to the pellet size (The range was between 40µl for 
a large pellet and 15 µl for a small one). Tubes were then vortexed, centrifuged 
quickly and incubated twice for 5 minutes at 65C°on a heating block. The tubes 
were kept on ice at all time during nanodrop measurement and then stored at  
-80C°. 
 
 
2.4.1.1 Isolation of RNA from formalin –fixed paraffin- embedded samples  
Extraction of RNA from formalin-fixed paraffin-embedded tissue (FFPE) was 
required for some samples where there was no fresh stored tissue. Many 
protocols have been described to extract RNA from FFPE samples. The first 
successful RNA extraction from FFPE samples was in 1988 [174]. In most of these 
protocols the RNA is extracted by spin column purification according to similar 
basic principles: deparaffinization, followed by cell disruption with heated 
proteinase K. After proteinase K incubation, RNA is isolated by alcohol 
precipitation [175]. 
The Ambien kit 1975 was used (recover all total nucleic acid isolation kit, Life 
technologies, Paisley, UK) and the accompanied protocol was followed. A 
histological section of 10-µm thickness was cut from each block using a 
conventional microtome. A separate blade was used for each block to prevent 
contamination. Each section was picked up by a cleaned forceps and placed into 
an Eppendorf tube. The section was then deparaffinazed by adding 1 ml of 
xylene to the tube, mixed then centrifuged at 10,000 rpm for 5 minutes at 4C. 
This was then followed by repeated addition of 1 ml absolute alcohol to the 
pellet, vortexed then centrifuged at full speed for 5 minutes. Alcohol was 
aspirated and discarded without disturbing the pellet. The pellet was allowed to 
air dry at room temperature for 10 min before the addition of lysis buffer. 400µl 
of digestion buffer and 4µl of protease were added to the samples (from the 
kit).  
The tubes were mixed gently, then placed into the rotatory oven at 50C°and 
incubated with rotation for 3 hours. Proteinase K incubation at high temperature 
is capable of efficiently degrading proteins that were covalently cross-linked 
with each other and RNA, thereby allowing more efficient RNA extraction [176]. 
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After proteinase K incubation, RNA was isolated by quantification and 
qualification of RNA by adding 480µl additive solution from the Ambion kit. At 
this stage, a filter cartridge was placed into one of the collection tubes supplied 
in the kit.  
The mixed solution was pipetted into the filter cartridge and centrifuged at 
10,000 rpm for 60 seconds to pass the mixture through the filter and the flow 
through solution discarded. The filter cartridge was then washed by 700µl and 
500µl of wash 1 and wash 2/3 solution respectively. DNase mix was added to the 
centre of the filter, where the mix including DNase buffer 6µl, DNase 4µl and 
nuclease free water 50µl. A master mix was made when more than one sample 
was being processed.  
The washing process was repeated after 30 minutes incubation at room 
temperature once with 500µl of wash 1 and washed twice with 500µl wash 2/3.  
The filter cartridge was transferred to a fresh collection tube and 15µl of 
nuclease free water, heated to 95C°, was added to the centre of the filter. The 
tube was then incubated for 60 seconds at room temperature then centrifuged 
for 1 minute at 13,000 to pass the mixture through. The collected sample 
volume was checked by the Nanodrop and stored at -80C°. 
 
   
2.4.2 RNA quantification and qualification 
The quantity of total RNA extracted was measured using an automated 
spectrophotometer (RNA 6000 Nanodrop). The concentration of total RNA in an 
aliquot of 1µl of sample was determined in µg/µl and the ratio of optical density 
at a wavelength of 260nm to a wavelength of 280nm (260:280) was additionally 
calculated. The sample was considered not to have sufficient purity for use in 
further work when it had a 260:280 ratio of less than 1.6. Quality and integrity 
of the extracted RNA was examined by Agilent 2100 Bioanalyser system. This was 
as a paid service performed by the Biochemistry Department, University of 
Glasgow (Glasgow Biomedical Research Building).  Only RNA that displayed intact 
18S and 28S peaks was reverse transcribed (RT) to cDNA for real-time PCR 
analysis. RNA integrity number (RIN) for the tested samples with clear 18S, 28S 
peaks was between 3 to 9.  
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2.4.3 Selection of endogenous control gene 
This was based on previous work by Dr Salha Abukhnjr were B-actin was found to 
have the narrowest standard deviation compared to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and 18S.  
The primer probes used for gene expression and quantification of human ACTB (B 
actin) and vascular endothelial growth factor-A (VEGF-A) were purchased as 
predesigned, inventoried Spans exons Taqman Gene Expression Assays from Life 
Technologies (table2-5). Quantification was implemeneted on an Applied 
Biosystems 7900 using a 96 well plate. The thermal cycler conditions were 50oC 
for 2 minutes, 95oC for 10 minutes followed by 40 cycles of 95oC for 15 seconds 
and 60oC for 1 minute. 
Table 2-5: Target assay mixed and endogenous control probe in QPCR 
Gene Symbol Gene Name Assay ID Supplier 
B actin Human ACTB (B actin) 
endogenous control 
4310881E Life 
technologies 
VEGF-A Vascular endothelial 
growth factor A (VEGF-
A) 
Hs00900055>m
1 
Life 
technologies 
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2.5  Magnetic Resonance Imaging (MRI) study  
2.5.1 Measuring the dominant fibroid: 
Sagittal T2 4MM and Coronal T2 4MM were used to measure the dominant fibroid. 
The anterior-posterior (A-P) diameter and the longitudinal diameter of the 
fibroid were measured in centimetres on the sagittal T2 4MM images. The 
transverse diameter of the fibroid was measured on the coronal T2 4MM images. 
The MRI slice where the fibroid was of maximum size was used. Careful attention 
was taken to the placement of the measurement callipers when measuring the 
fibroid and inclusion of non-fibroid uterine tissue was avoided (Fig 2-3). In 
certain cases where the margin/plain between the fibroid tissue and the uterine 
tissue was not easily identified, contrast enhanced images (sagittal & coronal 
LAVA C+) was used to accurately assess the margin as these MRI sequences 
produce a marked contrast difference between fibroid and uterine tissue (fig 2-
4). 
 
 
Figure 2-3: T2 weighted MRI pelvis. Image A (left) shows a transverse diameter of a fibroid 
measured on a coronal section MRI slice. Image B Right) shows A-P & longitudinal 
diameters measures on a transverse section MRI slice.  
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Figure 2-4 Contrast enhanced MRI pelvis showing marked plane between fibroid tissue and 
the myometrium post-UAE 
 
2.5.2 Measuring the fibroid uterus: 
A similar approach using sagittal T2 4MM and coronal T2 4MM was used to 
measure the fibroid uterus in centimetres.  The A-P diameter and the 
longitudinal diameter of the uterus was measured on the sagittal T2 4MM 
images. The transverse diameter of the uterus was measured on the coronal T2 
4MM images. The slice where the uterus was of maximum size was used and this 
measurement incorporated the fibroids. In cases of a pedunculated fibroid that 
had a stalk then the uterus was measured without incorporating the fibroid 
measurements.   
 
 
2.5.3 Calculating the volume of the fibroid and uterus 
The volume of each fibroid was calculated in cm3 using the standard prolate 
ellipse formula AP x CC x TR x 0.523 [177]. A similar method was used to 
measure the uterine volume. We also sub grouped the above according to the 
volume and looked at the response following UAE. (section 4.10.2) 
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2.5.4 Assessing the endometrium: 
In some analysis in chapter 5 the endometrial thickness was measured in 
millimetres in a mid-sagittal slice using the sagittal T2 4MM sequence. The 
normal endometrium is homogeneously hyper-intense on T2 weighted imaging, 
regardless of the phase of the menstrual cycle and well outlined by the low 
signal myometrial junctional zone. 
The measurement was performed by placing the callipers from the basal 
endometrial surface across the endometrial canal (cavity) to the opposite basal 
surface. Care was taken not to include the myometrium in the measurement by 
zooming the relevant section of the MRI image up to x3 zoom.  Although the 
timing of the period was not recorded at the time of MRI, it was thought that 
significant changes to the endometrial thickness would still be recognizable.  
 
 
Figure 2-5 T2 weighted MRI of the uterus with callipers used to measure the endometrial 
thickness. Coronal section (left) and sagittal section (right). 
 
 
2.5.5 Diffusion weighted MRI 
We will discuss in detail later in chapter 5 the concept of diffusion weighed MRI 
and how to assess damage to cell membrane through measuring the ADC values 
(Apparent Diffusion Coefficient). Initially, our aim was to measure this for all the 
patients in the study. However, we soon realised that there is a protocol 
variation between the different hospital sites that provide MRI facilities within 
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NHS Greater Glasgow and Clyde. The make of the MRI machines were also 
different. Therefore we only measured the ADC value of 20 patients in a 
retrospective manner. These patients were involved in a study that compared 
different embolic agents. The advantage of this is that all patients received 
DWMRI pre-UAE; 24hour post UAE & 6 months post UAE. They were all performed 
in the same hospital, the same MRI machine and a standardised MRI protocol. 
Only under these circumstances would the results of ADC calculations and 
analysis be valid. (section 5.7)   
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2.5.6 Pictorial blood assessment chart (PBAC) 
The participants in the histological studies were given a PBAC diary to fill in 
prospectively for one period prior to the UAE procedure (fig 2-6). The scoring 
method used to evaluate the PBAC score of the diary was not revealed to the 
patients. A further PBAC diary was sent to the patients to fill in by post 6 months 
from the day of UAE fig (2-7). 
The PBAC diary consists of a series of diagrams representing lightly, moderately 
and heavily soiled tampons or towels. The participant would mark the 
appropriate box at the time that each sanitary product was discarded. In 
addition, passage of clots (size equated to that of 1p and 5p coinage) and 
episodes of flooding were recorded.  The diaries where collected and scored as 
follows: 
 
Towels: A lightly stained towel will score 1 point, a moderately stained towel 
will score 5 points and a towel which is fully saturated with blood will score 20 
points. 
Tampons: A lightly stained tampon will score 1 point, a moderately stained 
tampon will score 5 points and a tampon which is fully saturated with blood will 
score 10 points. 
Clots and Flooding: Clots were divided into 1p size which score 1 point and 50p 
size which would score 5 points. Flooding was scored as 5 points.  
Each individual PBAC chart was scored and a score of 100 or greater indicated 
HMB. The capacity to absorb blood varies widely between mini and a super plus 
tampons and the same goes for different towels (with and without wings). 
Therefore the accuracy of this method may be limited due to the wide variety of 
sanitary products in the retail market. Despite our attempt to address this issue 
by including a space on the PBAC diary for the brand and variant of the sanitary 
products used, not all the women in this study filled this section.  
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Figure 2-6: PBAC Chart 
Figure 2-7: Example of a completed PBAC Chart 
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2.6 Statistics 
Descriptive statistics were used when it was appropriate. TaquMan data were 
collected on Microsoft excel sheet for RNA analysis. Mann-Whitney test was used 
to compare between groups for non-parametric data and results expressed in 
median values with a 95% confidence interval. Paired t-testing was used to 
compare parametric data and the results expressed in mean +/- standard 
deviation. One way ANOVA test used when appropriate and Pearson’s & 
Spearman Rho correlation coefficients were used for association between 
variables after testing for normality. 
 
Results were statistically significant with p value ≤ 0.05. Details of when each 
test was used are addressed in each relevant chapter under the statistics/results 
section. Minitab 17 statistical software was used for data analysis and creating 
graphs that were then edited using Microsoft word 2010 software. Microsoft 
excel 2010 was used to draw graphs. 
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3. Chapter 3: Laboratory  
The expression of VEGF-A, COX 2 & Ki67 and the microvascular density 
in the endometrium of women with fibroids undergoing uterine artery 
embolisation 
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3.1 Vascular Endothelial Growth Factor 
3.1.1 Introduction: 
Throughout each menstrual cycle, the endometrium undergoes remarkable 
changes from regeneration and growth to apoptosis and shedding.  These cyclic 
endometrial modifications are controlled by the variations of sex steroids 
concentrations and the discontinuation of ovarian steroid support will trigger a 
dynamic array of events characteristic of menstruation. New vascular support 
develops via angiogenesis, vascular remodelling in the endometrium during each 
menstrual cycle. This in turn supports the regeneration and growth of 
endometrial cells. [34]  
This vascular remodelling is regulated by several angiogenic factors in the human 
endometrium [178]. One of these factors is vascular endothelial growth factor 
(VEGF). It stimulates endothelial cell proliferation, permeability, migration and 
assembly into capillary tissue. The role of VEGF in early developmental 
angiogenesis is emphasized by the finding that the loss of a single VEGF allele 
will result in defective vascularization and early embryonic demise. [179] 
The proliferation of the endometrium is a result of neovascularisation and this 
has been shown to be directly related to increases in VEGF [180]. Blockade of 
VEGF using a potent VEGF blocker completely inhibits neovascularisation during 
endometrial regeneration and has no marked effect on pre-existing or newly 
formed vessels. This suggests that VEGF is essential for neoangiogenesis but not 
the survival of mature vessels in the endometrial vascular bed [181]. 
 
3.1.2 VEGF isoforms and receptors 
VEGF is a secreted heparin-binding polypeptide mitogen with a target cell 
specificity restricted to vascular endothelial cells. In vivo it induces 
microvascular permeability and plays a central role in angiogenesis and 
vasculogenesis. Through alternative mRNA splicing, a single gene gives rise to 
five isoforms of VEGF. These are identified according to their amino acid residue 
length (121/120, 145, 165/164, 189/188, 206) Fig 3-1. The two shorter ones are 
efficiently secreted while the longer ones are mostly cell-associated which 
suggests multiple physiological roles for this family of polypeptides. [182] [183] 
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VEGF 165 is the predominant isoform while VEGF145 and VEGF189 are the less 
frequently reported splice variants [16, 179]. Two VEGF receptor tyrosine 
kinases (VEGFRs) have been identified, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-
1). VEGFR-2 seems to mediate almost all observed endothelial cell responses to 
VEGF, whereas roles for VEGFR-1 are more elusive. VEGFR-1 might act 
predominantly as a ligand-binding molecule, sequestering VEGF from VEGFR-2 
signalling. Several isoform-specific VEGF receptors exist that modulate VEGF 
activity. Neuropilin-1 acts as a co-receptor for VEGF165, enhancing its binding to 
VEGFR-2 and its bioactivity. Heparan sulphate proteoglycans (HSPGs), as well as 
binding certain VEGF isoforms, interact with both VEGFR-1 and VEGFR-2. HSPGs 
have a wide variety of functions, such as the ability to partially restore lost 
function to damaged VEGF165 and thereby prolonging its biological activity. 
[182] 
 
Figure 3-1: Splice variants of human VEGF.  
 
 
3.1.3 VEGF in the endometrium 
Following shedding at menstruation, the human endometrial functional layer 
regrows from the basal layer during the proliferative phase of the menstrual 
cycle, increasing several-fold in thickness over the space of a few days. Such 
remarkable growth is accompanied by expansion of the vascular tree involving 
angiogenesis and arteriogenesis. Significant arteriogenesis continues during the 
secretary stage of the cycle, with growth and coiling of the endometrial spiral 
arterioles [184]. Hypoxia, after menstruation enhances angiogenesis by inducing 
human stromal cells to express VEGF [185]. VEGF regulates the growth and 
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differentiation of the endometrium during the menstrual cycle. This is by 
regulating the epithelial and stromal development in the endometrium under the 
influence of oestrogen and progesterone [181]. However one study has shown 
that hypoxia is not required for human endometrial breakdown or repair in a 
xenograft model of menstruation [186]. 
Abnormal bleeding is a result of unrestrained angiogenesis leading to large 
fragile endometrial vessels. Aberrant angiogenesis therefore may underlie 
abnormal menstrual bleeding associated with uterine fibroids. The normal 
menstrual cycle haemostasis and menstruation is a well-ordered and highly 
regulated process. In contrast to this, heavy menstrual bleeding reflects a 
derangement in these physiological processes and the levels of VEGF [187] .  
 
Oestrogen has been found to stimulate VEGF production in the endometrium and 
may have a role in promoting fibroid growth by stimulating angiogenesis [188].  
Ovarian sex steroids are known to play a role in the proliferation and 
maintenance of uterine leiomyomas. Therefore, a state of low oestrogen such as 
that in menopause is associated with the shrinkage of uterine fibroids.  
 
A similar state can be obtained with the use of Gonadotrophin releasing hormone 
agonist (GnRH-agonist). This reversibly suppresses the ovarian function, lowering 
the oestradiol level to a menopausal level and therefore reduces fibroid size 
[189]. GnRH-agonist therapy is used preoperatively in premenopausal women 
with fibroids awaiting surgery to reduce the size of the fibroid uterus. It has 
been shown that once GnRH-agonist treatment is stopped, uterine fibroids 
return to their original size [190].  
 
Many studies, whether histochemical or PCR studies, have focused on the 
patterns of VEGF-A gene expression in human endometrium in normal and heavy 
menstrual bleeding. Therefore treatment of fibroids should theoretically alter 
the level of VEGF. This study focuses on the patterns of VEGF-A and its main 
receptors gene expression in the endometrium of women with heavy menstrual 
bleeding secondary to uterine fibroids and how this changes post UAE. 
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3.1.3.1 Unpublished VEGF work  
In this section we will look at unpublished research that was undertaken by Dr 
Salha Abukhnjr at the University of Glasgow looking at the patterns of expression 
of VEGF in the endometrium of women suffering from HMB with and without 
uterine fibroids. With her permission we will summarise the results.  
In women with HMB and normal uteri, immunohistochemistry showed that VGEF 
expression in the endometrium was highest in the menstrual phase and lowest 
during the early secretory phase. There was significant differences between the 
two levels (95% Cl (129.99, 30.00) P= 0.019). The expression of VEFG-A was 
higher in the proliferative phase than the early secretory phase (95% Cl (99.97, 
0.02) p=0.04). When using RT-PCR, the VEGF-A mRNA expression in the 
endometrium varied significantly across the menstrual cycle (p=0.006). No 
difference in the expression of VEGFA was found between the different 
menstrual phases. 
In women with uterine fibroids, the pattern of VEGF-A expression in the 
endometrium increased across the menstrual cycle with no significant difference 
between the different phases. The RT-PCR showed that the relative VEGF-A 
mRNA expression was significantly higher in the proliferative phase and mid-late 
secretory phase than the early secretory phase (P= 0.008, p=0.009, respectively, 
Mann-Whitney test). There was no difference between the proliferative and mid- 
late secretory phase. 
However, there was no difference in VEGF-A expression in the endometrium 
throughout the menstrual cycle between women with HMB and normal uteri and 
women with HMB and uterine fibroids except in the early secretory phase (97% Cl  
(30.03, 0.00), p<0.05). This was higher in endometrial samples for women with 
uterine fibroids. RT-PCR data found no difference in the expression of VEGF-A in 
endometrium of women in these two groups.  
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3.2 Cyclooxygenase-2 
In women suffering from HMB significant expression of COX-2 in the 
endometrium has been demonstrated when compared to woman with normal 
menstrual blood loss [25]. A positive relationship between the volume of blood 
loss and COX-2 in the endometrium of women with HMB has been previously 
demonstrated [191].  
COX-1 is an enzyme expressed in nearly all body tissues and generates PGs for 
normal physiological function and inflammatory response. However, there have 
been studies that link the development of endometrial carcinoma to 
upregulation in the expression of COX1 [192]. COX2 has also been identified as 
having a role in different pathological conditions such as rheumatic diseases, 
inflammation and tumorigenesis [193]. 
Although PGs play a primary role as mediators in diseases such as inflammation 
and cancer, they also play a crucial role in normal physiological functions such as 
that of the female reproductive tract [194]. Reproduction in mice deficient in 
COX1 and COX2 were studied. The results showed that COX1 plays a role in 
determining the normal gestational period and parturition while COX2 plays a 
role in ovulation, fertilization and implantation. Any reduction in COX2 was seen 
to be detrimental to these processes [194-197]. In the human female, 
dysregulation in endometrial prostanoids can cause menstrual disorders such as 
HMB [31, 198]. 
The process of normal menstruation is under the influence of the sex steroid 
hormones by which cyclical breakdown and remodelling of the endometrium 
occurs. Towards the end of the menstrual cycle and at the time of progesterone 
withdrawal, COX2 expression is upregulated in the functional layer of the 
endometrium [23, 24, 199] with subsequent synthesis of PGE2 and PGF2α (a 
vasoconstrictor) and an increase in the expression of prostaglandin E2 receptors 
[200, 201]. 
The expression of COX-2 in the endometrium of women with uterine fibroids 
before and after uterine artery embolisation will be studied in this thesis. 
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3.2.1.1 Unpublished COX2 work  
In this section we will look at unpublished research that was undertaken by Dr 
Salha Abukhnjr at the University of Glasgow looking at the patterns of expression 
of COX-2 in the endometrium of women suffering from HMB with and without 
uterine fibroids. With her permission we will summarise the results.  
In women with HMB and normal uteri (without uterine fibroids), 
immunohistochemistry showed that COX2 expression in the endometrium was 
higher during the mid-secretory than the menstrual phase (2.3±0.3, 1.2±0.2 
respectively, p<0.05). However, in women with HMB who had uterine fibroids, 
there were no significant differences in the expression of COX2 across the 
menstrual cycle but wide infiltration of COX2 protein was found in the fibroid 
tissue.  
 
3.3 Microvessel Density (MVD) 
Microvessel density is a measure of the number of vessels per high power 
(microscope) field and therefore reflects inter-capillary distance. Oxygen and 
nutrient consumption limit how far away from the vasculature tumour cells can 
remain viable.  
Quantification of tumour vasculature may provide an indication of tumour 
angiogenic activity. One often-quantified aspect of tumour vasculature is micro-
vessel density. It has been used in a wide variety of cancers as a prognostic 
indicator but has not been much used in benign tumours such as fibroids [202].  
There have been studies that have looked at the relationship between MVD and 
the levels of angiogenic factors such as VEGF [203]. Goteri et al found no 
correlation between VEGF expression and an increased MVD in the endometrium. 
However, the study was looking at women suffering with adenomyosis and not 
uterine fibroids [204].  
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Contrary to the normal belief MVD does not reflect angiogenic activity or 
angiogenic dependence of a tumour [205]. MVD may serve as a surrogate marker 
for the efficacy of antiangiogenic therapy and success of treatment. UAE is 
considered a global antiangiogenic therapy as it blocks the main blood supply to 
the uterus by interrupting the blood flow through the uterine arteries. Although 
most research in this field is directed towards malignant tumours, a great deal 
can be learnt from studying non-malignant tumours such as fibroids.  
MVD has not been widely utilized in the field of gynaecology oncology nor benign 
gynaecology.  Measurement of MVD has been used as a prognostic indicator for 
human breast and prostate carcinomas.  This helps in assessing the stage of 
disease, survival rate, recurrence rate and planning the treatment course [205].  
Changes in MVD of the endometrium can appear very early once exposed to 
progesterone. This can be as early as 3 weeks after exposure [206]. Rogers et al 
found that MVD in the endometrium is higher in women with levonorgestrel 
implants than controls and that bleeding occurred despite having thin 
endometrium on ultrasound scan [207]. Czekierdowski et al found a significant 
difference in MVD between normal endometrium and that showing cancerous 
changes [208]. 
To date, there have been no human studies that looked at MVD before and after 
UAE. Tan et al described a study on female guinea pigs undergoing UAE and 
found that UAE causes a temporary decrease in MVD which reverses over time 
and none of the guinea pigs had a fibroid uterus [209]. 
We measured the change in MVD in the endometrium before & after UAE to 
assess if there is any significant change after exposing the uterus to an anti-
angiogenic treatment such as UAE. 
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3.4 Ki67 
Ki67 is a monoclonal antibody and a cellular marker for proliferation and its 
expression is strictly associated with cell proliferation.  It is unique in that its 
antigen is absent from resting cells (G0) and is present in all active phases of the 
cell cycle (G1 & G2) [210] (fig 3-2). Gerdes et al first used Ki67 to determine the 
proportion of proliferating cells in malignant non-Hodgkin’s lymphoma in 1984 
[211]. The name was derived from the city of origin (Kiel) and the number of 
original clone in the 96-well plate. It was first thought to be an antigen but later 
found to be a protein[210]. Further research made it evident that Ki67 antibody 
could be used to estimate the growth fraction in any human cell population.  
It has been shown that secretory endometrium that showed increased Ki67 
expression can be used to aid the diagnosis of endometrial hyperplasia [212]. 
There have been studies looking at Ki67 in endometrial carcinoma and comparing 
it to normal endometrium. They concluded that high Ki67 expression correlates 
to morphologic features of aggressiveness of cancer. On the other hand, in 
normal endometrium, its expression pattern corresponded to the time of the 
period the endometrium was collected at [213].  
There may also be a role for Ki67 expression in assessing endometrial 
proliferation in women with fertility and conception disorders. Insufficient cell 
proliferation of the endometrium has been linked to recurrent miscarriage and 
implantation failures [214]. Such dysregulation in endometrial proliferation may 
explain subfertility in women with uterine fibroids. 
As the human endometrium undergoes a proliferative phase throughout the 
menstrual cycle it was felt appropriate to measure the expression of Ki67 in the 
endometrium before and after UAE. A treatment modality that reduces 
menstrual blood loss may lead to a detectable change in the expression of Ki67 
that could partly explain the mechanism of how it works. 
Although the levels of expression of Ki67 have not been studied in the various 
stages of the human endometrium, they have been studied in rodents. The 
expression was found to change according to the stage of the rodent estrous 
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cycle [215]. To date there has been no study looking at the change in Ki67 
expression in the endometrium before and after UAE and this may serve as a 
pilot study paving the way for more research.  
 
 
Figure 3-2: The cell cycle 
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3.5 The method 
3.5.1 Subjects 
The subjects studied were women aged between 42 – 52 years who presented to 
the tertiary interventional radiology outpatient clinic in Gartnavel general 
hospital and the Gynaecological Outpatients service, Glasgow Royal Infirmary. 
These women complained of heavy menstrual bleeding with known uterine 
fibroids diagnosed by ultrasound or MRI. Initially recruitment was for subjects 
that had not received any hormonal preparation in the last three months 
preceding biopsy collection. However, recruitment was poor therefore patients 
who were on hormonal treatment were also recruited into the study. It was felt 
to be unethical to ask a patient to stop hormonal preparations for the 
study.Ethical approval had previously been obtained from the West of Scotland 
REC 5 research ethics committee and a major amendment was submitted and 
approval was granted (appendix 1). A patient information leaflet was given to 
each patient and allowed a minimum of one week prior to deciding to join the 
study. Written informed consent was obtained from each patient before tissue 
collection and menstrual blood loss was assessed using the Pictorial Blood Loss 
Assessment Chart (PBAC) as in chapter 6. 
3.5.2 Power calculation: 
We aimed for a power of 90% or equivalent with a type II error probability of 
2.0. UAE in women with HMB secondary to uterine fibroids leads to a reduction 
in menstrual blood loss of about 125ml after 6-9 months following treatment 
[216]. We sought help from Dr David Young, statistician, NHS advisor. 
Table 3-1: Power calculation 
Parameter Power Pre-UAE & post-
UAE difference 
SD Sample 
size 
Reference 
Effect of 
UAE 
90% 60% difference  1 22 Khaund et al  
[216] 
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3.5.3 Tissue collection  
Endometrial samples were obtained by means of endometrial sampling using a 
Pipelle® sampler. The first sample was taken pre-UAE and the second was taken 
6 months post-UAE. See section 2.2.1-2.2.2 for biopsies handling and storage. 
Endometrial biopsies were dated according to Noyes criteria (Noyes et al., 1975) 
by a single pathologist (Prof. Alistair Williams, University of Edinburgh) and using 
the reported last menstrual periods (LMP) (table 3.1).  Circulating oestradiol and 
progesterone concentrations were measured at the time of endometrial biopsies 
and were consistent with the histological assessment (Table 3-2). 
Table 3-2:  Summary of endometrial biopsies collected from women with uterine fibroids 
both pre and 6 months post UAE according to phase of cycle 
Histological dating of the sample No. of 
samples 
Proliferative 10 
Early secretory 3 
Mid Secretory 6 
Inactive endometrium 6 
Inadequate for staging (insufficient 
sample or endometritis) 
6 
Chronic endometritis 2 
Non endometrial samples (cervical) 2 
                                        Total = 36 
 
Table 3-3: Summary of blood samples for hormonal profile 
Stage of the 
endometrium 
Blood samples from women with uterine fibroids and HMB  
Mean oestradiol 
(range)(pmol/l) 
Mean progesterone 
(range) (nmol/l) 
Mean LH 
(range)  
(nmol/l) 
Mean FSH    
(range)  
(nmol/l) 
Proliferative 729 < 2.0 16.4 9.2 
Early secretory 468 3.2 22.3 14.4 
Mid secretary  167 5.1 3.3 3.8 
inactive 126 <2.0 < 0.5 < 0.5 
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3.5.4 Immunohistochemistry  
3.5.4.1 VEGF-A immunohistochemistry 
To investigate the expression of the VEGFA in human endometrium tissue before 
and after uterine artery embolisation, the standard immunohistochemistry 
protocol was followed to rehydrate sections (section 2.3.5). Human kidney was 
used as a positive control (fig 3-3 & 3-4). The programme for the auto-stainer 
was as follows:  
 
1-Place slides in a humid staining chamber and cover with TBS buffer pH7.6, to 
which Tween 20 has been added. Leave for 5 min. 
2-Drain off TBS buffer; wipe excess from around section 
3-Incubate with 2.5% normal horse serum (NHS) for 20 min provided in the 
ImPRESS kit (Vector) together with the ImPRESS link reagent. 
4-Drain NHS from sections without washing and wipe excess from around 
sections. 
5-Incubate in biotinylated anti goat VEGF-A at 1:200 for 30 mins, diluted in 
buffer (10% horse serum TBStw)  
6-Rinse thoroughly with TBS buffer pH 7.6, Tween 20 for 3x 5min. 
7-Incubate sections in biotinylated anti-horse 1:200 for 30 min and wash slides in 
diluted in 10% horse serum TBStw (buffer) for 5 min. 
8-Incubate section with Streptavidin ABC reagent (Goat IgG) for 30min then wash 
with buffer 
9- Wash with TBStw then with Dako DAB – made from Vector DAB kit (DAB, DAKO 
Corp, Ca, USA). One drop substrate added to 1ml diluent (1 x 10 min). Rinse in 
distilled water and place in running tap water for at least 5 min. 
10-The counter staining protocol was then followed as (section 2.3.5). 
 Sections were scanned and uploaded to Digital Slidebox  
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3.5.4.2 COX-2 immunohistochemistry 
To investigate the expression of the COX2 in the human endometrium before and 
after uterine artery embolisation, the standard immunohistochemistry protocol 
was followed (2.3.5). Human colon was used as positive controls for optimising 
the immunohistochemistry protocol (fig 3-6). The programme for the auto-
stainer was as follows: 
1-Place slides in a humid staining chamber and cover with TBS buffer pH7.6, to 
which Tween 20 has been added. Leave for 5 min. 
2-Drain off TBS buffer; wipe excess from around section 
3-Incubate with 2.5% normal horse serum (NHS) for 20 min provided in the 
ImPRESS kit (Vector) together with the ImPRESS link reagent . 
4-Drain NHS from sections without washing and wipe excess from around 
sections. 
5-Incubate in biotinylated anti goat COX-2 at 1:500 for 30 mins, diluted in buffer 
(10% horse serum TBStw)  
6-Rinse thoroughly with TBS buffer pH 7.6, Tween 20 for 3x 5min. 
7-Incubate sections in biotinylated anti-rabbit 1:200 for 30 min and wash slides 
in diluted in 10% horse serum TBStw (buffer) for 5 min. 
8-Incubate section with Streptavidin ABC reagent (Goat IgG) for 30min then wash 
with buffer 
9- Wash with TBStw then with Dako DAB – made from Vector DAB kit (DAB, DAKO 
Corp, Ca, USA). One drop substrate added to 1ml diluent (1 x 10 min). Rinse in 
distilled water and place in running tap water for at least 5 min. 
10-The counter staining protocol was then followed as (section 2.3.5). 
Sections were scanned and uploaded to Digital Slidebox  
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3.5.4.3 Ki67 immunohistochemistry 
To investigate the expression of the Ki67 in the human endometrium before and 
after uterine artery embolisation, the standard immunohistochemistry protocol 
was followed (2.3.5). Human colon was used as positive controls for optimising 
the immunohistochemistry protocol (fig 3-8). The programme for the auto-
stainer was as follows: 
1-Antigen retrieval using Menarini antigen access unit, EDTA buffer pH8 
2-Peroxidase block (ThermoFisher) for 10 min 
3-Incubate with 2.5% normal horse serum (NHS) for 20 min provided in the 
ImPRESS kit (Vector) together with the ImPRESS link reagent . 
4-Drain NHS from sections without washing and wipe excess from around 
sections. 
5-Incubate with 1:200 anti-Rabbit Ki67 for 45min 
6- Incubate sections in biotinylated anti-goat 1:200 for 30 min and wash slides in 
diluted in buffer for 5 min 
7-Incubate in VECTASTAIN™ Elite ABC Peroxidase reagent (rabbit IgG) for 30min 
then wash with buffer 
8- Wash with TBStw then with Dako DAB 
9- The counter staining protocol was then followed as (section 2.3.5). 
Sections were scanned and uploaded to Digital Slidebox  
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3.5.4.4 CD34 immunohistochemistry  
To measure MVD in the human endometrium before and after uterine artery 
embolisation, the standard immunohistochemistry protocol was followed (2.3.5). 
Human colon was used as positive controls for optimising the 
immunohistochemistry protocol (fig 3-7). The programme for the auto-stainer 
was as follows: 
1-Antigen retrieval using Menarini antigen access unit, EDTA buffer pH8 
2-Peroxidase block (ThermoFisher) for 10 min 
3-Incubate with 2.5% normal horse serum (NHS) for 20 min provided in the 
ImPRESS kit (Vector) together with the ImPRESS link reagent. 
4-Drain NHS from sections without washing and wipe excess from around 
sections. 
5-Incubate with 1:150 anti-mouse CD34 for 60min at 25oC 
6- Incubate sections in biotinylated anti-rabbit 1:200 for 30 min and wash slides 
in diluted in buffer for 5 min 
7-Incubate in VECTASTAIN™ Elite ABC Peroxidase reagent (mouse IgG) for 30min 
then wash with buffer 
8- Wash with TBStw then with Dako DAB 
9- The counter staining protocol was then followed as (section 2.3.5). 
Sections were scanned and uploaded to Digital Slidebox  
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Figure 3-3: Human kidney tissue was used as a positive control for VEGF-A IHC. Pre-
staining (left) & post staining (right) 
 
 
Figure 3-4:  Strong expression of VEGF-A protein in the endometrial stroma (arrow) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: Human colon was used as a positive control for COX-2, MVD & Ki67. Pre-
staining (left) & post staining (right) 
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Figure 3-6: Weak expression of COX-2 in the endometrial stroma (arrow) 
 
 
Figure 3-7: Micro vessels demonstrated after staining with anti-CD34 
 
 
Figure 3-8: Moderate expression of Ki67 in the endometrial stroma (arrow) 
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Figure 3-9: Stages of the endometrium as seen on H&E staining. A: Inactive, B: Secretory & 
C: Proliferative stage 
 
A 
B 
C 
113 
 
3.5.5 Quantitative RT-PCR for VEGF-A 
RNA was extracted with TRI-reagent (Ambion, life technologies, Paisley, UK) 
following manufacturer’s guidelines using phase lock tubes (micro-centrifuge, 
Greiner bio-one GmbH, Stone House- England, UK). Using MultiScribe 
(Invetrogen, Life technologies, Paisley, UK) RNA samples were reverse 
transcribed. Then according to the manufacturer's instructions they were primed 
with random hexamers (see section 2.4). When no fresh endometrial sample was 
available, RNA was extracted from fixed paraffin embedded samples using 
Ambien kit 1975 (Recover All total nucleic acid isolation kit-Life technology, 
paisley, UK) according to the manufacturer's instructions (see section 2.4.1.1). 
Quality of RNA was assessed using an automated spectrophotometer RNA 6000 
Nanodrop (Lab tech.com, Ringmer, East Sussex, UK), only half of the RNA 
samples were tested by the Agilent 2100 Bioanalyser system in combination with 
RNA 6000 nano chips (see details in section2.4.3). Once the RNA was extracted 
and quantified, the PCR reactions were carried out using an ABI Prism 7900 
(Applied Biosystems) using duplicate samples. A no template control (containing 
water) was included.  
The primer utilised in this study did not distinguish between the different VEGF 
isoforms. Pre-validated primers and probes were purchased for VEGF-A (Life 
technology, Paisley, UK). Gene expression was normalised to B-actin ribosomal 
RNA (Applied Biosystems) as an internal standard. Data were analysed and 
processed using Sequence Detector System (SDS version 2.3) according to the 
manufacturer’s instructions. Results are expressed as relative to a standard 
cDNA obtained from a single sample of endometrial tissue and included in all 
reactions. The quantitative RT-PCR laboratory work excluding the statistical 
analysis was performed by researcher Salha Abukhnjr.  
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3.5.6 Histo-scoring & analysis  
Scoring of immunostaining intensity of VEGF-A & COX-2 in stromal endometrial 
tissue was performed using the histo-scoring method. 
The immunostaining of intensity of epitopes in VEGF and COX-2 antibodies 
stained sections was assessed in the semi-quantitative manner on the 4- point 
scale: 0= no immunostaining, 1= mild immunostaining, 2= moderate 
immunostaining, 3= intense immunostaining. 
Training in histo-scoring was undertaken using the computerised image analysis 
system (Version 4.0, Digital Image Hub, Leica biosystems) as a direct feedback 
method. Once a strong correlation between scores derived from the image 
analysis and subjective scores by the observers was obtained, formal scoring was 
started. All tissue sections were scored both by me and one independent 
observer who was unaware of the patients’ data. A histo-score correlation 
coefficient between the two observers was accepted at ≥ 0.7. Three separate 
areas that subjectively best represented each histology slide were scored at 10X 
and the average score was used in the analysis. 
 
The computerised image analysis system (Version 4.0, Digital Image Hub, Leica 
biosystems) was used to assess proliferation through Ki67 expression. The 
stained cells measuring algorithm was optimised and analysis was performed at 
20X. Three 3 separate areas that subjectively best represented the overall 
histology slide were analysed after annotating the areas to be scored using a 
polygon and avoiding glandular tissue. The average reading of the three 
automated cellular H-Score for nuclear staining was used as the overall Ki67 H-
Score for that specific histology slide.  
 
The automated image analysis system was also used in objectively measuring 
microvascular density (MVD). The micro-vessel detection algorithm was 
optimised with the help of Clare Orange. Slides that were stained with anti-CD34 
were analysed at 20X. Although the automated system at times could not 
exclude larger vessels, it was thought that a standardised objective method of 
analysis for both before and after UAE would be superior to a subjective vessels 
calculation method.  Density in a three dimensional structure is usually derived 
from mass divided by volume. However, we derived MVD by dividing the total 
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number of vessels by the area measured. The average view area for the 
computer monitor used was 230 µm. We noticed that the automated image 
analysis system used pixels as unit of length rather than µm (international 
system of units). Therefore we manually divided the number of vessels by 230µm 
to obtain a more accurate result rather than relying on the auto-calculation of 
the software.     
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3.6 Statistics 
Data were subjected to statistical analysis using paired t-sample tests for 
normally distributed paired data. Some data that was non-parametric were 
normalised by natural logarithm prior to analysis. Mann-Whitney test was used to 
compare non-parametric non-paired data. Descriptive graphical analysis was 
used when there were too few samples to compare. Minitab 17 statistical 
software was used for the analysis and graphs were drawn using Microsoft Excel 
& Minitab 17. 
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3.7 Results 
Endometrial sampling was undertaken in 18 patients both pre-UAE and 6 months 
post-UAE using the Pipelle® sampler. There were 6 samples that were 
inadequate for dating due to an insufficient endometrial sample being taken. 
Two samples from the same patient were only cervical tissue. Two post-UAE 
samples showed chronic endometritis were therefore excluded (table 2-1). 
 
3.7.1 Paired and unpaired samples 
In this chapter we will use the term “Paired samples” when both pre-UAE & 
post-UAE endometrial samples are from the same patient and same stage of the 
cycle (table 3-3). This will be used to form a direct comparison were the samples 
compared are from the same patient and at the same menstrual phase. Our aim 
was to achieve a high number of paired samples however this proved to be 
difficult.  
The term “Non-paired samples” will be used when comparing endometrial 
samples from different stages of the cycle grouped together (table 3-4). This 
was used when the post-UAE sample was found to be at a different phase of the 
menstrual cycle. We felt there was still some value in performing such a 
comparison as it would show an overall change in the endometrium at different 
phases. Comparing non-paired samples also allowed us to use endometrial 
samples from patients that did not have an equivalent pre or post-UAE sample.  
 
Table 3-4: Paired samples by menstrual cycle stage 
Stage Before UAE After UAE 
Proliferative  2 2 
Early secretory 1 1 
Mid secretory 2 2 
 
 
Table 3-5: Total number of samples by menstrual cycle stage 
Stage Before UAE After UAE 
Proliferative  4 6 
Secretory 6 4 
Inactive/progesterone effect  3 3 
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3.7.2 VEGF Expression: 
3.7.2.1 VEGF expression by immunohistochemistry 
Analysis was first performed by comparing all pre-UAE samples to all post-UAE 
samples irrespective of the stage of the menstrual cycle or pairing based on 
advice and feedback from Professor Alistair Williams, Consultant 
Histopathologist, Edinburgh Royal Infirmary. We used a Mann Whitney U test and 
found no significant difference in the expression of VEGF between pre-UAE & 
post UAE samples (p=0.45) (Fig 3-10). The difference was still not significant 
when excluding inactive samples (p=0.73) 
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Figure 3-10: Box plot showing VEGF expression in all samples before and after UAE 
 
We looked at all paired samples regardless of the stage of the cycle. As the 
samples were paired but not normally distributed we used the natural Log and 
analysed them using a paired t-test and found no significant difference in the H-
Score pre & post-UAE (p=0.274) despite an observed upward trend (Fig 3-11). 
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Figure 3-11: Line plot showing an upward trend of the expression of VEGF in the 
endometrium of patients with paired samples 
 
However, when we looked at the paired samples in the proliferative group we 
found an increasing trend in VEGF expression post UAE. (Fig 3-12 & 3-13). A 
statistical test comparing two samples would not give an accurate result. This 
was not the case for the secretory phase or the inactive samples.  
 
 
  
Figure 3-12: The change in VEGF expression in proliferative stage paired samples.  
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Figure 3-13: Line plot showing the change in expression of VEGF in the proliferative stage 
paired samples  
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Table 3-6: Summary of statistical testing for VEGF expression by immunohistochemistry 
 
 
 
 
 
 
 
 
 
*Median for Mann Whitney U 
Group  VEGF H-Score 
was calculated from 
Pre-UAE 
N= 
Post- UAE  
N= 
Statistical test  Pre-UAE              
Mean  ± STD or 
Median* 
Post-UAE            
Mean  ± STD or 
Median* 
P= 
All samples 13 13 Mann-Whitney *75 *80 0.457 
All samples 
(excluding inactive) 
10 10 Mann-Whitney *77.5 *80 0.73 
Paired samples (all) 7 7 Log & paired   
T-testing 
1.8 ± 0.13 1.89 ± 0.09 0.27 
Paired samples 
(excluding inactive) 
5 5 Log & paired   
T-testing 
1.80 ± 0.15 1.88 ± 0.11 0.454 
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3.7.2.2 VEGF RNA relative expression by PCR: 
Although the total number of paraffin block samples available for 
immunohistochemistry was 26 from 16 patients, we only had 10 frozen samples 
from 5 patients. As previously mentioned, when only a small amount of 
endometrium was obtained, we opted to send this to the histopathology 
department to be embedded in paraffin with the plan of future RNA extraction 
from paraffin (section 2.2.1). VEGF RNA relative expression was analysed from 
both frozen and paraffin block samples (Fig 3-15 & 3-16). A summary of the 
statistical analysis is included in table 3-7.  
 
Figure 3-14: RT PCR for VEGF from paraffin blocks 
 
 
 
Figure 3-15: RT PCR for VEGF from frozen samples 
Parrafin	samples	
for	RT	PCR	(26)
Pre-UAE	(13)
RT	PCR	results	
(6)	
Post	UAE	(13)
RT	PCR	results
(4)
Frozen	samples	
for	RT	PCR	(10)
Pre-UAE	(5)
RT	PCR	results
(3)	
Post	UAE	(5)
RT	PCR	results
(4)
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 3.7.2.2.1 Correlation	testing	
 
We looked at the correlation between the results extracted from paraffin to 
those extracted from frozen samples and we did not find any correlation. This 
may be due to the limited number of samples to compare. 
We therefore analysed them as one group (paraffin & frozen) rather than two 
separate groups. We also looked at the correlation of the expression of VEGF by 
immunohistochemistry and that by RT-PCR (paraffin & frozen) and found no 
correlation between the results.  3.7.2.2.2 Comparing	VEGF	RT-PCR	results	extracted	from	both	paraffin	and	frozen	samples	together		
 
We compared pre-UAE VEGF RNA extracted from both frozen and paraffin block 
samples grouped together (n=9) to that post-UAE (n=8). As these samples were 
non-paired we used Mann-Whitney test and the results showed no significant 
difference (p=0.09) despite an upward trend in the samples post-UAE.  
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Figure 3-16 Box plot showing the difference in VEGF RT PCR pre & post-UAE extracted from 
both paraffin and frozen non paired samples grouped together 
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We then looked at only paired results from both paraffin and frozen samples. We 
used the natural logarithm as the results were paired but not normally 
distributed and tested with paired t-test. The results showed a significant 
increase in VEGF relative expression post -UAE (p=0.003).   
 
Figure 3-17 Bar chart showing the difference in the mean of VEGF RT PCR extracted from 
paired paraffin and frozen paired samples  
 
3.7.2.2.3 Comparing	VEGF	RT-PCR	results	extracted	from	paraffin	samples	only	
 
When looking at this group irrespective of stage of the cycle we found a 
significant increase in VEGF relative expression in post UAE samples (P= 0.036). 
We could not test the difference of paired samples as there was only one paired 
sample in the proliferative stage which showed an increase in VEGF relative 
expression in post UAE. 
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Figure: 3-18 Box plot showing the difference in VEGF RT PCR pre & post-UAE extracted 
from paraffin non paired samples only 
 
3.7.2.2.4 Comparing	VEGF	RT-PCR	results	extracted	from	frozen	samples	only	
We also looked at the paired results in this group irrespective of stage of the 
cycle (n=3). We used the natural logarithm as the results were paired but not 
normally distributed and tested with paired t-test. The results showed a 
significant increase in VEGF relative expression post-UAE (p=0.026). 
    
Figure: 3-19 bar chart showing the difference in the mean between VEGF RT PCR extracted 
from frozen paired samples  
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Table 3-7: Summary of statistical analysis for VEGF RT-PCR results 
 
 
 
 
 
 
 
 
* Median for Mann Whitney U test 
Group  of samples VEGF was 
extracted from for RT PCR 
Pre-UAE 
N= 
Post- UAE  
N= 
Statistical test  Pre-UAE              
Mean  ± STD  
or Median * 
Post-UAE            
Mean  ± STD or 
Median * 
P= 
Paraffin and frozen (non-paired) 9 8 Mann-Whitney  *56.8 *425.7 0.09 
Paraffin and frozen (Paired & 
excluding inactive samples) 
4 4 Log & paired             
T-testing 
1.9 ± 0.5 2.66 ± 0.59 0.003 
Paraffin only (non-paired 
excluding inactive samples) 
5 3 Mann-Whitney 68.5 1235.8 0.036 
Frozen samples (paired results) 3 3 Log & paired   
T-testing 
1.74 ± 0.47 2.49 ± 0.59 0.026 
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3.7.3 COX-2 expression 
Analysis was performed by comparing all pre-UAE samples to all post-UAE 
samples irrespective of the stage of the menstrual cycle or pairing. We 
performed a Mann Whitney U test and found no significant difference in the 
expression of COX-2 between pre-UAE & post UAE samples (p=0.25). We also 
found no difference in COX-2 when we excluded all inactive sample results 
(0.07) (Fig 3-21). 
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Figure 3-20: Box plot showing the change in COX-2 expression in all samples  
 
We then looked at all paired samples regardless of the stage of the cycle. As 
these samples were paired but not normally distributed we used the natural Log 
and analysed them using a paired t-test. We found no significant difference in 
the H-Score pre & post-UAE (p=0.8). We also found no significant difference 
when excluding inactive samples (p= 0.07) despite an observed downward trend 
in COX-2 expression post-UAE (Fig 3-22. 
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Figure 3-21: Line plot showing a downward trend of the expression of COX-2 in the 
endometrium of patients with paired samples (excluding inactive samples) 
 
We then looked at the paired samples separately in the proliferative group, the 
secretory group & the inactive sample. Despite finding a downward trend we 
could not statistically test this due to the small number of paired samples.  
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Table 3-8: Summary of statistical testing for COX-2 expression by immunohistochemistry 
 
 
 
 
 
 
 
 
 
 
*Median for Mann Whitney U test 
Group of samples  
COX 2 H-Score was 
calculated from 
Pre-UAE 
N= 
Post- UAE  
N= 
Statistical test  Pre-UAE              
Mean  ± STD or 
Median* 
Post-UAE            
Mean  ± STD or 
Median* 
P= 
All samples 13 13 Mann-Whitney *10 *5 0.25 
All samples excluding 
inactive 
10 10 Mann-Whitney *10 *5 0.07 
Paired samples (all 
stages) 
7 7 Log & paired   
T-testing 
1.05 ± 0.32 1.07 ± 0.32 0.8 
Paired samples 
(excluding inactive) 
5 5 Log & paired   
T-testing 
1.19 ± 0.26 1.07 ± 0.28 0.51 
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3.7.1 Micro-Vascular Density 
The method used in measuring MVD has been explained in section 3.5.5. To 
clarify the values of MVD & to avoid negative LOG results all values in this 
section have been displayed as E-05 (x10-5). 
Analysis was first performed by comparing all pre-UAE samples to all post-UAE 
samples irrespective of the stage of the menstrual cycle or pairing. There was an 
observed increase in MVD post UAE. However, we performed a Mann Whitney U 
test and found no significant difference in the MVD of the endometrial samples 
pre-UAE & & post UAE (p=0.45) (Fig 3-22). We also found no difference when we 
excluded all inactive sample results (p=0.27). 
 
 
Figure 3-22: Box plot showing the change in MVD in the endometrium of all samples 
 
 
We then looked at all paired samples regardless of the stage of the cycle. As 
these samples were paired but not normally distributed we used the natural Log 
and analysed them using a paired t-test. We found a significant increase in the 
MVD of the endometrium post-UAE (p=0.01) (Fig 3-23). Interestingly in samples 
from normally cycling women an observed increase in MVD post-UAE remained 
although the difference was not significant (p=0.1) (Fig 3-24). 
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Figure 3-23: Line plot showing the change in MVD post-UAE for all paired endometrial 
samples 
 
 
Figure 3-24: Line plot showing the change in MVD post-UAE for paired endometrial samples 
for cycling women 
 
We then looked at the paired samples separately in the proliferative group, the 
secretory group & the inactive sample. Despite finding an upward trend we 
could not statistically test this due to the small number of paired samples.  
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 Table 3-9: Summary of statistical testing for MVD by immunohistochemistry  
 
 
 
 
 
 
 
 
 
 
 
*Median for Mann Whitney U test  
Group of samples  
MVD calculated from 
Pre-UAE 
N= 
Post- UAE  
N= 
Statistical test  Pre-UAE              
Mean  ± STD or 
Median* 
Post-UAE            
Mean  ± STD or 
Median* 
P= 
All samples 13 13 Mann-Whitney * 11.08 x10-5 17.04 x10-5 0.45 
All samples excluding 
inactive 
10 10 Mann-Whitney * 14.13  x10-5 16.02  x10-5 0.27 
Paired samples (all 
stages) 
7 7 Log & paired   
T-testing 
0.82 ± 0.38 1.29 ± 0.16 0.01 
Paired samples 
(excluding inactive) 
5 5 Log & paired   
T-testing 
0.96 ± 0.29 1.24 ± 0.11 0.1 
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3.7.2 Ki67 expression (Proliferation marker) 
Automated scoring was used rather than manual scoring as Ki67 marker has been 
extensively used by Glasgow University pathology department previously. The 
automated scoring algorithm had previously been optimised and calibrated and 
required minimal change. Therefore no manual scoring was undertaken in this 
section.   
All inactive samples were excluded in the analysis as they showed no 
proliferation. We first performed an analysis comparing all pre-UAE samples to 
all post-UAE samples irrespective of the stage of the menstrual cycle or pairing. 
We found the difference to be statistically insignificant (p= 0.23)(Figure 3-25).  
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Figure 3-25: Box plot showing the change in Ki67 expression in the endometrium of all 
samples 
 
We then looked at all paired samples regardless of the stage of the cycle. As 
these samples were paired but not normally distributed we used the natural Log 
and analysed them using a paired t-test. We found no difference in Ki67 
expression post UAE for all samples (p=0.20).  
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We were unable to test paired samples according to the stage of the sample as 
the numbers were small. However we found an increasing trend in proliferation 
in proliferative stage samples post UAE. We looked at the secretory phase 
samples and it was only the early secretory phase sample had a similar trend (Fig 
3-26). 
 
 
Figure 3-26: Line plot showing the change in Ki67 expression post-UAE for all paired 
endometrial samples 
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Table 3-10: Summary of statistical testing for Ki67 expression by immunohistochemistry  
 
 
 
 
 
 
*Median for Mann Whitney U test  
Group of samples  
Ki67 expression from 
Pre-UAE 
N= 
Post- UAE  
N= 
Statistical test  Pre-UAE                 
Mean  ± STD or 
Median* 
Post-UAE               
Mean  ± STD or 
Median* 
P= 
All samples excluding 
inactive 
10 9 Mann-Whitney *37.5 *75 0.23 
Paired samples 
(excluding inactive) 
5 5 Log & paired   
T-testing 
1.34 ± 0.32  1.62 ± 0.4  0.20 
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3.7.3 Discussion 
In this chapter we set out to find how UAE affects the endometrium and leads to cessation 
of heavy menstrual bleeding in women with fibroids. We looked at the expression of VEGF, 
COX-2, Ki67 and the microvascular density of the endometrium both before and after UAE. 
We found an overall trend of increased VEGF expression and increased microvascular 
density in the endometrium post-UAE. We also found an overall trend of decreased 
expression of COX-2 post UAE. However, proliferation of the endometrium in the 
proliferative stage and early secretory stages of the endometrium seemed to increase post 
UAE. We could not assess statistical significance in many of the groups that were compared 
due to low sample numbers and this was the main weakness in this study.  
We only looked at the endometrium in this study rather than fibroid tissue itself. To 
directly compare fibroid tissues would have required invasive interventional radiology 
biopsy sampling that is outside the scope of this small study. Endometrium was obtained 
through Pipelle™ endometrial sampling which is a relatively well tolerated procedure.  A 
diagnostic dilatation and curettage (D&C) would have resulted in more endometrial tissue 
and sampled a larger aspect of the endometrial cavity [217]. It would have also avoided 
cervical samples that lead to a decrease in sample size. However, this would have required 
a formal general anaesthetic that would have been unethical to perform in an 
asymptomatic patient post-UAE. Also, we could realistically only obtain samples pre-UAE 
and once post UAE. It would have been beneficial to obtain samples immediately after UAE 
& also at 3 months post UAE however this would not have been tolerated by the subjects in 
the study and would have led to a high dropout rate. 
Endometrial tissue that was collected was processed by the main pathology laboratory at 
the Queen Elizabeth Hospital and there is a standardised protocol for this. However, fresh 
samples that were frozen may have been affected by the two different methods of freezing 
after transfer from RNA Later. This was explained in the methodology in chapter 2. RNA 
extraction was successful in 10 out of 26 paraffin block samples. However 7 out of 10 frozen 
samples produced a RNA relative expression result. As there was only a small amount of 
endometrium frozen, RT PCR was only performed for VEGF. 
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We did however manage to look at four different markers in the endometrium despite the 
small amount of tissue obtained. The results are interesting and do point towards a change 
in these markers post-UAE and may well direct future research towards looking at other 
relative markers. The samples stored in paraffin have been added to the tissue bank and 
future sample collection may result in a better powered study that statistically significant 
results can be extracted from. The cost of this study was low as both pre & post-UAE MRI 
was part of the clinical assessment package for each patient. The researcher (myself) was a 
senior gynaecology registrar who is experienced in performing endometrial sampling and did 
not require training or supervision. Access to ward 56A at Princess Royal Maternity Unit and 
to Clinic F at Stobhill hospital was relatively easy for both the researcher and the subjects 
studied. 
Immunohistochemistry is a well-established laboratory procedure and expertise in staining 
of some of the markers studied was available. The use of the IHC auto-stainer helped the 
researcher in maintaining the same standard for the different batches that were stained 
therefore reducing intra-observer variation.  
We took all post-UAE samples at the time of the period that corresponded to the pre-UAE 
samples dating. Our aim was to pair these samples so that sub-group comparison could be 
made. Unfortunately, only 7/13 samples were paired and 2/7 paired samples were inactive 
and could not be dated to a specific stage of the menstrual cycle. The irregularity in the 
bleeding pattern post UAE was the main contributing factor in addition to subjects not able 
to attend an appointment for endometrial sampling at the required time. 
Initial results were discussed with Professor Alistair Williams, Consultant Histopathologist, 
Edinburgh Royal Infirmary who advised that a meaningful result may be obtained by 
grouping samples from different stages of the cycle and looking at the overall difference. 
This type of whole group analysis was performed as well as sub-group analysis. However, 
the number of samples were small and at times we could only compare samples from two 
patients (n=2) and these results should be treated with caution. They do however open a 
debate for further research into this area and further narrow our search for the elusive 
endometrial marker that changes after UAE. This marker may then help in developing 
targeted strategies through translational research to alleviate the effects of uterine 
fibroids. 
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We analysed paired and non-paired samples with both inclusion and exclusion of inactive 
samples but found no statistically significant difference in VEGF expression.  We observed 
the largest increase in VEGF expression in the proliferative stage of the cycle. This is the 
stage of the cycle when the endometrium regenerates & neovascularisation occurs. It may 
be that higher VEGF levels lead to a lower rate of aberrant vessel formation. We know that 
aberrant angiogenesis underlies abnormal menstrual bleeding associated with uterine 
fibroids [187]. The rise of VEGF may reflect new vessel formation or an ongoing endometrial 
repair process post-UAE.  
We also found a sharp increase in VEGF RT PCR post- UAE in proliferative stage paraffin 
samples but as there was only one paired sample we could not statistically test it. As a 
total cohort, we found significant increases in VEGF RT PCR post UAE. This was true for 
paired paraffin & frozen samples grouped together excluding inactive samples, non-paired 
paraffin samples and non-paired frozen samples (p= 0.003, 0.036 & 0.026 respectively).  
The COX-2 expression in the endometrial samples studied was mostly weak. It is usually at 
its highest while menstruating and no samples from this stage were obtained in our study 
[218].  When looking at the expression of COX-2 in the endometrium we observed an overall 
downward trend post-UAE which did not reach statistical significance. Ma et al described 
inhibition of VEGF expression after targeted interruption of COX-2 gene pointing to a 
directly proportionate relationship [219]. However, it may be that UAE has a global effect 
on endometrial marker, causing the observed inversely proportionate relationship between 
VEGF and COX-2.  
We found an overall increasing trend in microvascular density post-UAE compared to pre-
UAE in all paired samples. Such comparison yielded a significant result (p= 0.01). This is 
probably because the uterus as a whole has undergone an acute ischemic event and has 
compensated by forming new blood vessels. The statistical significance of these results was 
reduced after removing inactive samples most likely due to a decrease in sample size. 
Despite a significant increase in VEGF & MVD in the post-UAE samples we did not find such 
an increase in the expression of proliferation marker Ki67. Under normal hormonal 
conditions, proliferation of the endometrium increases in association with VEGF & MVD and 
supports the thickening of the endometrium preparing it for implantation. Although there 
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was an increasing trend in Ki67 expression in the proliferative endometrium, there was no 
significant difference in the H-Score of paired samples (0.34).    
Overall, we observed a change in our studied markers. There was an increasing trend in 
VEGF, Ki67 & MVD and a decreasing trend in COX-2 post UAE. The lack of statistical 
significance is likely to be due to small numbers. Future work that involves collecting 
further samples or re-testing for other markers is being considered.   
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4. Chapter 4: The factors that play a role in the success of 
UAE and its complications. 
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4.1 Introduction: 
Uterine artery embolisation (UAE) is a non-invasive treatment for uterine fibroids. In 1995 
Ravina et al was first to report that embolisation of the uterine arteries in a fibroid uterus 
would lead to avascular necrosis of the fibroid, causing volume reduction in the fibroid 
uterus and fibroids [132]. It has therefore emerged as a satisfactory alternative to 
hysterectomy and multiple myomectomies [148, 220].  
There is widespread acceptance amongst gynaecologists and interventional radiologists of 
UAE as a treatment for uterine fibroids. UAE requires great familiarity with the pelvic 
arterial anatomy and variations in the vascularisation of uterine fibroid tumours may 
account for treatment failures. The uterine arteries which are branches of the anterior 
division of the internal iliac artery provide the predominant vascularisation for the uterus 
and the fibroid tumour [221]. However the ovarian arteries and the round ligament arteries 
also play a role in supplying blood to the uterus [222]. Angiography using pre-UAE MRI and 
intra-operative fluoroscopy is useful for comprehensive assessment of the anatomy of the 
internal iliac artery, its pattern of division, and its branches. 
In many reports, heavy menstrual bleeding associated with fibroids is improved in 85% of 
patients who undergo UAE [220]. The likely explanation is due to reduced blood flow and 
changes in vascular supply to the fibroid uterus.   Pressure symptoms are also helped in 70-
90% of patients, this is mainly due to uterine volume and fibroid volume reduction of up to 
40% [223].  
 
Imaging is very important in pre-procedural planning for uterine fibroid embolisation. 
Deciding who is an appropriate candidate for the procedure involves careful evaluation of 
uterine fibroid tumours, particularly their number, size, and location and the degree of 
vascularisation which can be achieved using different imaging modalities. Magnetic 
Resonance Imaging (MRI) facilitates accurate imaging and assessment of symptomatic 
uterine fibroids and helps in evaluating the efficacy of UAE. Pre-embolisation MRI is 
recommended by many radiologists because it allows differential diagnosis of other diseases 
that can mimic fibroids such as adenomyosis and other space occupying pelvic lesions such 
as solid ovarian cysts [224]. Fibroids usually appear isointense to the surrounding 
myometrium on T1 weighted imaging (T1-WI) and hypointense on T2 weighted imaging (T2-
WI).  
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The current standard of practice is to use a gadolinium-based contrast agent (GBCA) 
enhanced pelvic MRI. When gadolinium is used as a contrast agent, then fibroids that have a 
vascular supply appear to enhance [225]. This then helps monitor the response to treatment 
by subjectively comparing before and after treatment contrast enhancement. Response is 
also assessed by the measuring the change in both volume and vascularity of fibroids post 
UAE. 
The morphology of a fibroid can change and can be described as necrotic, calcified or 
oedematous. The MRI signal can change once treatment is initiated. After UAE, early MRI 
signals show disappearance of contrast enhancement and subsequently a volume reduction 
of the fibroids. These signal characteristics are secondary to hyaline degeneration of the 
fibroid [224]. They are considered as morphological imaging criteria that are in keeping 
with a successful procedure [226]. However, this may not always reflect resolution of 
clinical symptoms but may aid the clinician and the patient in planning further treatment. 
 
 
 
 
 
 
 
4.2 The standard pelvic MRI analysis: 
The pelvic MRI that is obtained in a woman with a suspected fibroid is usually 
reported/analysed by a consultant radiologist with a special interest in gynaecology MRI. It 
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may also be reported by a middle grade doctor in radiology (registrar) under direct 
supervision of a consultant radiologist. The images produced by the MRI scanner can be 
rendered by the MRI software to scan through the subject imaged in both coronal and 
sagittal planes producing a three dimensional image. 
The factors taken into consideration when viewing an MRI of a fibroid uterus to assess the 
suitability for UAE are: 
4.2.1 Number of Fibroids 
Women present with one or more fibroids within their uterus. Although the number of 
fibroids can help assess suitability for surgery such as myomectomy, there is no evidence 
that they can influence the outcome.  
Firouznia et al demonstrated an association between fibroid number pre-UAE and outcome 
measures post-UAE, including size reduction of the fibroid and the uterus. The reduction in 
mean fibroid volumes was similar in patients with single and multiple fibroids [227]. 
Another study failed to predict the clinical outcome after UAE of women whom presented 
with a single fibroid [228].   
 
4.2.2 Size of Uterus/Fibroids 
There have been a few studies looking at the size of fibroid uterus and its response to UAE. 
Parthipun et al found no increased incidence of complications in women with large-
diameter fibroids (large fibroids were classified as ≥ 10 cm) and large uterine volumes (large 
uterine volume were classified as ≥ 750 cm3)[229] . Katsumori et al also looked at uterine 
fibroids with any single diameter of 10cm or larger as a risk factor and no increased risk was 
found to patients undergoing UAE with such large fibroid size [230]. Berczi et al compared 
fibroids with <10 cm largest diameter to those >10 cm and found no significant difference in 
the effectiveness of UAE treatment or complication rate [231]. Prollius et al considered a 
uterine volume of ≥ 780cm3 to be a large uterus rather than relying on a single 
measurement of >10cm. Smeets et al used a cut-off volume of 700cm3 to differentiate 
between small and large fibroids and found no difference in the effectiveness of UAE 
between these two groups [232]. We will use similar cut-offs in the analysis later in this 
chapter. 
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Another study looked at the correlation between fibroid and uterine volume to the 
menstrual blood loss and found a negative correlation between the diameter of the largest 
fibroid to the menstrual blood loss and the same for uterine volume [73].  
The importance of the size of a fibroid is still a matter of debate. There is no definite 
answer on whether UAE should be offered as a treatment modality in women with large 
fibroids. 
 
4.2.3 Location of fibroids 
Both pelvic MRI & pelvic ultrasound are used in determining the location of uterine fibroids, 
however MRI has been shown to be highly accurate in determining uterine fibroid location 
[225, 233]. The fibroid tumour location seems to play a more important role than fibroid 
size in governing the outcome of UAE role [234].  
Submucosal fibroids exhibit volume reductions greater than 50% by magnetic resonance 
imaging after UAE [235].  However, women with submucosal leiomyomas at the time of 
embolisation are more likely to have post-procedural complications as these fibroids can 
migrate into the cavity after UAE. The majority of these are expelled spontaneously 
without significant symptoms. In some instances, submucosal fibroids greater than 6 cm in 
size that become endocavitary may cause complications requiring further intervention. The 
intervention is usually in the form of dilatation and curettage that is usually performed 
under a general anaesthetic. It is important to consider this when counselling patients 
contemplating UAE [236, 237].  Such fibroid expulsion is not limited to submucosal fibroids 
and there have been case reports of expulsion of intramural fibroids [238, 
239].  Expulsion of myomas after uterine artery embolisation occurs relatively frequently 
and may be one of the ways to attain cure rather than be considered a complication. 
 
4.2.4 Degree of vascularisation    
In the initial studies about the outcome after UAE, ultrasound was used to evaluate the 
uterus and the fibroids after treatment [132]. The disappearance of fibroid vascularisation 
was observed using Doppler ultrasound after successful embolisation [240]. Although 
ultrasound is inexpensive, it does have limitations when assessing fibroids both pre & post 
UAE. Therefore, most current UAE procedures are followed up by contrast enhanced MRI 
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which shows signal intensity changes including increased signal intensity on T1-weighted 
images and homogeneous decreased signal intensity on T2-weighted images. MRI can also 
show lack of contrast uptake that is consistent with haemorrhagic infarction and hyaline 
degeneration [241]. 
 
Contrast enhanced Magnetic Resonance Imaging (MRI) before UAE is highly useful in the 
evaluation of patients referred for UAE. Gadolinium based contrast enhanced MRI is used to 
determine the viability of tumours and detect other findings prior to UAE.  A woman with 
non-viable fibroid tumours should therefore not undergo UAE [242].  The degree of 
infarction (lack of contrast enhancement) 
of uterine fibroids after embolisation on enhanced MRI is related to long-
term clinical outcomes. Complete infarction of fibroid tissue induces a higher rate of 
symptom control, compared with incomplete infarction of fibroid tissue. This is reflected by 
a lower rate of post-procedure intervention [243].  
 
An infarcted fibroid that has responded well to UAE appears dark on contrast enhanced MRI. 
This reflects the absence of contrast material, which in itself reflects a lack of vascularity 
of the fibroid and therefore procedure success from an imaging aspect (fig 4-1). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 4-1: Fibroid showing contrast enhancement pre-UAE (left) and non-contrast 
enhancement post UAE (right). 
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4.2.5 Age of Patient 
Uterine fibroids are more common in adults than in adolescent females. In one study the 
mean age of women who reported a diagnosis of uterine fibroids was 8 years older than 
women without the diagnosis [244]. There has been a report of a symptomatic fibroid in a 
girl as young as 13 years old [245].  Other case reports of girls as young as 16 years 
presenting with large fibroids and requiring surgery are in the literature [246, 247]. Fields 
et al has produced a case series of young-adult women between the ages of 13 and 21 and 
compared their management with the adult population [248]. Van Voorhis et al looked at 
risk factors for development of fibroids and found increasing age was nearly significant as a 
risk factor [249].  
A few studies have looked at age as a predictor of response to UAE, these have  found that 
age did not correlate with a reduction in the size of fibroids after UAE [250, 251]. However, 
Jha et al found that increased age was a predictor of failure [252].  
The age of the patient when UAE is performed may become more important when 
comparing the long-term results from studies involving patients who are near the age of 
menopause, when there is a greater likelihood that the symptoms will resolve. This could 
be due to age-related changes that occur to the uterus in general and to the fibroid in 
particular in this age group rather than the effect of UAE alone [253]. It may be fair to say 
that some synergistic mechanism between age-related changes and UAE is more pronounced 
nearer to menopause. 
 
4.3 MRI of the endometrium following UAE:  
The endometrium demonstrates a wide spectrum of normal and pathologic appearances 
throughout menarche, during the pre-pubertal and postmenopausal stages of a woman’s 
life. Imaging with ultrasound is almost always the first modality used to assess endometrial 
disease due to it being inexpensive, non-invasive and correlates well with MRI [254]. 
Although it is well documented that MRI is useful for assessing the quantitative & 
morphological changes of the fibroid uterus before and after UAE [252]. The endometrial 
changes observed on MRI following UAE have not been widely studied. There have been 
some reports of UAE-associated endometrial thinning that are linked to placenta accreta in 
a subsequent pregnancy [255]. Permanent amenorrhea secondary to endometrial atrophy 
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after UAE is a risk that patients should be counselled about.  Such complication could lead 
to a devastating outcome for a women wanting to become pregnant as it may lead to 
reduced fertility after embolisation or the inability to become pregnant secondary to 
failure of implantation [256]. 
There have been studies that have used MRI to look at endometrial proliferation and 
thickening during the use of tamoxifen for breast cancer. Tamoxifen has pro-oestrogenic 
effects on the endometrium and can lead to hyperplasia and endometrial cancer. These 
studies have recommended MRI as a diagnostic tool in following up endometrial changes 
[257, 258]. MRI could therefore be a useful diagnostic tool in assessing endometrial changes 
post UAE.  
 
 
 
 
 
 
 
4.4 The UAE procedure: 
The main objective of UAE is to completely infarct the fibroid tissue within the uterus while 
preserving the uterus, ovaries and surrounding pelvis tissues. This is achieved by completely 
occluding the uterine arteries with an embolic agent using a percutaneous approach. Stasis 
of contrast material in the uterine arteries is the usual angiographic end point that signifies 
a technically successful UAE procedure. The procedure is concluded when a standing 
column of contrast material is observed in the uterine artery or when reflux of contrast 
material toward the uterine artery origin or into the hypogastric artery is observed under 
fluoroscopy [132, 220]. 
UAE is performed by an interventional radiologist who is competent in embolisation 
techniques.  A C-arm fluoroscopic unit which supports road mapping of the vessels is used. 
In order to lower radiation exposure, the radiologist should use modern angiographic units 
with flat panel detectors and strictly apply dose reduction methods such as pulsed 
fluoroscopy [259].    
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The patient is usually consented in the outpatient department prior to the procedure or on 
the day of the procedure. This should include explaining the risk of failure of the procedure 
and the risk of developing uterine ischemia that can lead to an emergency hysterectomy 
and irreversible loss of fertility [260]. Ovarian failure can also complicate UAE due to 
uterine artery and ovarian artery anastomosis and has been found in 7% of the population 
[261]. In such cases coil embolisation may be required prior to UAE to prevent non-target 
embolisation of the ovary with embolic material particles [262, 263].  
Although the majority of women undergoing UAE have heavy periods, amenorrhea is not 
usually what they desire especially in women undergoing UAE as a fertility-sparing option. 
Endometrial injury caused by ischemic endometrial damage is usually the cause of post 
procedural amenorrhea [263].  
 
Patients are admitted to hospital on the day of the procedure to a gynaecological, surgical 
or vascular ward. Pain is expected as an early side-effect of successful UAE and joint 
protocols should be in place and adhered to in managing post UAE pain (Appendix 4).  
Vascular access with percutaneous femoral artery approach is followed by trans-catheter 
delivery of the embolic agent into the uterine artery on one side under fluoroscopic 
guidance.  The embolic agents used are either gelfoam or polyvinyl alcohol embolisation 
particles (PVA). Once stasis is achieved, the contra-lateral uterine artery is then embolised 
in a similar fashion.  
Once stasis of both uterine arteries has been achieved, the catheter is removed and 
haemostasis over the femoral artery is achieved by manually pressing over the incision area 
for up to 5 minutes to compress the femoral artery and prevent haematoma formation. The 
procedure time is reported to average around 61 min and fluoroscopy time (X-ray radiation 
exposure) around 19 min [223]. 
 
4.5 Complications after UAE 
When comparing UAE to other forms of treatments for fibroids, re-intervention rates and 
long term follow up should be taken into account. The majority of patients undergoing UAE 
will be followed up for 6 months post procedure. This is usually in the form of imaging 
studies with contrast enhanced MRI being the most informative. However, the use of 
ultrasound for fibroid uterus volume assessment post UAE is also reliable [264]. 
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There have been two main studies that have compared UAE to surgical intervention for the 
treatment of fibroids. These studies are the REST and EMMY trials. Both being randomised 
controlled trials and both followed up the patients for a period of five years. Although the 
primary outcome of both these trials was to look at the quality of life of women after 
fibroid treatment. The secondary outcomes included re-intervention rates [148, 265].   
The largest series to date that has assessed complications secondary to UAE is the FIBROID 
registry which involved 3000 patients. It reported around 5% major adverse events in the 
first 30 days following hospital discharge [266]. A broad range of complications can occur 
after UAE and the rates of these vary widely between studies. One study by Spies et al 
looked at 400 consecutive UAE procedures and  reported a peri-procedural complication 
rate of 8.5% with a serious complications rate of 1.25% [267]. Later in this chapter we will 
be looking at re-intervention rates in a cohort of patients in Glasgow who underwent UAE. 
We will try and establish whether the initial fibroid size pre-UAE and fibroid shrinkage 6 
months post-UAE correlate to re-intervention rates up to 18 months post UAE.  
 
4.5.1 Post embolisation syndrome (PES): 
It is a post procedural complication that is reported in up to 3% of women undergoing UAE 
but some estimate a higher incidence [268]. It is defined as the development of post 
embolisation pain associated with nausea and/or vomiting, generalised malaise, low grade 
fever and a mild to moderate rise in inflammatory markers [269]. It usually affects patients 
who have infarcted all or part of a bodily organ after an embolisation procedure and in UAE 
this organ is usually the uterus. The pain after UAE is usually pelvic in site and crampy in 
nature and usually starts 2-3 hours post embolisation. Pron et al looked at post UAE pain 
which rose from a pre-UAE score of 0/10 in the majority of patients to an average score of 
7/10 post-procedure [223]. 
The cause of PES in UAE is thought to be ischemia of the normal myometrium [270]. The 
mechanism of ischemia is not fully understood and it has only been studied best in patients 
with cardiac-origin angina pain. This mechanism is thought to be by formation of adenosine 
triphosphate, which secondary to anaerobic metabolism leads to acidosis and the loss of 
cell membrane integrity. Intracellular chemical mediators such as lactate and adenosine 
are released which effect chemo-sensitive receptors and therefore cause PES [271].  
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4.5.2 Infection: 
Uterine infection is a complication of UAE which may occur soon after UAE but can also 
occur weeks or months post procedure [267, 272]. It can present in the form of sudden 
onset severe pain, vaginal discharge and/or bleeding. Infection should be aggressively 
treated therefore; readmission to hospital post UAE is common. Patient education is vital to 
avoid late presentation and serious complications such as hysterectomy [273]. The 
incidence of complications secondary to intrauterine infection was reported as 1.2% in a 
case series of 414 UAE procedures. This required intravenous antibiotic therapy and/or 
surgery [274]. As the symptoms of infection and PES overlap it would be beneficial to treat 
PES with antibiotics and therefore avoid late complications such as sepsis.   
 
4.5.3 Fibroid expulsion and need for hysteroscopy: 
There is a risk of fibroid expulsion, when UAE is performed in the presence of a submucosal 
fibroid or an intramural fibroid with a substantial submucosal component. Although most 
women tolerate fibroid expulsion well, approximately 50% may need surgical intervention 
[275]. The expulsion of an infarcted fibroid often leads to further intervention in the form 
of hysteroscopy, transvaginal myomectomy or even hysterectomy [276]. However, Laverage 
et al reported a case of multiple large fibroids being expelled vaginally after UAE without 
the need for re-intervention [277]. Nulliparous women showed a trend toward undergoing 
urgent and elective hysterectomy to manage such complication compared with parous 
women [275]. This may be due to difficulty in dilating the cervical os. The use of PGE2 such 
as vaginal misoprostol prior to hysteroscopy in cases of fibroid expulsion may prove to be of 
benefit. This method is called cervical primary and has been used in elective trans-cervical 
fibroid resection and found that it reduced the need for cervical dilation and facilitated 
such surgery [278].  
 
4.5.4 Non-target embolisation (off-target organ embolisation): 
Ovarian vasculature embolisation due to utero-ovarian collaterals has been well 
documented. This leads to degradation of ovarian function, which increases the risk of 
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premature menopause especially in women over 45 years old [135]. One small study found 
that women under the age of 45 who underwent UAE experienced transient post-
menopausal symptoms which included amenorrhea, hot flushes and elevated FSH. This was 
observed in up to 6% of women undergoing UAE and usually resolved by 10 months post UAE 
[279]. The loss of ovarian function can be very distressing for women wanting to preserve 
their fertility and appropriate counselling should be undertaken.  
The uterine artery can sometimes share a common trunk with the vaginal arteries or forms 
an anastomosis within the broad ligament [280]. This can lead to embolic particles passing 
through the vaginal arteries resulting in vaginal ischemia. This can lead to sexual 
dysfunction and chronic dyspareunia [281] . One of the rare identified causes of non-target 
embolisation is due to intra-fibroid arterial-venous fistula which was reported as fatal 
[282]. Other forms of interventional radiology treatments use emboli coils to induce stasis 
and there have been case report regarding coil migration that may lead to catastrophic 
outcomes (appendix 5).    
 
4.5.5 Venous Thromboembolism (VTE)  
It is thought that VTE such as pulmonary embolism (PE) & deep venous thrombosis (DVT) 
develop after UAE due to development of a prothrombotic state similar to that seen in a 
surgical procedure [283]. There have been 2 case reports of PE after UAE which have been 
fatal [284, 285]. Luckily, the incidence of such events is low and has been reported as 
(0.3%) [286].  
DVT reported as a complication after UAE has a reported incidence of 0.4-0.5% [267, 286]. 
It has been reported just days after the UAE procedure with the majority of cases occurring 
within 3-5 days post UAE. 
There should be a high level of suspicion of VTE after UAE when a patients presents with 
symptoms suggesting PE or DVT. Patient education has an important role in early 
presentation and diagnosis. 
 
4.5.6 Re-intervention (UAE, myomectomy & hysterectomy) 
Initial long term data showed the risk of re-intervention following UAE to be 20% [287]. Re-
intervention in this context is defined as a subsequent need for repeat UAE, myomectomy 
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or hysterectomy. Data published from the EMMY trial and the REST trial showed even higher 
re-intervention rates [148, 265]. In the EMMY trial follow up data where recorded for 81/88 
patients that underwent UAE. This showed 23/81 (28.4%) subsequently had a hysterectomy 
due to lack of symptom improvement. In the REST trial 106 patients underwent UAE with a 
5-year re-intervention rate of 32% for treatment failure or complications [148].   
The high re-intervention rate may influence how widely UAE is offered in a financially 
struggling national health service (NHS).  
Although cost is a factor when comparing UAE to hysterectomy, it may be that a 
hysterectomy is not an acceptable option for some patients.  Inarguably fertility ceases 
with hysterectomy however, UAE aims to at least preserve it or even improve it. Currently 
there is an ongoing trial comparing the quality of life for women randomised to either 
myomectomy or UAE (FEMME trial). Data from this trial will also look at re-intervention 
rates in both these two groups up to 5 years after the initial procedure. In this chapter we 
will look at short term re-intervention rates following UAE.  
 
 
4.5.7 Death 
There have been reported cases of death following UAE. Fortunately, the mortality risk is 
low at 0.05 per 1000 which compares favourably to the mortality risk of hysterectomy 
∼0.38 per 1000 [288, 289]. Death has been reported mainly secondary to septicaemia and 
sepsis from a necrotic uterus [290, 291]. Cases of PE and non-target embolisation are other 
causes of death that we mentioned earlier. 
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4.6 Patients and methods: 
4.6.1 Subjects: 
The study population was identified using the Clinical Research Information System (CRIS) 
at Gartnavel Hospital, Glasgow. Patients who had undergone their first UAE procedure 
between 1st of January 2010 and 31st of December 2014 in NHS Greater Glasgow and Clyde 
(n=171) were identified using a search by exam name: Embolisation of uterine fibroid, code 
IUTFDE.  
 
4.6.2 Exclusion criteria: 
1-Subjects having a repeat UAE within the study period. 
2-Subjects with incomplete MRI imaging.  
3-Women who had the post UAE MRI not within the follow-up period for this study. 
4-Women who had two UAE procedures in the study period, the second UAE procedure 
imaging was excluded from the analysis.  
5-Women with no follow up data 
 
All the exclusion criteria were applied and the cohort was reduced to n=133 for analysis of 
fibroid/uterine volume change post UAE. 
While exclusion criteria (2,3) were not applied when looking at complication rates following 
UAE as post-UAE imaging was not essential. 
 
4.6.3 Ethical approval: 
Caldecott guardian approval was obtained and the local R&D team at the Western 
Infirmary, Glasgow was approached.  Once R&D approved the study, it was uploaded and 
transferred using the Integrated Research Application System (IRAS) to the next available 
ethics committee.  
The Proportionate Review Sub-Committee of the NRES Committee East of England - 
Cambridge South reviewed the ethics application on 09 February 2015 and gave a 
favourable opinion (Appendix 3). 
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4.7 MRI Images 
The standard imaging protocol for pelvic MRI for fibroids in NHS GG&C is T2 weighted Fast 
Recovery Fast Spin Echo (FRFSE) images acquired in the sagittal and coronal planes (TR 
4960ms, TE 85ms, FOV 240mm, 256 x 384 matrix, slice thickness 4mm, echo train length 
16). Sagittal T1 weighted Liver Acquisition and Volume Acquisition (LAVA) images were 
acquired before and after injection of gadolinium contrast agent (Gadovist, Bayer plc, 
Berkshire, UK). LAVA is a 3D spoiled gradient echo sequence and the following imaging 
parameters were applied: TR 4.72ms, TE 2.32ms, FOV 280mm, matrix (frequency x phase) 
320 x 192, slice thickness 5mm. There was slight deviation from this protocol according to 
different sites however, all patients in this study had T2 sagittal and coronal planes images. 
MRI Images were loaded on the picture archiving and communication system (PACS) from 
the national archive using the Community Health Index number (CHI Number). This is a 
population register, which is used in Scotland for health care purposes and access is given 
to medical staff after line manager written approval. The CHI number uniquely identifies a 
person in this index and is made of 10 characters. The first 6 characters from the left are 
the patient’s date of birth and the remaining four characters are used to differentiate 
between two individuals with similar dates of birth. 
 
The date of the UAE procedure was checked against the database obtained through CRIS 
and the dates of the pre-UAE and post UAE MRI was recorded. The time from pre-UAE MRI 
to event date and from event date to post UAE MRI was calculated. NHS GG&C uses a 6 
weeks post procedure outpatient clinic review. This helps identify and address any 
problems that may arise in the immediate post procedure duration. A further 6 months post 
procedure MRI is usually organised at this appointment. This is used to evaluate the success 
of the UAE procedure by measuring shrinkage of the uterus and fibroids, and contrast fill 
defect in the fibroids. Patients are shown their before and after UAE MRI in a side by side 
layout for direct comparison and a brief description. This usually re-enforces the success of 
this procedure in a patient that has symptom improvement as a result of UAE. 
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4.8 MRI image analysis 
Training in MRI image analysis of a fibroid uterus was undertaken. This was supervised by Dr 
Sue Lassman, Consultant radiologist with special interest in MRI and gynaecology imaging. 
This was in the form of direct supervised sessions that included measuring fibroid 
diameters, calculating fibroid volume, assessing the location, calculating uterine diameters, 
calculating uterine volume and measuring endometrial thickness on MRI images. The basis 
of contrast enhancement was also learnt. However, this is a subjective observation and 
would be difficult to reproduce therefore was not used in this thesis. Measurement of the 
fibroid and the uterus and volume calculations have previously been described (section 
2.5). 
 
 
4.8.1 Calculating shrinkage (change in size after UAE): 
The change in the size of the fibroid uterus and the dominant fibroid was assessed and 
calculated as a percentage rather than absolute numbers due to the wide variation in the 
size of the uteri and the fibroids measured. 
 
The term “Uterine shrinkage” and “Dominant fibroid shrinkage” were calculated as follows: 
 
Dominant Fibroid shrinkage = 
(Vol. of dominant Fibroid post UAE/ Vol. of dominant Fibroid pre UAE – 1) x 100 
 
Fibroid Uterus Shrinkage = 
(Volume of fibroid uterus post UAE/Volume of fibroid uterus pre UAE -1) x 100 
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4.9 Statistics 
Descriptive statistics were used when it was appropriate. Paired t-testing and independent 
T-testing was used to compare parametric data and the results expressed in mean 
plus/minus standard deviation. One way ANOVA test was used when appropriate with 
Bonferroni post hoc test when indicated.  Spearman’s correlation test was used to test 
association between variables. 
 
Results were statistically significant with p value ≤ 0.05. Details of when each test was used 
are addressed in each relevant section. Minitab 17 statistical software was used for data 
analysis and creating graphs that were then edited using Microsoft word 2010 software. 
Microsoft excel 2010 was also used to draw graphs. 
 
4.10 Results  
The number of patients that underwent UAE in 5 years was n=171, after exclusions were 
made the cohort used in this analysis n= 133 (table 4-1). The timing of the post-UAE MRI 
was the main exclusion criteria that reduced the cohort number that was analysed. We 
included women who had the post-UAE MRI at 6 months +/- 6 weeks after the UAE 
procedure (182 days +/- 42). Therefore, only women who had the post UAE MRI 140 – 224 
days after the procedure were included in this section of the analysis.  
Table 4-1: Showing the reason why patients were excluded 
Reason for exclusion Number of patients 
Post UAE MRI was performed within 140 
days (6 months- 6 weeks) 
16 
Post UAE MI was performed after 334 
days 
(6 months+/- 6 weeks) 
11 
No post UAE MRI 3 
No Pre-UAE MRI 8 
Total excluded 38 
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4.10.1 Uterine and fibroid volume 
Initially we compared the change in the dominant fibroid volume and uterine volume post-
UAE. A paired t-test was used to compare pre-UAE to Post UAE volume of the uterus and 
the dominant fibroid. This shows that there is a statistically significant reduction in both 
the mean uterine volume and the mean dominant fibroid volume after a UAE procedure. 
The mean uterine volume reduced by an average 336.8cm3 and the mean dominant fibroid 
volume reduced by an average of 144 cm3 (table 4-2, fig 4-3 & 4-4). 
Table 4-2: The change in uterine volume and dominant fibroid volume 
 
 N 
Pre-UAE 
Mean +/-STD cm3 
Post UAE 
Mean +/-STD cm3 
P  value 
Uterine volume 132 882.28 +/- 660.9 545.47 +/- 508.5 < 0.01 
Dominant  fibroid 
volume 
127 385 +/- 407.2 241.14 +/ -329.6 < 0.01 
 
 
 
Figure 4-2: The average change in uterine volume  
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Figure 4-3: The average change in dominant fibroid volume  
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4.10.2 Large uterus & large dominant fibroids  
As mentioned in 4.2.2 a large uterus is that with a volume ≥ 780cm3 and a large fibroid is 
that with either a single diameter ≥10cm or a volume of ≥ 700 cm3.  
An independent sample t–test was used to test for significant differences in treatment 
effect (shrinkage) between large/small uterus and large/small fibroid.  
We found that small fibroids < 700 cm3 shrunk significantly more than large fibroids ≥ 700 
cm3 (p < 0.05). However we could not find a similar effect when comparing large uterine 
volumes to small uterine volumes. This may be due to a fibroid uterus usually contains 
multiple fibroids of varying sizes. (Tables 4-3 & 4-4). 
 
Table 4-3: Comparison between small and large fibroids shrinkage 
 
 Shrinkage post-UAE 
of a small fibroid % 
 
Shrinkage post-UAE 
of a large fibroid % 
P value 
Mean 
shrinkage  
±STD 
45.74 ± 2.7 34.5 ± 4.72 <0.05 
 
 
Table 4-4: Comparison between small and large fibroid uterus shrinkage 
 
 Shrinkage post-UAE 
of a small uterus % 
 
Shrinkage post-UAE 
of a large uterus% 
P value 
Mean shrinkage  
±STD 
37.97 ± 2.67 38.36 ± 3.17 >0.05 
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4.10.3 Age of the patient 
The majority of patients who underwent UAE were between 40 & 50 years with a peak at 
around 45 years. This is the age that is clinically associated with pre-menopause and period 
irregularities are common. Around 80% of the women undergoing UAE in this study were 
above the age of 40. This is the main difficulty that studies which look at fertility face as 
fertility significantly declines after the age of 35. (fig 4-5, 4-6). 
 
Figure 4-4: Histogram showing the age at time of UAE 
 
 
Figure 4-5: Pie chart of age distribution of women undergoing UAE 
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To assess if there is a relationship between age of the patient and the uterine volume pre-
UAE or the dominant fibroid volume pre-UAE we ran a non-parametric correlation test 
(Spearman’s) and the independent variable was age. 
Table 4-5: Spearman's correlation of age & pre-UAE volumes 
Correlation with age 
Number of 
observations 
Rho P value 
Uterus volume pre UAE 133 -0.170 0.053 
Dominant fibroid volume pre-
UAE 
128 -0.162 0.067 
 
There was a weak negative correlation between age and volume of the uterus pre-UAE (rho 
= -0.170). There was also a weak negative correlation between age and volume of the 
dominant fibroid pre-UAE (rho = -0.162). This means that with age we expect on average a 
smaller fibroid uterus and a smaller dominant fibroid. When plotting the age of a woman 
undergoing UAE vs. the volume of the uterus pre-UAE and the volume of the dominant 
fibroid pre-UAE, it becomes obvious that the majority of patients are aged between 40-50 
years and have a dominant fibroid volume under 500cm3 and uterine volume under 
1000cm3. (fig 4-7, 4-8) 
 
Figure 4-6: Scatter chart of the volume of uterus pre-UAE in relation to age of the patient  
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Figure 4-7: Scatter chart showing the volume of the dominant fibroid pre-UAE & age of the patient at the 
time of UAE 
 
We tested the correlation between age and uterine shrinkage and found this to be weak 
(rho= 0.127) and statistically insignificant.  
 
When looking at age as a factor affecting shrinkage we found that women in the age group 
40-50 years seemed to have the least average shrinkage (response) to UAE. However, those 
above the age of 50 years had the best response to UAE. This may indicate a synergistic 
effect of menopause and UAE resulting in maximum shrinkage. (fig 4-9, 4-10). 
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Figure 4-8: Average uterine shrinkage (%) by age group 
 
 
Figure 4-9: Average dominant fibroid shrinkage (%) by age group 
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4.10.4 Location of the dominant fibroid: 
The majority of patients had dominant fibroids that were intramural in location (52.6%). 
This was followed by subserosal fibroids (31.6%) and then submucosal (6.8%). The total 
percentage of patients with dominant fibroids that are in contact with the uterine cavity 
(submucosal or intramural with submucosal element) were 11.3% of the sample. 
 
 
 
Figure 4-10: Dominant fibroid distribution by location 
 
To test if the dominant fibroid location is a significant factor that plays a role in its 
shrinkage we used a one–way Anova and post hoc test (Bonferroni) to look at the difference 
between shrinkage of the dominant fibroid according to different location groups. 
Table 4-6: Average dominant fibroid shrinkage according to location 
Location of fibroid N 
Shrinkage % 
Mean ±STD 
Submucosal 9 69.63  ±  20.5 
Intramural with submucosal element 6 62.29  ± 37.0 
Intramural 70 42.98  ±  24.5 
Subserosal 42 37.79  ± 27.7 
  
 
 We concluded that shrinkage of the dominant fibroid may be dependent on its location and 
two group differences reached statistical significance. The first was that submucosal 
im
55%
im/sm
5%
sm
7%
ss
33%
165 
 
 
 
dominant fibroids shrunk by an average of 26.6% more than intramural dominant fibroids (p 
< 0.05). The second was that submucosal dominant fibroids shrunk by an average of 31.8% 
more than subserosal fibroids (p < 0.05). This is probably due to the way expelled 
submucosal fibroid volume was calculated as zero & shrinkage as 100% in this study.  
 
Table 4-6 demonstrates that the most shrinkage was seen in dominant fibroids that are 
submucosal or have a submucosal element followed by intramural fibroids then subserosal 
fibroids. This suggests an inversely proportionate relationship between proximity of a 
fibroid to the endometrial cavity and fibroid shrinkage post UAE. 
 
Dominant fibroid shrinkage                    1 
 Distance from endometrial cavity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.10.5 Single & multi-fibroid uterus 
Women attend for UAE with a varying number of fibroids in their uterus. Some will have a 
single fibroid and some will have multiple. It is not yet known if these women will respond 
in a different manner to UAE. The uteri of women who presented with a single fibroid 
uterus shrunk on average by 44.1% compared to that of women with a multi-fibroid uterus 
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which shrunk on average by 35.6%. We compared these two groups using an independent t-
test and we found a significant difference (p < 0.05). (fig 4-12).  
 
 
Figure 4-11: Difference in mean uterine shrinkage (%) according to number of fibroid 
 
 
Figure 4-12: The difference in volume shrinkage of dominant fibroids in single fibroid uterus and a multi-
fibroid uterus (cm3)  
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4.10.6 Complications following UAE  
The complication rates after UAE were recorded at 6 months and at 18 months post UAE. 
However follow up data was not available for 2 patients and a further 2 patients had a 
repeat UAE procedure throughout the study time line. The second procedure was excluded 
from the study. This resulted in the total number of patients studied n=167. The timing of 
the MRI post-UAE was not an exclusion criteria. 
The analysis of this section was completed on 09/06/2016 (18 months from when the last 
patient underwent UAE on 31/12/2014). 
 
4.10.6.1 Six months follow up after UAE 
We looked at the re-intervention rates 6 months after UAE and divided them as follows: 
a- Hysterectomy  
2 patients (1.1%) required a hysterectomy in the first 6 months post UAE. These were both 
emergency hysterectomies. The first was performed at day 25 post procedure for severe 
abdominal pain and HMB. The second was performed at day 59 post procedure due to sepsis 
and the presences of a large necrotic mass in the uterus 
 
b- Myomectomy  
1 patient (0.59%) had a re-intervention with a myomectomy within the first 6 months 
following UAE 
 
c- Repeat UAE 
4 patients (2.3%) had a repeat UAE procedure within the first 6 months following UAE 
 
There were also 8 emergency admissions (4.7%) for post embolisation-like syndrome that 
were all treated conservatively. 
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Figure 4-13: Re-intervention rate at 6 months 
Figure 4-14: Re-intervention by procedures within 6 months (n=7) 
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4.10.6.2 Eighteen Months follow up after UAE 
a- Hysterectomy  
11 patients (6.5%) had a re-intervention with a hysterectomy in the first 18 months post 
UAE 
 
b- Myomectomy  
8 patients (4.7%) had a re-intervention with a myomectomy within the first 18 months 
following UAE 
 
c- Repeat UAE 
7 patients (4.1%) had a re-intervention with a repeat UAE procedure within the first 18 
months following UAE 
 
Emergency and elective admission within 18 months post UAE: 
 
13 patients (7.7%) required a procedure-related emergency admission within the immediate 
18 months post UAE.  The main cause of admission was pain. 
 
19 patients (11.3%) required a procedure-related elective admission to the gynaecology 
department post UAE within the immediate 18 months following UAE. The main reason for 
this was to undergo re-intervention.  
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Figure 4-15: Re-intervention rate at 18 months 
 
 
Figure 4-16: Re-intervention by procedures at 18 months (n=26) 
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4.10.6.3 Comparing 6 to 18 months re-intervention 
There was an overall increase in all re-intervention rates at 18 months. The highest rate of 
intervention was in the form of a hysterectomy.  (fig 4-17) 
 
 
Figure 4-17: Line chart of re-intervention rates 
 
 
4.10.7 Pregnancy within the 18 months of procedure: 
There were a total of 4 pregnancies post-UAE in this study group and conclusions regarding 
the effect of UAE on future fertility cannot be drawn from this.  
Table 4-7: Pregnancy outcomes at 18 months post UAE 
Age at 
UAE 
Duration post- UAE 
until pregnancy 
Outcome of pregnancies 
30 487 days Termination of pregnancy (Social reasons) 
36 258 days Miscarriage requiring medical evacuation 
of retained products of conception 
36 53 days Delivered by elective caesarean section at 
38 weeks 
31 231 days Delivered by elective caesarean section at 
37 weeks  
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4.11 Discussion 
In most fibroid studies that looked at change in fibroid size, the dominant fibroid 
measurement was taken into account rather than all fibroids. When this study was started 
the intention was to measure the volume of all fibroids with any one diameter over 3cm 
and analyse the changes after UAE. This method was abandoned as it was felt that a fibroid 
would then be used as an entity devoid of the woman suffering from the symptoms it 
causes. It also proved time consuming and difficult to gain re-producible data. 
After UAE both the uterine volume and dominate fibroid volume significantly reduced in 
size. Only 5.2% of patients did not have uterine shrinkage and 5.4% did not have dominant 
fibroid shrinkage. Most interventional radiology units only offer UAE as a treatment for 
HMB. However, the high success rate of UAE and the percentage of both uterine volume 
shrinkage and dominant fibroid shrinkage suggest that pressure symptoms caused by a space 
occupying lesion may also improve. It maybe that a change of practice should be introduced 
and UAE should also target women that present predominantly with pressure symptoms and 
offer them an alternative to major surgery.  
Patients present to interventional radiology clinics with different uterine and fibroid sizes. 
It is often perceived by the gynaecologist and even the patient that a large fibroid uterus 
will not respond to UAE. Although there is no clear consensus of what constitutes a large 
fibroid uterus or a large fibroid. We used the literature cut off of volume ≥ 780cm3 to 
classify a uterus as a large uterus a cut off ≥ 700 cm3 to classify a fibroid as large. We found 
that small dominant fibroids < 700ml did indeed shrink significantly more than large fibroids 
(p < 0.05). However we could not find a similar effect when comparing women presenting 
with large uterine volumes to those with small uterine volumes.  
Women around the age of 45y represented the highest percentage of those undergoing UAE. 
This relatively late presentation when undergoing UAE may be due to some women seeking 
conservative and non-invasive treatment options prior to UAE. Some woman may feel that 
UAE is a form of surgery and better postponed until other treatment options have been 
exhausted. There may be an underlying feeling that if UAE fails then major surgery such as 
myomectomy or hysterectomy are the only alternative options left to pursue. We found 
that older women presented on average with a smaller fibroid uterus size and smaller 
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dominant fibroid. Clinically, this may mean that woman nearer the age of menopause have 
already started the process of fibroid shrinkage that we expect in post-menopausal women. 
We found that women aged 50 years and over had the best response to UAE both from 
uterine volume shrinkage and dominant fibroid shrinkage. This may indicate a synergistic 
effect of menopause and UAE resulting in maximum shrinkage. We conclude from this that 
women closer to the age of menopause should not be denied UAE based on age as they 
seem to be the best responders especially if pressure effect is one of the main symptoms at 
presentation.  
One of the variable aspects of fibroids response to UAE that has not been studied well is the 
location of the fibroids pre-UAE. The majority of the patients in this cohort presented with 
an intramural dominant fibroid (55%). We found statistically significant difference in 
uterine shrinkage between submucosal and intramural fibroids and also between 
submucosal and subserosal fibroids. This suggests an inversely proportionate relationship 
between proximity of a fibroid to the endometrial cavity and fibroid shrinkage post UAE. 
We concluded that fibroids closer to the endometrial cavity (submucosal) tend to shrink 
more than fibroids further away from the endometrial cavity (subserosal). This is however 
in keeping with the fact that woman with submucosal fibroids are at higher risk of expulsion 
of fibroids after UAE which in this study we deemed as 100% shrinkage [276]. Appropriate 
counselling of such a complication is warranted in women with submucosal fibroids 
embarking on UAE as a treatment modality. 
We also found that patients presenting with a single fibroid uterus responded better than 
those presenting with a multi-fibroid uterus. This was true for both uterine volume 
shrinkage and dominant fibroid shrinkage. 
The complications and re-intervention rates were looked at for both 6 months and 18 
months post UAE. Most studies have not looked at long term outcomes and not followed up 
patients for more than 6 months. Data was obtained from the Information Services Division 
for Scotland (ISD) and this was cross-referenced with hospital notes looking at elective and 
emergency admissions and new clinic referrals post UAE. We found an increase in all re-
interventions at 18 months follow-up. When comparing complications rates at 18 months to 
those at 6 months, hysterectomy increased from 1.1% to 6.5%, myomectomy increased from 
0.59% to 4.7% and repeat UAE increased from 2.3% to 4.1%. This amounts to a total re-
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intervention rate of 4.1% at 6 months and 15.3% at 18 months. This rate is predicted to rise 
when further follow up data becomes available [148].   
UAE is a safe procedure and the complication rates are low especially serious complications 
such as a need for emergency hysterectomy [265]. This was found to be 1.1% (2 patients) in 
our study. The reduction in volume (shrinkage effect) of both the fibroid uterus and the 
fibroid itself is significant. However, there has been no specific study looking at the effect 
of UAE on pressure symptoms mainly because UAE was established as a treatment for HMB 
and any alleviation of pressure symptoms is considered to be an additional benefit rather 
than a desired consequence.  
The safety aspect of UAE with regard to post procedure pregnancy is still a matter of 
debate and we are eagerly awaiting the results of the FEMME trial that is the first study of 
UAE that did not exclude women wanting to maintain their fertility. In our study 4 women 
became pregnant post-UAE and 2 of these women delivered a live baby by elective 
caesarean section at term.  
The main limitation of this study was that it was a retrospective study and that it relied 
heavily on MRI scans that were performed for pre-UAE assessment rather than within a 
study context. This resulted in a number of post-UAE MRI scans not being performed within 
the time limits set by this study and a 6 months +/- 6 weeks approach was necessary to 
obtain valid comparisons and increase the cohort of the study. Post UAE MRI timing was fed 
back to the radiology department and improvements were recommended. This limitation 
led to the exclusion of 38 patients whom had pre or post UAE outside the time limits set by 
this study. We aim to continue following the patients in our study for a total of 5 years.  
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5. Chapter 5 
Diffusion Weighted Magnetic Resonance Imaging (DWMRI) 
and its role in UAE   
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5.1 Diffusion-weighted Magnetic resonance Imaging (DWI) 
Diffusion-weighted imaging (DWI) is a non-contrast enhanced functional MRI technique 
available in the majority of clinical MRI units. It can provide information on the motion of 
water molecules in tissues. It permits the quantitative evaluation of tumour tissue such as 
fibroids. This is through a quantitative parameter, called apparent diffusion coefficient 
(ADC). The ADC maps that are generated using DWI provide accurate quantification of the 
cellular motion of water molecules[292]. This movement is dependent on the cellularity of 
the tissue/lesion allowing tissue characterisation, and possibly reflecting cell death [293]. A 
simplistic, though conveniently useful concept is that ADC values are inversely related to 
tumour cellularity. That is, tissues having relatively high cell density tend to exhibit lower 
ADC values due to the impeded water movement amongst the cell-packed environment. 
Treatment which leads to cell necrosis such as UAE will therefore alter cell membrane 
permeability and water homeostasis, leading to changes in tumour cell density and changes 
to ADC [294]. The changes in DWI signal and ADC results can only be hypothesized, as there 
is no gold-standard procedure which measures water movement between cells. The 
underlying physical phenomena which contribute to loss of signal on diffusion- weighted 
images remain incompletely understood. 
Benign pathological processes such as uterine fibroids may alter cellular structure and 
membranous permeability, with ultimate shifting of water molecules between tissue 
compartments [295].  ADC measurements of tissues or lesions may serve as a clinical follow-
up tool after medical or locoregional therapy such as UAE [296]. 
A small number of studies have attempted to predict the volumetric response of fibroids 
following UAE using DWI MRI. Liapi et al [297] looked a 32 fibroids in 11 patients and 
concluded that ADC maps obtained from DWI MRI may serve as an imaging tool for assessing 
treatment response after UAE. Hecth et al [298] replicated this by retrospectively looking 
at 28 leiomyomas in 11 women who underwent UAE. These women had a pre-UAE MRI and a 
follow up MRI > 120 days post procedure. They found Pre-UAE ADC values correlated 
significantly with percent volume response following UAE. On the other hand a further 
study of 17 women ( 27 fibroids) found that DWI MRI and ADC reflected early and delayed 
changes in fibroids after UAE but they were not able to significantly demonstrate a 
relationship with the outcome [299].  
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5.2 Diffusion weighted MRI technique and image analysis: 
Stejskal and Tanner first described spin echoes in the presence of a time dependent 
magnetic field gradient in 1965 [300]. This was later the basis of developing DWMRI. It 
involves a modified spin-echo T2 MRI sequence, to which a symmetrical pair of diffusion 
sensitising gradients is applied around the 180 degree refocusing pulse. Static molecules 
obtain phase information from the first diffusion gradient, but this information is then re-
phased by the second gradient without a change in the measured signal intensity. Mobile 
water molecules acquire different phase information from the first gradient, but, because 
of their motion, their signal will not be completely re-phased by the second gradient, 
leading to a signal loss. Hence, the motion of water molecules is detected as attenuation of 
the measured signal intensity on DWI. The sensitivity of the DWI sequence to the movement 
of water molecules can vary by changing the gradient amplitude, the duration of the 
applied gradient and the time interval between the paired gradients. Collectively this can 
change the diffusion sensitivity and is known as the b-value.  This is directly proportional to 
the three factors listed above [243]. To quantitatively characterise the DWI images, they 
are acquired with at least two different b-values. Usually b= zero and a larger b value (250, 
500, 1000). The higher the b-value the more accurate the ADC value is to detect water 
motion at the expense of image clarity leading to image distortion (fig 5-2). The slope of a 
logarithmic plot between the b-values on the x-axis and the relative signal intensity on the 
y-axis gives us the apparent diffusion coefficient (ADC) value in units of s/mm2 (fig 5-1). 
 
Figure 5-1: ADC Value calculation (slope of log between b-value and signal intensity 
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DWI is a well-established technique in cerebral imaging [301]. However, its application to 
imaging of other parts of the body is new. It is now being used as a part of the imaging 
protocols for pelvic malignancies and fibroids [302]. The aim of this study was to assess 
whether using DWI offered any additional information over a standard MRI pelvis when 
imaging uterine fibroids. We wanted to assess if the ADC value can be used as a predictor of 
the response of the fibroid uterus to UAE and if it could improve the safety profile of UAE.  
 
 
 
 
 
.  
Figure 5-2 Differences between a normal MRI (upper left) and a DWMRI at b=250 (upper 
right), b=500 (lower left) and b=1000 (lower right) 
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5.3 Uterine artery Embolisation procedure: 
UAE was carried out by one of three experienced interventional radiologists using a 
standard technique. This involved a right common femoral artery puncture and each uterine 
artery selected with a 2.7 French co-axial catheter (Progreat, Terumo UK Ltd, Surrey, UK.) 
and embolisation carried out on each side to complete stasis. The embolisation agent used 
was either Spongostan or embosphere. 
Spongostan Absorbable Haemostatic Gelatin Sponge (Ethicon Medical Ltd. Livingston, 
Scotland) was manually cut into approximately 1mm squares and mixed with iodinated 
contrast (Omnipaque 300) to form a ‘slurry’ using a 5-10cc reservoir syringe and a 1-2cc 
delivery syringe connected via a three way tap. The residual sponge was weighed to 
quantify the amount used. Embospheres (Merit Medical Ltd, Coatbridge, Scotland) were 
used according to the manufacturer instruction for use namely mixed with an equal volume 
of contrast and the first two ampoules on each size being size 500-700 microns and if more 
was needed then the particle size was increased to 700-900 microns. Pain was managed 
using an agreed hospital protocol (appendix 4).  
The standard imaging protocol was as follows: T2 weighted Fast Recovery Fast Spin Echo 
(FRFSE) images acquired in the sagittal and coronal planes (TR 4960ms, TE 85ms, FOV 
240mm, 256 x 384 matrix, slice thickness 4mm, echo train length 16). Sagittal T1 weighted 
Liver Acquisition and Volume Acquisition (LAVA) images were acquired before and after 
injection of gadolinium contrast agent (Gadovist, Bayer plc, Berkshire, UK). LAVA is a 3D 
spoiled gradient echo sequence and the following imaging parameters were applied: TR 
4.72ms, TE 2.32ms, FOV 280mm, matrix (frequency x phase) 320 x 192, slice thickness 
5mm. 
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5.4 Methods 
A pilot study was conducted in one large tertiary referral hospital in the UK. The aim was to 
compare two embolic agents (Gelfoam and Embosphere) used in UAE. 20 Patients were 
randomised between March 2011 and January 2012 to receive either embolic agent and 6 
month follow up was complete in August 2012.  
The study was approved by the regional ethics committee. All patients were provided with 
a written information sheet at least 24 hours in advance of being consented. Patients were 
initially seen at an Interventional radiology clinic and a 1 month and a 6 months follow up 
took place at the same clinic. Each patient underwent a Pre-UAE, 24 hour post UAE and a 6 
months Post UAE DWMRI. The study was funded by a research grant from the British Society 
of Interventional Radiology. Data in this chapter relates only to the DWI imaging of all 20 
patients in this study. Although direct comparison between the two groups was made in 
relation to uterine volume and dominant fibroid shrinkage, this was not the case for DWI 
analysis. It was felt that comparing baseline DWI MRI to post procedure MRI of the whole 
group would help answer the questions set out earlier in this chapter.  
5.5 Study Population: 
Women at least 18 years old were eligible if they had one or more fibroids of more than 
2cm diameter causing HMB as the main symtpom. Exclusion criteria included a 
contraindication to contrast enhanced magnetic resonance imaging (CEMRI), recent or 
ongoing pelvic infection, severe allergy to iodinated contrast media and the presence of 
significant other pelvic pathology e.g. adenomyosis. 
5.6 Image analysis  
All analysis was carried out on a GE workstation (ADW 4.0; GE Healthcare). Only the 
dominant fibroid was evaluated in each patient. The following variables were assessed pre-
UAE, 24 hours post UAE and 6 months post-UAE: uterine volume, dominant fibroid volume, 
endometrial thickness, ADC measurement of dominant fibroid, myometrium and when 
possible for the endometrium. 
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5.6.1 Analysis of diffusion-weighted images 
A GE MRI workstation at the Beatson West of Scotland Cancer Centre in Glasgow was used. 
Images for each patient were loaded from the MRI central server onto the GE workstation. 
The b=0, b=250, b=500 and b=1000 diffusion images were analysed using FuncTool v. 4.4.05 
software (GE Healthcare) on the GE workstation and used to generate a corresponding ADC 
map (fig 5-4 & 5-5). To calculate the ADC value, a circular region of interest (ROI) was 
drawn encompassing the dominant fibroid, but taking care to avoid the myometrium (to 
avoid any partial volume averaging), and an ADC value was calculated. From the same data 
set, ADC values were also calculated for the myometrium and when possible for the 
endometrium. The ROI for this was used at the same location of the uterus on the pre- and 
post-embolisation scans. The ROI for the fibroid and myometrium varied between 10mm2 
and 30mm2, depending on fibroid size and the myometrial thickness. The ROI for the 
endometrium varied between 2mm2 and 4mm2, depending on the endometrial thickness (fig 
5-3).  
5.6.1 Volume measurements 
The dimensions of the fibroids were measured along the anteroposterior (AP), craniocaudal 
(CC) and the transverse long axis (TR). The volume of the dominant fibroid was calculated 
using a standard prolate ellipse formula (AP x CC x TR x 0.5233) [177]. This same method 
was used to calculate the volume of the uterus incorporating the fibroid/fibroids (section 
2.5). 
 
 
 
 
 
182 
 
 
 
 
 
  
Figure 5-3 Calculation of ADC value by selecting a region of interest (ROI). Fibroid 
(upper left), Myometrium (upper right) and endometrium (lower left) 
183 
 
 
 
 
  
Figure 5-4  Functool software window showing DWI view, ADC curve & ADC 
colour map 
Figure 5-5 DWMRI and ADC colour map to assist in finding ROI 
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5.7 Statistics 
Paired t-test and Mann Whitney test were used to assess changes in paired samples. 
Pearson’s correlation was used to assess the relationship between groups of data. Minitab 
17 statistical software package was used to for analysis and drawing graphs. Some graphs 
were drawn using Microsoft excel. 
5.8 Results 
As both the change in uterine volume and dominant fibroid volume post-UAE were 
significant (p < 0.05), the results of ADC analysis were grouped as pre & post-UAE ADC 
values rather than basing them on the embolic agent used (n=20). 
Table 5-1: summary of statistics 
The Character N= 20 
Age 
Range 32-53 
44.5 ± 5.64 
Pre-UAE Uterine Volume 932mm3 ± 669mm3 
6 months Post UAE Uterine Volume  656mm3 ± 547 mm3 
Uterine volume shrinkage (all) 
N=20 
219.6 mm3 ± 305.8 mm3 
Uterine Volume shrinkage ( only those 
that shrunk) 
N= 16 
315.9 mm3 ± 253.9 mm3 
Location of largest fibroid 
Submucosal 
Subserosal 
Intramural 
 
n= 2 
n= 5 
n= 13 
Number of fibroids for each patient 
Single 
Two 
(multiple) >2 
 
N= 7 
N= 2 
N= 11 
Pre-UAE volume of dominant fibroid 441 mm3 ± 494 mm3 
6 months post UAE volume of dominant 314 mm3 ± 406 mm3 
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fibroid 
Dominant fibroid shrinkage (all) 216.9 mm3 ± 245.7 mm3  
Dominant fibroid shrinkage 
(only fibroids that shrunk) 
232.1 mm3 ± 242.5 mm3 
Single fibroid uterus shrinkage 231 mm3 ± 168.2 mm3  
Multiple fibroid uterus shrinkage 93.6 mm3 ± 122.5 mm3 
 
5.9 Uterine volume and dominant fibroid volume: 
This randomized trial comparing Gelfoam with Embospheres was intentionally designed as a 
pilot study to compare the outcome of using these two embolic agents. There was 
insufficient data in the literature on which to base a power calculation for a definitive 
study. The only significant difference found between the two groups was in the reduction of 
uterine volume at 6 months post UAE which amounted to 281cm2 in favour of Embospheres 
(p<0.01). When combining both groups together there was a significant reduction in both 
uterine volume and dominant fibroid 6 months post-UAE compared to baseline (table 5-2). 
Table 5-2: Change in uterine volume and dominant fibroid volume  
 
 Mean Pre-UAE 
cm3 
Mean Post-UAE 
cm3 
Average 
shrinkage 
P 
Uterus volume 907.84 688.27 24.2% < 0.05 
Dominant fibroid 
volume 
462.47 330.04 29.1% < 0.05 
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5.10 The dominant fibroid  
5.10.1.1 Change in ADC value 
We found a significant reduction in ADC values of the dominant fibroids between baseline 
(pre-UAE) and 6 months post-UAE for each level of (B) sensitivity. This indicates that this 
method can detect the changes that occur in the dominant fibroid. These measurements 
are objective and reproducible. 
Table 5-3: Pre & Post-UAE ADC values at different levels of sensitivity 
Sensitivity 
b= 
Pre-UAE 
Mean ± stand dev 
6m Post-UAE 
Mean ± stand dev 
p-value 
250 0.001674 ±  0.000356   0.001425 ± 0.000504   < 0.01 
500 0.001372 ± 0.000393   0.001106 ± 0.000469   < 0.01 
1000 0.000940 ± 0.000335   0.000716 ± 0.000450   < 0.05 
 
 
 
Figure 5-6: The change in Pre-UAE & Post-UAE ADC values at different levels of sensitivity 
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5.10.1.2 ADC value pre & post UAE 
We tested the correlation between pre-UAE ADC values and Post-UAE ADC values of the 
dominant fibroid. We found a moderately positive and statistically significant correlation at 
all levels of sensitivity (Table 5-4 & fig 5-7). This indicates that knowing the ADC value of 
the dominant fibroid pre-UAE may predict the ADC value of that fibroid post-UAE. Clinically 
this may be used as a predictor of the response to UAE. It could also alleviate the need for 
contrast material in those patients with a sensitivity/contraindication to contrast. As the 
change in ADC values can be used as an objective measurement of fibroid necrosis (death) 
rather than the subjective change in contrast uptake that is widely used. 
 
Table 5-4: Pearson's correlation between pre-UAE & post UAE ADC values of the dominant fibroid (* ρ is 
Pearson’s correlation coefficient value) 
 
Level of 
sensitivity (b=)  
Pearson’s Correlation between pre-UAE ADC 
and post-UAE ADC & p value 
P value 
250 *ρ = 0.55   0.01 
500 ρ = 0.71 < 0.001 
100 ρ = 0.68  0.001 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7: Linear regression showing the correlation between pre & post UAE ADC values of the 
dominant fibroid 
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5.10.1.3 Dominant fibroid volume reduction 
Using Pearson’s correlation, we found a statistically significant correlation between 
dominant fibroid volume reduction and both pre-UAE and post-UAE ADC values, for all 
levels of sensitivity.  However, the relationship was much stronger between dominant 
fibroid volume reduction and pre-UAE ADC values. This points further to the possibility of 
predicting how much the dominant fibroid would shrink based on its ADC value. 
Table 5-5: Correlation of pre/post UAE ADC and dominant fibroid volume reduction at different levels of 
sensitivity  
 ADC 
Sensitivity                
(b=) 
Correaltion of Dominant 
fibroid volume reduction 
with Pre-UAE ADC 
Correaltion of Dominant 
fibroid volume reduction 
with Post-UAE ADC 
250 ρ = 0.736, p < 0.001 ρ = 0.44,  p = 0.05 
500 ρ = 0.713, p < 0.001 ρ = 0.51,  p = 0.02 
1000 ρ = 0.722, p < 0.001 ρ = 0.4,    p = 0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-8: Linear regression showing the relationship between pre-UAE ADC values of the dominant 
fibroid at b=250 and the dominant fibroid volume reduction  
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Figure 5-9: Linear regression showing the relationship between pre-UAE ADC values of the dominant 
fibroid at b=500 and the dominant fibroid volume reduction 
 
 
Figure 5-10: Linear regression showing the relationship between pre-UAE ADC values of the dominant 
fibroid at b=1000 and the dominant fibroid volume reduction 
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5.10.1.4 Dominant fibroid shrinkage 
Using Pearson’s correlation, we found a weak correlation between dominant fibroid 
shrinkage and pre/post UAE ADC values, for all levels of sensitivity.  However, these did not 
reach statistical significance.  
Table 5-6: Correlation of pre/post UAE ADC value and dominant fibroid shrinkage at different levels of 
sensitivity 
ADC Sensitivity 
b= 
Correaltion of Dominant 
fibroid shrinkage with Pre-
UAE ADC 
Correaltion of Dominant 
fibroid shrinkage with 
Post-UAE ADC 
250 ρ = 0.17   p = 0.46 ρ = 0.22  p = 0.33 
500 ρ = 0.29   p = 0.2 ρ = 0.29  p = 0.21 
1000 ρ = 0.18   p = 0.44 ρ = 0.22  p = 0.34 
 
We conclude from this that both Pre-UAE ADC values and post-UAE ADC values of the 
dominant fibroid positively correlate with dominant fibroid volume reduction at all 
sensitivities. These are absolute values of volume derived by deducting the post-UAE fibroid 
volume from the pre-UAE fibroid volume.  
When this volume reduction was changed into a percentage using shrinkage as a response, 
we could not find any correlation with either the pre or post UAE ADC values for all levels 
of sensitivity.  
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5.11 The fibroid uterus 
Similar analysis was performed looking at the relationship between the ADC of the 
dominant fibroid and the volume of the uterus and its response to UAE. 
5.11.1 Uterine volume reduction 
It is not possible to calculate the ADC value of the fibroid uterus as it is composed of 
different layers and sometimes multiple fibroids. We therefore looked at the correlation 
between the ADC value of the dominant fibroid and the change in the uterine size. We 
found no statistically significant relationship between the uterine volume reduction and the 
pre/post UAE ADC value of the dominant fibroid at all levels of sensitivity (table 5-7 & fig 5-
11). 
Table 5-7: Correlation between fibroid uterus volume reduction and pre/post UAE ADC of the dominant 
fibroid at different levels of sensitivity 
 
ADC 
Sensitivity b= 
Correlation between 
uterine volume reduction 
& Pre-UAE ADC of 
dominant fibroid 
Correlation between 
uterine volume reduction 
& Post-UAE ADC of 
dominant fibroid 
250 ρ = 0.19  p= 0.4 ρ =0.023  p= 0.9 
500 ρ = 0.38  p= 0.09 ρ =0.076  p= 0.74 
1000 ρ = 0.45  p= 0.78 ρ =0.065  p= 0.78 
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Figure 5-11 Line plot showing no correlation between uterine volume reduction and Pre-UAE ADC of the 
dominant fibroid at b=1000 
 
 
5.11.1  Uterine shrinkage 
We looked at the correlation between uterine shrinkage and the Pre-UAE dominant fibroid 
ADC value and found no statistically significant relationship at all levels of sensitivity (table 
5-8 & fig 5-12).  
Table 5-8: Correlation between uterine shrinkage and pre/post UAE ADC of the dominant fibroid at 
different levels of sensitivity 
 ADC 
Sensitivity  
b= 
Correlation between uterine 
shrinkage and Pre-UAE ADC of 
dominant fibroid  
Correlation between uterine 
shrinkage and Post-UAE ADC of 
dominant fibroid 
250 ρ = -0.21  p = 0.36 ρ = -0.33  p = 0.15 
500 ρ = -0.1    p = 0.67 ρ = -0.22  p = 0.34 
1000 ρ = 0.01    p = 0.96 ρ = -0.2    p= 0.39 
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We therefore conclude that the pre-UAE ADC value of the dominant fibroid explains much 
more of the variability in dominant fibroid volume reduction than it does for dominant 
fibroid shrinkage, uterine volume reduction and uterine volume shrinkage. This result is 
probably because we are only assessing the largest fibroid rather than all fibroids in a 
multi-fibroid uterus.  
 
 
 
5.12 The Uterine components (Myometrium and Endometrium): 
In this study a DWMRI was performed at Pre-UAE, 1 day post UAE and 6 months post UAE. 
This gives a unique insight into the changes that may occur at the level of the myometrium 
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Figure 5-12 Line plot showing no correlation between pre-UAE ADC value of dominant 
fibroid and uterine shrinkage 
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and the endometrium immediately after UAE. By calculating the ADC value of these layers 
at the three different time intervals above, we attempted to detect when the cellular 
damage occurs. Assessing the changes to both the myometrium and the endometrium will 
aid in assessing UAE safety especially in those women that would like to keep their fertility. 
The ADC calculations in this section were performed at the highest level of sensitivity for 
this study (b=1000).  
5.12.1 The Myometrium: 
The ADC value of the myometrium was calculated by selecting a sufficient ROI that was 
separate from the endometrium or an existing fibroid. The same area was selected again on 
day 1 post-UAE DWMRI images and 6 months post-UAE DWMRI images. The ADC value was 
calculated at the highest sensitivity (b=1000).  
5.12.1.1 Difference in ADC value of the myometrium between pre-UAE and day 1 
We calculated the ADC value of the myometrium pre-UAE and day one post UAE in 11 
patients (55% of the cohort). In nine patients we were unable to obtain both pre-UAE & one 
day post-UAE ADC values.  As the distribution was non-parametric but paired we used 
Wilcoxon signed-rank test and found the difference was non-significant (table 5-9). 
Table 5-9: The difference in myometrial ADC values pre and 1 day post UAE 
 Myometrium ADC 
pre-UAE (n= 11) 
Myometrium ADC  
day 1 post-UAE 
(n=11) 
P value  
Median 0.0093 0.00104 > 0.05 
5.12.1.2 Difference in ADC value of the myometrium between pre-UAE and 6 
months post UAE 
Paired ADC values were calculated in 15 patients (75% of the cohort).  In five patients we 
were unable to obtain both pre-UAE & 6 months post-UAE ADC values. We used a Wilcoxon 
signed-rank test and found the difference was non-significant (table 5-10). 
Table 5-10: The difference in myometrial ADC values pre and 6 months post UAE 
 Myometrium ADC 
pre-UAE (n= 15) 
Myometrium ADC 
6 months post-UAE 
P value (95% 
CI) 
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(n=15) 
Median 0.00107 0.00132 >0.05 
 
 
The above results indicate that the ADC value of the myometrium is neither changed 24 
hours post UAE nor at 6 months post UAE compared to the pre-UAE values. As the ADC value 
reflects the integrity of the cell membrane, therefore, no significant change to its value 
signifies no myometrial damage secondary to UAE. We conclude that despite the main blood 
supply of the uterus is blocked with UAE, the myometrium is not affected.  
5.12.1 The Endometrium: 
The ADC value of the endometrium was calculated by selecting a ROI on the endometrium 
on a DWMRI images with the widest section of endometrium. Care was taken not to include 
any myometrium or existing fibroid tissue. This was achieved by magnifying the 
endometrium to x 5 magnification. At the same time, the endometrial thickness was 
measured in mm. The measurements were performed on the pre-UAE DWMRI and repeated 
on the day 1 post-UAE DWMRI images and the 6 months post-UAE DWMRI images. The ADC 
value was calculated at the highest diffusion sensitivity (b=1000).  
5.12.1.1 Difference in ADC value of the endometrium between pre-UAE and  day 1 
post UAE 
Paired ADC values were obtained in 10 patients (50% of the cohort). A Wilcoxon Signed Rank 
test was performed. The difference in ADC values before UAE and at day 1 post UAE was 
not significant (table 5-11). This suggests no disruption to endometrial cellular membrane 
integrity in the immediate period after UAE. 
Table 5-11: The difference in endometrial ADC values pre and 1 day post UAE 
 Endometrium ADC 
pre-UAE (n= 10) 
Endometrium ADC 
day 1 post-UAE 
(n=10) 
P value (95% 
CI) 
Median 0.00114 0.00142 P >0.05 
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5.12.1.2 Difference in ADC value of the endometrium between pre-UAE and 6 
months post UAE 
Paired ADC values were calculated in 14 patients (70% of the cohort). A Wilcoxon Signed 
Rank test was performed which showed no significant difference in ADC value of the 
endometrium pre-UAE and 6 months post UAE (table 5-12).  
Table 5-12: The difference in endometrial ADC values pre and 6 months post UAE 
 Endometrium ADC 
pre-UAE (n= 14) 
Endometrium ADC 
6 months post-UAE 
(n=14) 
P value (95% 
CI) 
Median 0.0011 0.0013 P > 0.05 
 
This above analysis suggests no change to cellular integrity at 24 hours & 6 months post UAE 
compared to pre-UAE ADC values. This suggests that the cellular structure of the 
endometrium remains intact post UAE. 
 
5.12.1.3 Endometrial thickness: 
We could not control for when the 6 months post UAE MRI was performed in relation to the 
menstrual cycle. Despite this we felt that comparing the endometrial thickness post-UAE 
with the pre-UAE thickness is of value. We did not feel that a 24 hour comparison was 
meaningful and only compared pre-UAE to 6 months post UAE. The mean endometrial 
thickness post UAE was 4.46mm. This is encouraging as not only was the endometrium 
measurable but it was of similar value to the pre-UAE mean 4.36mm. We were able to 
calculate the difference in endometrial thickness in 18 patients (90% of the group). As the 
endometrial thickness was normally distributed we used a paired t-test and found no 
significant difference in the endometrial thickness between pre and 6 months post-UAE 
(table 5-13 & fig 5-13).  
Table 5-13: Paired t-test showing the change in endometrial thickness 
 Endometrium 
Thickness (mm)  pre-
Endometrium Thickness 
(mm) 6 months post- P value  
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UAE ± STD  (n= 18) UAE ± STD (n=18) 
Mean 4.36 ± 1.9 4.46 ± 2.2 >0.05 
 
 
 
Figure 5-13: The mean endometrial thickness pre and post UAE 
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5.13 Discussion: 
Diffusion weighted MRI is a relatively new clinical method of assessing uterine fibroids. It 
has been shown to aid in to distinguishing between a benign fibroid (leiomyoma) and a 
smooth muscle tumour of the uterus (leiomyosarcomas). This can be achieved by 
calculating the ADC value of uterine tumours and comparing it to a reference range [95]. 
Although further studies are needed to further validate this.  
Fibroids are composed of densely packed smooth muscle cells with varying amount of 
intervening collagen. Prior to embolisation, these clusters of cells with intact cell 
membranes result in a restricted pattern of diffusion of water between the cells. Following 
UAE there is infarction of the fibroid and loss of the cellular architecture. This can be 
quantified by measuring the ADC value on MRI images with diffusion weighted sequences.  
In this study, our aim was to assess the relationship between the ADC value of a fibroid and 
its likelihood to respond to uterine artery embolisation. Through DWMRI and ADC 
measurement we also looked at the changes that occur in the different layers of the uterus 
in response to UAE.  
This study was a prospective pilot study and benefited from a strict imaging protocol that 
was replicated for each patient. It did however suffer from a lack of power to detect true 
correlations between pairs of variables. However, it does pave the way for further research 
in the field of DWMRI especially in gynaecology. The study benefited from the use of a 3 
Tesla (3T) MRI machine that is able to produce high resolution images. However, this 
machine was not capable of taking Diffusion weighted images at the same time as standard 
T1 & T2 weighted images. This resulted in minor movement artefacts that resulted in the 
inability of measuring ADC in a few of the subjects. Newer machines can compensate for 
this. Future software may be able to show the ADC map on top of the T1 & T2 weighted 
images (overlap) rather than in separate windows.  
The aim of this study was to assess the changes in ADC value of the different components of 
the fibroid uterus and how this value changed after UAE. We wanted to compare the ADC 
value at baseline of the dominant fibroid, the myometrium and the endometrium to the 
value 24 hours post-UAE and 6 months post-UAE. As ADC values can reflect cellular damage, 
we intended to evaluate if the uterine components other than the target fibroid are 
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altered. A secondary aim was to assess if ADC could predict uterine fibroid shrinkage. This 
would then be used to predict the outcome of UAE prior to the intended procedure.  
We found a significant reduction in the ADC value of the dominant fibroid between baseline 
(pre-UAE) and 6 months post embolisation at each level of sensitivity in this study. This 
reduction in ADC value suggests that cellular integrity is disrupted, causing cellular 
dehydration and cell death. This is evident in lack of contrast enhancement of fibroids that 
clinicians class as a “dead” fibroid and is used as a marker of success of UAE. Such marker 
can be clearly seen on a post UAE contrast enhanced MRI. Due to my late involvement in 
this study, I was unable to influence the imaging protocols as the DWMRI was performed in 
a transverse (coronal) plane which made it more difficult to obtain ADC values than if the 
sequences were obtained in a sagittal plane. This has been fed back to the respective MRI 
departments and a change of MRI protocol is being discussed for future research. 
A moderately positive and statistically significant correlation was found between baseline 
ADC of the dominant fibroid (pre-UAE) and the volume reduction of that fibroid 6 months 
after UAE. This correlation was significant for each level of sensitivity (b= 250, 500, 1000). 
This suggests that knowing the ADC value of the dominant fibroid prior to UAE may be an 
indicator of how much loss in volume will occur post UAE. This may be individualised for 
each specific fibroid and is probably why no correlation was found when % shrinkage was 
used that doesn’t take into account the volume of the fibroid. We were unable to find a 
significant correlation between the dominant fibroid and either the uterine volume 
reduction or uterine shrinkage post UAE. This may because a fibroid uterus does not 
necessarily have only one fibroid. 
The aim of uterine artery embolisation is to treat fibroids and fibroid related symptoms. A 
successful UAE procedure is one that achieves this goal with no damage to surrounding 
uterine tissue (myometrium and endometrium). The ADC calculations for the myometrium 
and endometrium were based only on b = 1000 values as it was felt that there may be 
perfusion-related discrepancies in images acquired at lower b-values. The signal-to-noise 
ratio in the b = 1000 images were adequate for ADC calculation. However, it was not 
possible to measure the required ADC values for all the twenty study participants at this 
level of sensitivity due to image degradation. This will continue to be a challenge until 
image overlapping software is developed and DWMRI can be captured at the same time as 
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routine sequences. The later has become a reality but is only available in specialised 
centres.  
It was not possible to measure the ADC value of the myometrium in each participant in this 
study due to difficulty in locating an area of myometrium that would not overlap with an 
area of fibroid tissue or endometrium.  We compared pre-UAE myometrial ADC with Day 1 
post UAE Myometrial ADC and found no significant difference. This indicates that 
myometrial cells may have regenerated after damage within the first 24 with acute pain 
being an indicator of damage. The other more likely explanation is that no damage 
occurred to the myometrial cells due to collateral supply and therefore the ADC value was 
unchanged. We arrived at a similar result that no difference was found when we compared 
the 6 months post UAE myometrial ADC value to that of pre-UAE. A previous study had 
unexpectedly found that the mean ADC value of the myometrium following embolisation 
was slightly reduced after UAE. The author suggests that it may have represented a 
technical problem rather than reflected a degree of myometrial damage [303]. However, 
another study looking at the perfusion of myometrium after UAE found a similar result to 
our study with no change in myometrial ADC. It too suggested that this was likely due to the 
development of collateral circulation supplying the myometrium [241].   
The endometrium is vital for reproduction and the effect UAE has on the endometrium has 
not been studied well. In chapter 3 we looked at this in detail from a histological point of 
view. However, from an imaging perspective, specifically DWMRI, we compared 
endometrial ADC values pre-UAE to those 6 months post UAE. Although we had some 
difficulty in distinguishing the endometrium from surrounding myometrium at high 
sensitivity b=1000, meaningful analysis was performed. We found no statistically significant 
difference in the mean ADC value of the endometrium 24 hours post-UAE & 6 months post 
UAE to the mean ADC value of the endometrium pre-UAE. This indicates no change to 
cellular membrane integrity post UAE and suggests no damage has occurred. The 
endometrial thickness was also used as a crude marker of endometrial function. We found 
no significant difference between endometrial thickness at baseline and that at 6 months 
post-UAE (p=0.92). This supports ongoing normal endometrial function after UAE. This may 
aid women who want to preserve their fertility and are undecided regarding this treatment 
modality.  
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Research using DWMRI may help pave the way to prove that UAE is a safe treatment 
modality for fibroids and its effect could potentially be predicted for each individual 
patient. It may well prove to be a way of determining successful UAE procedures without 
the need for contrast enhancement. It may also give insight into the exact timing that the 
different components of the uterus are exposed to the hypoxia-like conditions associated 
with UAE.  
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6. Chapter 6 
The role of Pictorial Menstrual Blood Loss Charts (PBAC) in 
assessing the success of uterine artery embolisation (UAE).  
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6.1 Blood loss estimation and symptom relief: 
Heavy menstrual bleeding (HMB) is one of the most common complaints that women 
present to gynaecological services with [304]. It is defined as excessive menstrual blood loss 
which interferes with a woman’s physical, social, emotional and/or material quality of life, 
however, this is subjective [37]. A clinician’s usual practice is to enquire about the length 
of the period, days of heavy bleeding, presence of clots and flooding to subjectively 
diagnose HMB. However, such enquires have been shown to have no correlation with the 
severity of the complaint [305]. Objectively it is defined as more than 80ml during the 
period, although this definition is used for research purposes only [306]. 
There is a great deal of confusion regarding the terminologies used for abnormalities of 
menstrual blood loss. HMB is now a preferred description compared to menorrhagia or 
excessive per vaginal loss as it is easily understood and easily translatable [307].  
HMB causes 1 in 20 women of reproductive age to consult their GPs and it accounts for 20% 
of all referrals to the gynaecology outpatients department. The quality of life is negatively 
affected and there is significant distress amongst women who are plagued with this 
symptom [308]. Clinically HMB can cause anaemia which can further exacerbate the 
physical symptoms [309]. 
Fibroids mainly cause HMB but can also give rise to pelvic pain, pelvic pressure and 
dysmenorrhea. Reproductive dysfunction and infertility may also be the main presenting 
symptom of fibroids [310].  
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6.2 The methods of determining menstrual blood loss: 
6.2.1 Alkaline Hematin Method 
Originally described by Hallberg and Nilsson in 1964 the Alkaline Hematin method is 
considered the gold standard method for menstrual blood loss quantification [311]. 
Measurement of menstrual blood loss involves extraction of haem from used sanitary towels 
using 5% sodium hydroxide, (about 100ml/ sanitary product). This is followed by incubation 
of the sanitary products in 5% sodium hydroxide solution for 48 hours to allow conversion of 
haemoglobin to haem. During the same time period a stored sample of the patient’s venous 
blood should be used to create a 1:200 dilution of blood with 5% sodium hydroxide and an 
aliquot should be stored alongside the menstrual blood collection. After 48 hours, an 
aliquot from the mixture of sanitary products and 5% sodium hydroxide is obtained, filtered 
and diluted by measured addition of further sodium hydroxide. This then creates a close 
colour match with the control venous blood solution. The optical density (OD) of menstrual 
blood loss solution and venous blood sample are then measured using spectrophotometry. 
The menstrual blood loss is then calculated as a proportion of the patient’s own venous 
blood using the following equation [312]. 
 
MBL =  (OD of Menstrual Blood Solution X Total Volume of added NaOH ) 
       OD Venous Blood x 200 
	
6.2.2 Pictorial Blood assessment chart (PBAC) 
Higham et al introduced the Pictorial Blood Assessment chart (PBAC) in 1990 as an accurate 
semi-quantitative method for measuring menstrual blood loss (MBL) [168]. This method 
takes into account the total number of towels and tampons and the degree to which each 
item of sanitary protection is soiled with blood for a given menstrual cycle. This is essential 
as women use a varying number of towels and tampons to collect a similar amount of 
menstrual blood loss and no correlation between the measured menstrual blood loss and 
the number of towels and tampons used has been found. The number of sanitary products 
used in any given cycle is highly dependent on the socio-economic status and the hygienic 
needs of each individual [77]. A pictorial chart score of 100 or more, when used as a 
205 
 
 
 
diagnostic test for HMB, was found to have a specificity and sensitivity of greater than 80% 
[168]. While Deeny et al reported the chart as useful with 88% sensitivity and 52% 
specificity [313].  
A number of studies set out to validate the use of the PBAC against the alkaline haematin 
method. Zakcherah et al concluded that the PBAC score is a semi-objective, simple and 
accurate tool to measure MBL and it can be used in clinical practice to help in managing 
women suffering from menstrual disorders.  [314]. PBAC use has also been validated in 
women suffering from HMB secondary to fibroids [315]. In such cases the positive predictive 
value of the PBAC to distinguish women with HMB against the Alkaline Hematin method 
total was 91%. Measuring blood loss using PBAC is not without its problems as there is high 
inter-individual variation in its use but on the other hand has low intra-individual variation. 
However, from a clinical point of view a low PBAC scores or decreasing scores can be used 
to determine satisfactory treatment end points [316].  
 
6.2.3 Other methods of blood assessment 
Estimation of menstrual blood loss volume based on menstrual diary, laboratory parameters 
and age has been tried in women suffering from HMB. This was found to correlate well with 
the Alkaline Hematin method & could serve as an alternative method in estimating blood 
loss. [317] . However, simple methods such as counting and weighing sanitary products or 
filling menstrual diaries, only provide qualitative data on blood loss which reduces the 
value they have in research studies [318].   
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6.3 The aim of this chapter 
Menstrual blood loss was estimated in patients undergoing UAE as part of the UAE study 
(chapter3) using the pictorial blood loss chart. Each study participant was shown how to fill 
in the PBAC diary prospectively for one menstrual period prior to UAE and one menstrual 
period 6 months post UAE. This was used to show the effect UAE had on reducing HMB 
associated with fibroids. In addition to this, we wished to determine if there was any 
correlation between the change in MBL and the endometrial markers that were studied in 
chapter 3 and the MRI-measurable changes in chapter 4. 
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6.4 Materials and methods 
The participants in the histological studies were given a PBAC diary to fill in prospectively 
for one period prior to the UAE procedure (fig 2-6 & 6-1). The scoring method used to 
evaluate the PBAC score of the diary was not revealed to the patients. A further PBAC diary 
was sent to the patients to fill in by post 6 months from the day of UAE. The PBAC diary 
consists of a series of diagrams representing lightly, moderately and heavily soiled tampons 
or towels. The participant would mark the appropriate box at the time that each sanitary 
product was discarded. In addition, passage of clots and episodes of flooding were 
recorded. (Section 2.5.6) 
 
Figure 6-1: Completed PBAC for one menstrual cycle 
 
Table 6-1: Illustrates an example of calculating a PBAC score from the PBAC chart above. 
18 Heavily soaked towels     18 x 20 
4 Moderately soaked towels   4 x 5 
7 Lightly stained towels    7 X 1 
Flooding     2 X 5 
                                 Total score 
= 
397 
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6.5 Statistical analysis 
We used a paired t-testing, Mann-Whitney test and one-way ANNOVA for statistical analysis 
to look at the changes in PBAC score, length of cycle and number of sanitary towels used 
pre and post UAE. Parametric (Pearson’s) and non-parametric (Wilcoxon-sign-rank) 
correlation tests were used to analyse the correlation between the changes in PBAC score 
and the changes in endometrial markers and MRI.  
6.6 Results: 
UAE is a treatment for HMB in women with uterine fibroids and therefore a reduction in 
PBAC score, period length & heaviness is expected after treatment. Sixteen women were 
included in this study that filled both a pre-UAE and a 6 months post-UAE PBAC diary. The 
mean age was 45.4 years (range 36-52).  
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6.6.1 The change in PBAC Score 
The participants PBAC scores pre-UAE ranged from 62 to 1419 (Mean =490, Median 260). The 
majority of individuals (15/16, 93.7%) had a pre-UAE PBAC score of >100 suggesting HMB. 
After treatment with UAE the number of individuals with PBAC > 100 significantly reduced 
(5/16, 31.2%). We found that the reduction in PBAC score 6 months post-UAE compared to 
pre-UAE was significant (P < 005). This translates to an overall reduction in HMB for this 
group of patients. 
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Figure 6-2  Box plot showing the change in PBAC score 
 
We also looked at the correlation between pre-UAE PBAC score and how much the score 
reduced after UAE using Spearman Rank test. We found this to be a significantly strong 
positive relationship (R-sq= 85.8%, ρ = 0.902, P-value < 0.001). This means that the higher 
the PBAC score the more it will reduce after treatment. Clinically this shows that women 
who are suffering from severe forms of HMB may benefit the most from UAE.   
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Figure 6-3 Correlation of Pre-UAE PBAC score vs PBAC score reduction 
 
6.6.2 The change in sanitary product use 
Each woman used an average of 31.5 sanitary products throughout their period. There was 
an unsurprisingly strong positive and significant correlation between the PBAC score pre-
UAE and the number of sanitary products used (R-Sq = 73.1%, , ρ = 0.87, P < 0.001) (fig 6-
3).  Higham et al found a similar positive correlation between the total number of sanitary 
products used and the menstrual blood loss in ml. [168]. We could not find a correlation 
between the pre-UAE PBAC score and the period length. It has been shown that during most 
cycles women report the heaviest bleeding on the second day of menstruation [319].
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Figure 6-4: Correlation of Pre-UAE PBAC Score & number of sanitary products used. 
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We found a significant reduction in sanitary product use (tampons and towels) post- UAE 
treatment (P = 0.01) (Fig 6-5). 
 
Figure 6-5: Bar chart showing the change in sanitary product use  
 
6.6.3 The change in period length 
The length of the period varies from one woman to another. The prolonged duration of a 
period for a woman with a fibroid uterus directly impacts on the quality of life. However, 
this did not appear to correlate to the PBAC score. We found the period length was 
significantly shorter after treatment with UAE (p=0.002) (Fig 6-6).
 
Figure 6-6 Bar chart showing the change in average period length 
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6.6.4 The uterus and the dominant fibroid 
To test if there are significant differences in PBAC score depending on the dominant fibroid 
location we ran a one–way ANOVA test. The results showed that there are no significant 
differences in PBAC score according to the location of the dominant fibroid. This was 
probably due to not enough variation in the data as the majority of patients in this group 
had dominant fibroids that were intramural. 
We could not find any relationship between pre-UAE PBAC score and any of the following: 
pre-UAE fibroid size, pre-UAE uterine size, fibroid shrinkage, uterine shrinkage or age of the 
patient at the time of UAE. 
  
6.7 Correlation between PBAC score & studied endometrial 
markers 
We looked at the correlation between the PBAC score and the expression of the different 
markers that we measured in the endometrium in chapter 3 both pre-UAE & post UAE. We 
found no significant correlation between them. 
Table 6-2: Showing the correlation between PBAC and endometrial marker expression 
Endometrial 
Marker 
Spearman Rho 
Correlation to  
Pre-UAE PBAC Score  
P =  Spearman Rho 
correlation to  
Post-UAE PBAC score 
P = 
VEGF-A -0.34 0.30  0.44 0.17 
COX-2 -0.27 0.41  -0.17 0.59 
MVD 0.14 0.67  0.33 0.31 
Ki67 0.38 0.24  0.5 0.09 
 
 
We also looked at the change in PBAC score compared to the change in the endometrial 
markers expression in the endometrium and found no significant correlation between them.  
213 
 
 
 
Table 6-3: Showing the correlation between the change in PBAC and the change in marker 
expression/measurement 
 
Endometrial 
Marker 
Spearman Rho correlation between change 
in PBAC score to the change in endometrial 
marker post-UAE  
P = 
VEGF-A -0.63 0.12 
COX-2 0.07 0.21 
MVD 0.46 0.29 
Ki67 0.02 0.95 
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6.8 Discussion 
Although the pictorial blood loss assessment chart is a subjective tool for estimating 
menstrual blood loss, it has been proven to be reliable. It has been validated against the 
objective estimation method of measuring blood loss (alkaline haematin method) [315]. 
Modern sanitary pads may impact on the validity of PBAC scores as they convert liquid to 
non-evaporating gel, therefore underestimation of blood loss may occur [320]. 
In this study instructions were given to the participants on how fill in the PBAC chart 
prospectively and no instruction on the method of calculating the PBAC score were given.  
Although some authors point out that about 50% of women who complain of heavy 
menstrual bleeding actually have normal menstrual bloods loss, in this study only one 
woman (6% of participants) had a PBAC score < 100. There is an obvious monthly menstrual 
bleeding variation and the use of medicines to alleviate heavy menstrual bleeding was not 
accounted for in this chapter.   
The median PBAC score in this study was high (340). This was 3 folds higher than the 
median score for Higham’s population in 1990. This may be explained by the fact that our 
study included women with fibroids will Higham’s study was of normally menstruating 
women [321]. Two PBAC scores in this study were ≥ 1000, which corresponds to 
approximately a blood loss of ≥750ml. This is a large amount of blood loss which on a 
recurrent monthly basis would render an individual severely anaemic. Even when these two 
patients were excluded from analysis, the results did not change.  
 
Some women may use small size and/or low absorbency sanitary materials and a direct 
comparison could not be made as most participants did not fill in the brand name used. A 
patients’ personal hygiene and their perception of the degree of soiling of a tampon or 
towels could also be an explanation for these high PBAC scores.  
 
The median PBAC score dropped significantly after UAE (363 to 85) and this is an 
encouraging finding. Most women who attend for UAE were seeking a reduction in 
menstrual blood loss and this result clearly describes this. As the PBAC score dropped, so 
did the length of the periods and the need for sanitary product use. Such an effect is 
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expected as these variables are directly linked to one another. Although, no quality of life 
questionnaires were used, the result from this study point towards an improvement in the 
quality of life of women whom were treated with UAE. 
 
We found a positive correlation between pre-UAE PBAC score and the amount it drops after 
UAE. This suggests that women who are suffering from severe forms of HMB and have very 
high PBAC scores are likely to benefit the most from UAE.   
We could not find a correlation between the pre-UAE PBAC score and the period length. 
Suggesting that although women with uterine fibroids have heavy periods they don’t 
necessarily have lengthier ones. We mentioned earlier in the chapter that the heaviest 
blood loss of a period is usually on day 2. 
The size of the fibroid uterus and the dominant fibroid pre-UAE did not correlate to the 
PBAC score. Clinically this is usually the case as many women with small fibroids present 
with HMB and others with large fibroids may be found incidentally or present with other 
symptoms like pressure.  
We found no significant correlation between the expression of markers studied in pre & 
post-UAE samples to their respective PBAC score. This suggests that a dramatic drop in 
PBAC score does not significantly change the markers studied. Another explanation is that 
clinical improvement does not reflect the changes in the endometrium or simply the 
number of samples were too small. 
The pictorial blood loss assessment chart is a semi-objective method for estimating blood 
loss. It is easy to understand and most patients find filling it non-taxing. It can be used to 
evaluate the effectiveness of certain treatments for heavy menstrual bleeding such as UAE. 
This is done by showing the difference in PBAC score before and after treatment.  However, 
its use in women with fibroids and those with very heavy bleeding might be limited and may 
not reflect the true blood loss. There is currently an ongoing study (FEMME Trial) that is 
collecting data from over 250 patients and comparing the pre-UAE PBAC score to those 6 
months and 12 months post UAE. It may be that a different conclusion can be reached with 
more samples.  
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7. Discussion 
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7.1 General Discussion 
Uterine fibroids are the most common benign tumour affecting women of reproductive age. 
They are widely prevalent and up to 50% of women suffering with fibroids are symptomatic 
[55]. Women seeking treatment for fibroids account for up to 20% of the gynaecology 
outpatient referrals [39]. Although a range of treatment options are available they mainly 
fall into two categories, medical and surgical treatments. Although well tolerated and 
relatively easy to administer, medical treatments until recently have only helped in 
symptom control. Apart from GnRH analogues, SPRMs seem to be a successful; non-invasive 
treatment that is aimed at both symptom control and fibroid size reduction. Long-term 
trials are in place assessing this group of drugs [125]. Surgical options such as hysterectomy 
and myomectomy have been the mainstream method of tackling fibroids. The advances in 
interventional radiology and the emergence of UAE in 1995, have given women a less 
invasive option that targets both symptoms and size of the fibroid uterus [132]. 
Although UAE is now a well-established method of treating women with fibroids, the exact 
mechanism of how it works and which patient achieves maximum benefit is not fully clear. 
However, it is clear that it acts on multiple layers within the fibroid uterus. HMB reduces 
after treatment, signalling a change in the endometrium’s response to the cyclical 
hormonal changes that affect it on a near monthly basis. The fibroid uterus generally and 
the fibroids specifically reduce in size pointing towards an effect on the myometrium. 
Reduction in subserosal fibroids proportionately reduces the surface area of the serosa as 
well. While shrinkage and expulsion of submucosal fibroids directly impacts on the function 
and regularity of the endometrial cavity which in turn may have a positive impact on 
fertility [83]. Our aim in this thesis was to explore the mechanisms by which UAE affects 
the endometrium and the impact of this procedure on the fibroid uterus. 
 
There is evidence that endometrial factors such as VEGF and the prostanoids 
/cyclooxygenase system may be involved in the control of menstrual blood loss. VEGF plays 
a role in restoring blood supply through angiogenesis to the endometrium after 
menstruation [185].  It also plays a critical role in angiogenesis of tumours such as fibroids. 
COX enzymes have been found to have a role in many reproductive tract pathologies such 
as HMB which is studied in this thesis [191]. Therefore studying the expression of VEGF-A & 
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COX-2 in the endometrium before and after UAE may explain the mechanism by which it 
affects this layer of the uterus. 
 
MVD is understudied in the endometrium and has never been studied in the endometrium of 
women after UAE. There has been one study that showed no correlation between VEGF & 
MVD in the endometrium of women with adenomyosis but not of women with uterine 
fibroids [204]. The aim was to assess the assess MVD across the menstrual cycle on women 
with fibroids and its rate of change following UAE. 
 
 Ki67 as a marker of proliferation and can be used to evaluate the growth fraction in any 
human cell population. It is absent from resting cells that are not dividing. The 
endometrium in women with endometrial hyperplasia who often present with irregular and 
heavy bleeding, has been shown to have increased proliferation and therefore increased 
expression of Ki67 [212]. Hence a treatment modality that reduces menstrual blood loss 
such as UAE, may lead to detectable change in the expression of Ki67.  
 
Women of different age groups present to the interventional radiology clinic requesting 
UAE. Some studies found age not to be an important factor in determining UAE success as it 
did not correlate to the change in size of the fibroids while others found increased age 
predicts failure of UAE [250, 252]. The number, size and location of fibroids at the time of 
presentation all seem to play a role in determining the outcome. MRI is best placed at 
objectively assessing these factors both before and after UAE. As with any intervention, 
UAE can fail and is not without risks and complications. The effect UAE has on a woman’s 
ability to reproduce is still not fully understood. Despite the importance of such an effect, 
it remains understudied because of the large numbers needed for any meaningful trial to be 
undertaken. This can mainly be attributed to the active exclusion of women wanting to 
retain their fertility from studies involving UAE [148, 265]. The results of the FEMME trial 
which did not have such exclusion are eagerly awaited [322]. Currently, pregnancy data 
following UAE is derived from case series rather than randomised controlled trials [323]. 
DWMRI has the ability to detect disruption to cellular membrane integrity through 
quantifying the diffusion of water between cells by objectively measuring the ADC value of 
the studied cell population. Using this MRI sequence before and after UAE can detect 
changes in specific regions of interest in the fibroid uterus. These changes can shed light on 
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what component of the uterus is affected by UAE and potentially its mechanism of action. 
ADC values are reproducible values and may form part of a standard MRI report in the 
future as it can quantify overall cell membrane disruption and cellular damage.  
 
The limitations of the endometrial sample study: 
1-It lacked power; this was mainly due to difficulty in recruiting as the larger FEMME trial 
was ongoing at the time. Endometrial sampling using a Pipelle™, although tolerated as a 
necessity, can become a laborious process for women if performed in the context of a study 
and some women who have previously experienced endometrial sampling refused to 
participate. 
2-Statistical analysis was not always possible between the groups compared as these 
numbers were small and only the trends were described.  
3-The inability to obtain fibroid samples before and after UAE as this would require CT-
guided biopsy which is not within the realm of this study. 
4-Not all the endometrial samples obtained could be used for this study as some showed a 
chronic endometritis picture that would alter the expression of the studied markers.  
5-Although the timing of the pre- and post-UAE were synchronised to coincide with the 
same phase of the menstrual cycle  
 
The strengths of endometrial sample study:  
1-It was a prospective study and we were able to look at four different markers in the 
endometrium despite the small amount of tissue obtained 
2-It benefited from direct comparisons that were made between endometrial samples taken 
from the same group of patients both before and after UAE allowing for paired comparisons 
to be made. 
3- The cost of this study was low as both pre & post-UAE MRI was part of the clinical 
assessment package for each patient. The researcher (myself) was a senior gynaecology 
registrar who is experienced in performing endometrial sampling and did not require 
training or supervision. 
 
 The study found VEGF-A expression tends to increase at 6 months post UAE signalling 
neovascularisation. The mean VEGF expression (H-Score) measured after IHC, increased in 
samples taken in the proliferative stage of the cycle. This stage of the cycle is immediately 
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after menstruation and involves regeneration of cells in the basilar zone of the 
endometrium. Such a process requires angiogenesis in which VEGF is essential [181]. It may 
be that the rise in VEGF helps in regulating the menstrual process and rearranging any 
abnormal physiology that caused HMB in the first instance [187]. Therefore a normal start 
to the regeneration process of the endometrium, then paves the way for the rest of the 
menstrual cycle to continue normally and improving HMB. This may explain why the changes 
in VEGF were more pronounced in the proliferative stage rather than the other stages of 
the cycle.  
 
This thesis found a similar rise in VEGF in post-UAE samples when studying the relative 
expression of VEGF RT-PCR. The limits of this part of the study were mainly due to sample 
size and the two different extraction methods used. After the move of the Pathology 
department from Glasgow Royal Infirmary to the South side of the City, it was no longer 
possible to snap freeze samples. Therefore extraction was performed from paraffin samples 
as well as from fresh frozen samples already collected. It was difficult to perform 
meaningful comparisons after RT PCR due to small sample numbers. However, unpublished 
data by fellow researcher Salha Abukhnjr suggests reasonable agreement between paraffin 
and fresh frozen sample results. Statistically significant results were found when looking at 
the cohort of samples from normally menstruating women (active samples). Results were 
only obtained from one subject were both pre-UAE & post-UAE samples were taken in the 
proliferative stage. This however showed a large rise in VEGF RT-PCR post-UAE echoing the 
results obtained from the IHC analysis. Another explanation of such rise is that VEGF is 
usually low in the proliferative stage of women with HMB and the observed increase 
represents a return to normal. A large sample is needed to study the expression of VEGF in 
the endometrium of women with fibroids at different stages of the cycle. 
 
This thesis found that COX-2 expression was mostly weak in the samples studied.  This is in 
keeping with the fact that the highest levels of COX-2 are seen in menstruating samples and 
none of the samples studied were in that stage of the cycle [218].  Excessive expression of 
COX-2 has been found in the endometrium of women with HMB [25]. It may be that the 
observed downward trend of COX-2 expression post UAE points towards regulation of the 
inflammatory process post UAE. This in turn is similar to the effect seen with the use of 
NSAIDs such as mefenamic acid – a COX inhibitor -that has been shown to reduce HMB [41, 
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104]. It is perceived undignified by most women to be examined while menstruating. 
However, future research into menstruating samples could alleviate the difficulty in pairing 
samples to the same stage of the sample and increase the sample size significantly in a 
study like this. 
 
This thesis also found a significant increase in MVD of the endometrium post UAE. This was 
evident in paired samples were direct comparison was made. MVD was found to rise in all 
samples from normally menstruating women and those with inactive samples. The uterine 
arteries are the main blood supply of the uterus and blocking these two vessels by UAE is an 
ischaemic event. This event leads to hypoxia-like conditions which are known to enhance 
the expression of VEGF and stimulate angiogenesis [15]. This should then be evident by an 
increase in MVD and such an effect was observed in the samples studied in this thesis.  
We studied the expression of Ki67 as a marker for proliferation and found an increasing 
trend of proliferation in the proliferative stage and early secretory stage samples post-UAE. 
The sample size was small and statistical analysis was not possible. This increasing trend 
echoes the changes seen in VEGF-A & MVD. Such directly proportionate change albeit a 
decreasing one has been seen in treatment of prostate cancer in mice suggesting a direct 
interaction between these processes [324]. We found no change to Ki67 expression in late 
secretory stage and inactive samples. Although the level of expression of Ki67 has not been 
compared in the various stages of human endometrium. A study involving mice has shown 
varying levels of expression throughout the rodents’ estrous cycle [215].  
This study found a significant reduction in PBAC scores post-UAE. However, we found no 
correlation between the expression of the studied endometrial markers and PBAC scores 
pre-UAE nor the change in PBAC scores post-UAE. This is probably because PBAC charts are 
designed to assess the change in one clinical symptom -HMB- that is subjective in each 
woman. While endometrial markers are affected by the changes occurring in the fibroid 
tissue post-UAE. It may also be explained by how different women completed the PBAC 
chart and the subjective perception of a lightly or heavily soiled pad or tampon.  
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This thesis looked at a cohort of patients who had undergone UAE over a 5 year period. The 
study found that 95% of the patients had a reduction in the size of their uterus & dominant 
fibroid. The mean dominant fibroid volume reduction ranged between 38-70% which is 
similar to the levels previous studies have reported[325]. The fibroid uterus reduced in 
volume by around 40%. When reviewing a sample of the case notes, we found the 
overwhelming majority had HMB pre-UAE. Therefore a 4% re-intervention rate at 6 months 
and a 15% re-intervention rate at 18 months reflect a short-medium term success rate and 
suggest resolution of main referral symptom. Although the complication rate of UAE is low, 
re-intervention rate and the need for additional treatment appear to increase with time. 
This reverberates with what has been found in other studies that looked at long term 
outcomes post UAE [148, 265]. 
The limitations of the five year UAE practice study are: 
1-It was a retrospective study and a large amount of follow up data and imaging was 
missing. 
2-Contrast enhancement of the fibroids was not analyzed and therefore not used as a 
separate confounder when assessing the change that occurs to the fibroid studied. This was 
done due to a wide variation in the practice of measuring contrast enhancement and it 
being a subjective technique.  
3-Only the dominant fibroid was measured rather than all fibroids and the reasoning behind 
this has been explained earlier in the thesis. 
4-The measurements of the dominant fibroid and the uterine diameters were performed by 
one researcher however, adequate training was given beforehand.   
  
The strengths of the five year UAE practice study are: 
1-Despite data loss, a large number of patients had complete data and imaging.  
2-The study benefited of the use of MRI for pre & post-UAE analysis which is the gold 
standard for imaging in fibroids.  
3-No funding was required for image analysis as the images were already stored on PACS 
and were readily accessible. 
4-The research was blinded to post-UAE images as all Pre-UAE images were analyzed first 
followed by post-UAE image analysis.  
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This study found that small or medium sized dominant fibroids (<700 cm3) shrunk by 11% 
more than large dominant fibroids. This suggests that these fibroids are more susceptible to 
UAE and it may be that they are exposed to a smaller -by surface area- vascular bed than 
larger fibroids. This result was different to what Czuczwar et al who found, however, a 
different cut-off value for large fibroids and a different method of measuring fibroids was 
used [326]. We could not demonstrate a difference in shrinkage between a large uterus 
(≥780 cm3) and a small uterus. This may be that the shrinkage of the uterus is reliant on the 
shrinkage of the different sized fibroids within it and cannot be used as a separate entity 
from the fibroids that are targeted. As we only looked at the dominant fibroids, analysis 
involving all fibroids within a uterus may yield a different outcome. Measuring and locating 
all fibroids in a multi-fibroid uterus can be a challenging process to even experienced 
radiologists.   
The mean age of presentation for women who undergo UAE was 45y. This late presentation 
has directly impacted on UAE studies looking at fertility. Our study could not find a 
correlation between the age of the woman at the time of UAE and the size of the fibroid 
uterus or the dominant fibroid. We did however; find a positive correlation with shrinkage. 
Women above the age of 50y were found to have the best response from UAE. As the 
average age that women in the UK reach menopause is 51y, we suggest a synergistic 
shrinkage effect between a peri-menopause state and UAE. One explanation of such 
outcome is the decrease in ovarian function that occurs after UAE and is concentrated in 
women older than 45 years [135]. Such a decrease may be accelerated by the effect of UAE 
and directly impact on the fibroid shrinkage. We conclude from this that women close to 
the age of menopause should be counselled appropriately regarding opting for UAE rather 
than surgery especially if pressure is the main symptom. Our study found this group of 
women to have the best MRI-measurable shrinkage which theoretically should reflect better 
resolution of pressure symptoms. 
The study also found that dominant fibroid shrinkage is related to its position. Submucosal 
fibroids shrunk more than intramural fibroids by 26.6% and more than subserosal fibroids by 
31.8%. This may be explained by the method that was used to measure submucosal fibroids 
that were expelled (100% shrinkage). Another explanation is that submucosal fibroids are 
more sensitive to the effects of UAE because of the distribution of embolic particles, more 
of which settle in the inner part of the myometrium [326]. Although fibroid expulsion is 
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considered a complication of UAE, the removal of submucosal fibroids leads to a significant 
increase in pregnancy rates and a decrease in miscarriage rates [83]. It might be that 
submucosal fibroid expulsion should be counselled as a positive outcome in women 
contemplating pregnancy.  
The study also found that women presenting with a single fibroid in the uterus had a larger 
uterine shrinkage compared to those with multiple fibroids. This may be that the limited 
volume of embolic particles used that initially causes uterine artery stasis is then 
distributed over a larger vascular bed in a multi-fibroid uterus after uterine artery 
recanalization. There are no studies that have looked at the volume of embolic particles 
used and the outcome of UAE as most studies have only looked at comparing the outcome 
of different embolic agents. 
Through studying DWMRI this thesis used the ADC value to evaluate the changes to the 
cellular membrane structure of the cells forming the layers of the uterus.  
 
The limitations of the DWI study are: 
1-Lack of power but this was mainly to do with it being a pilot study 
2-Analysis was performed by one observer as funding for a second researcher to perform a 
repeat analysis was not available. However, training in the use of DWMRI and the use of the 
software used for the analysis was undertaken. 
3-Only the ADC of the dominant fibroid was used and not for every fibroid in a multi-fibroid 
uterus. 
4-Image distortion at high b-values made ADC value calculations difficult and in some 
instances impossible.  
 
The strengths of the DWI study are: 
1-It was a prospective study and adequate funding was in place to support the researchers 
involved 
2-The MRI sequences used were refined prior to using them in this study by researchers that 
work in this field. 
3- Patients in the study underwent an MRI of the abdomen and pelvis on three separate 
occasions. The first and second MRI was done immediately pre and 24 hours post-UAE while 
the patient was an inpatient. This reduced dropout rates and helped to give a picture of 
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what happens in the immediate period after UAE. This period has rarely been studied 
before by MRI.     
 
This thesis found a significant reduction in ADC value of the dominant fibroid post UAE. This 
is a similar result to that described by Leapi et al [327].  This suggests a disruption to the 
cellular membrane of the densely packed cells of the fibroid leading to cell death and 
fibroid necrosis and shrinkage. A statistically significant correlation was found between the 
volume reduction of the dominant fibroid and its ADC value prior to UAE. It may be that 
ADC can be used to predict the outcome of UAE for the dominant fibroid and other fibroids 
within the uterus. However, there was no correlation between dominant fibroid ADC value 
and the change in volume of the fibroid uterus. It may be that because a fibroid uterus 
contains different sized fibroids with different locations and that ADC of a specific fibroid 
only predicts that fibroids’ change.  This in turn gives ADC a limited prediction of change 
value. Further research measuring the ADC value of all fibroids within a fibroid uterus may 
be required. It may then produce a more specific shrinkage prediction model. 
UAE is applied the uterus as a whole by blocking the two uterine arteries. Future advances 
in interventional radiology may see the rise of specific fibroid vessel targeting to avoid the 
unnecessary exposure of the whole uterus to the embolic agents used. Our study found that 
the ADC value of the myometrium was not changed in the first 24 hours post UAE nor was it 
changed 6 months post UAE. Despite finding no difference, this result signals the resilience 
of myometrial cells to the effect of UAE. It could also be explained by the specific targeting 
of the fibroid by the embolic particles used. Therefore, allowing an early end point to 
embolisation by settling in the fibroid tissue and minimalizing ischemic damage to the 
normal myometrium [328].  
DWMRI is able to detect adverse changes to the endometrium. ADC change in the 
endometrium has been shown to identify malignant changes as there is no overlap between 
the ADC values of endometrial cancer and that of the normal endometrium [327]. Our study 
found no difference when comparing ADC of the endometrium pre-UAE to that at 24 hours 
and at 6 months post-UAE. This result is encouraging as despite reduction in HMB, the 
cellular integrity of the endometrium is unaffected. This can be interpreted as no sign of 
adverse effect found in the endometrium post-UAE. 
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 A further encouraging result was that endometrial thickness was unchanged 6 months post 
UAE compared to baseline. Although this study did not specify/ sanction the timing of the 
MRI in relation to a woman’s menstrual period, group analysis across the different stages of 
the menstrual cycle found no change to endometrial thickness. A directly proportionate 
relationship has previously been found between endometrial thickness and IVF pregnancy 
rates [329]. Therefore, the lack of change in average endometrial thickness in our study 
suggests no change to fertility but no improvement either.   
  
227 
 
 
 
7.2 Conclusion  
• UAE caused an increasing trend in VEGF expression in the human endometrium which 
was more evident in the proliferate stage. It was also associated with a decreasing 
trend in COX-2 
• Significant increase in endometrial MVD was evident post UAE. 
• An increasing trend of Ki67 expression in post UAE samples was found. This suggests 
an interaction between VEGF, MVD & the proliferation of the endometrium. 
• PBAC is a useful aid to assess blood loss in UAE however the scores do not correlate 
with the studied endometrial markers or the MRI changes. 
• Women with a small and medium sized dominant fibroid or a single fibroid uterus and 
those approaching the age of menopause seem to gain the most benefit of UAE. 
• The position of the fibroid does impact on its shrinkage and submucosal fibroids 
appear to be the most affected by UAE. 
• DWMRI is a useful tool in assessing UAE outcomes and it shows that the different 
unaffected parts of the uterus remain unaffected by the ischemia-like conditions 
that UAE creates in the fibroid uterus.  
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7.3 Future work 
This varied work that included a prospective laboratory study and retrospective & 
prospective clinical MRI studies has proven to be an interesting challenge. Although the aim 
was to identify the elusive mechanism by which uterine fibroids – a benign condition - cause 
heavy menstrual bleeding, the work that I have done will definitely have an impact on any 
future research in gynaecological cancers that I plan to undertake.  
Regardless of the non-statistically significant results from comparing endometrial samples 
before and after UAE, the thesis supports further research into the role pre-UAE MRI has to 
play in the diagnosis and treatment of uterine fibroids. Previous unpublished work by my 
colleague Dr Salha Abu-Khnjr suggested up-regulation of the studied markers when 
comparing women with uterine fibroids to those without fibroids. These markers were used 
in this thesis to compare one specific treatment modality. It may be that this limited 
number of markers hold part of the answer to how UAE works and other markers may need 
to be studied on the samples obtained.  
Future work with selective progesterone receptor modulators such as Esmya™ (Ulipristal 
Acetate) may give a better insight on how fibroids affect the uterus globally and the 
endometrium specifically. In practice these drugs cause fibroid tissue to soften and 
sometimes shrink therefore directly opposing the growth element in fibroids. They cause 
amenorrhea which is a desirable symptom in women with fibroids. SPRMs are still in their 
infant stages in regard to fibroid treatment. Progesterone Receptor Modulator Associated 
Endometrial Changes (PAEC) is a side effect that may limit their use and could potentially 
prove them to be hazardous.  
Diffusion weighted MRI may hold answers to conditions and treatment modalities that 
damage cells. This thesis has shown that quantifying the changes after UAE can be 
accurately measurable.  Our MRI unit has a large archive of pelvic MRI scans with the DWI 
sequences that have never been reported or analysed. Since the start of this thesis to date 
there has been considerable interest in DWI especially in gynaecology imaging and more 
radiologists are giving these sequences the attention they need. DWI MRI can sometimes 
help in differentiating leiomyosarcomas from leiomyomas and avoid treatment delay. 
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Future research in gynaecology oncology could utilize DWI MRI as both a screening tool and 
also to test new chemo-therapeutic agents. It has certainly been utilised more recently in 
the field of obstetrics in diagnosing abnormally invasive placental conditions such as 
placenta accreta.  
Future plans are in place to analyse data from the FEMME trial and study the changes to 
Anti-müllerian hormone post UAE in 2017. I hope to continue to study the impact of UAE on 
the fibroid uterus through further research into DWI MRI. This imaging sequence may aid in 
both screening and treating benign and malignant gynaecological conditions. 
 
  
230 
 
 
 
Appendices 
Appendix 1  a. Ethical approval and substantial amendment (Group1) 
   b. Patient information sheet 
   c. Consent form 
   d. Baseline questionnaire 
   e. Follow up questionnaire  
 d. Pictorial blood loss estimation chart (PBAC) 
Appendix 2 Ethical approval (Group 2) 
Appendix 3 Protocol for the management of pain and nausea for patients 
attending for uterine artery embolisation (UAE), NHS GG&C 
Appendix 4 a. Review article: Fibroids diagnosis and management  
 b. Posters x2 presented at RCOG world congress 
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Uterine Artery Embolization Study 
 
Menstrual Blood Loss Diary - Please complete for a period prior to UAE  
 
Please would you record your use of tampons and sanitary towels in the table below. 
 
 
 
 
 
 
 
 
 
On the next page you will find a Menstrual Blood Loss Diary. Please would you place a tick 
under the day and next to the box that represents how marked your sanitary materials are 
each time you change them. Please enter a tick each time you change your tampon or 
towel. 
Record clots by indicating whether they are the size of a 1p or 50p coin in the ‘clots’ row 
under the relevant day. If you have a clot that is larger than a 50p please record this in 
comparison to the size of a golf ball (GB). 
e.g. under day 1 you may say that you had 1 clot the size of a 50p coin and 3 clots the size 
of a 1p coin and one clot the size of a golf ball. You would write this as 1 x 50p, 3 x 1p, 1 x 
GB. 
Record any incidences of flooding by placing a tick mark in the flooding row under the 
relevant day. 
 
PLEASE TURN OVER FOR YOUR DAILY BLOOD LOSS DIARY 
 
 
Date period started:  
Brand ___________________and Type__________________ of towel you used on days _______    _ 
Brand ___________________and Type__________________ of towel you used on days ______     __ 
Brand ___________________and Type__________________ of tampon you used on days _________ 
Brand ___________________and Type__________________ of tampon you used on days _________ 
(e.g. Tampax – Super Plus days 1-2 then Tampax - Regular days 3-4) 
 
 
239 
 
 
 
TOWEL Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
         
         
         
Clots         
Flooding         
TAMPON Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
         
         
         
Clots         
Flooding         
240 
 
 
 
Appendix 2 
  
241 
 
 
 
 
 
242 
 
 
 
Appendix 3 
  
243 
 
 
 
 
 
 
244 
 
 
 
245 
 
 
 
 
246 
 
 
 
List of References 
1.	 Press,	M.F.,	et	al.,	Immunohistochemical	assessment	of	estrogen	receptor	distribution	in	
the	human	endometrium	throughout	the	menstrual	cycle.	Lab	Invest,	1984.	51(5):	p.	495-
503.	
2.	 Kostiuchek,	I.N.,	et	al.,	[Expression	of	estrogen	and	progesterone	receptors	in	the	
endometrium	of	fertile	and	infertile	women].	Arkh	Patol,	2011.	73(5):	p.	30-2.	
3.	 Bergeron,	C.,	et	al.,	Immunocytochemical	study	of	progesterone	receptors	in	the	human	
endometrium	during	the	menstrual	cycle.	Lab	Invest,	1988.	59(6):	p.	862-9.	
4.	 Kearns,	M.	and	P.K.	Lala,	Life	history	of	decidual	cells:	a	review.	Am	J	Reprod	Immunol,	
1983.	3(2):	p.	78-82.	
5.	 Ferenczy,	A.	and	C.	Bergeron,	Histology	of	the	human	endometrium:	from	birth	to	
senescence.	Ann	N	Y	Acad	Sci,	1991.	622:	p.	6-27.	
6.	 Christiaens,	G.C.,	J.E.	Markee:	menstruation	in	intraocular	endometrial	transplants	in	the	
rhesus	monkey.	Eur	J	Obstet	Gynecol	Reprod	Biol,	1982.	14(1):	p.	63-5.	
7.	 Rogers,	P.A.	and	C.E.	Gargett,	Endometrial	angiogenesis.	Angiogenesis,	1998.	2(4):	p.	287-
94.	
8.	 Perrot-Applanat,	M.,	et	al.,	Ovarian	steroids	in	endometrial	angiogenesis.	Steroids,	2000.	
65(10-11):	p.	599-603.	
9.	 Iruela-Arispe,	M.L.,	J.C.	Rodriguez-Manzaneque,	and	G.	Abu-Jawdeh,	Endometrial	
endothelial	cells	express	estrogen	and	progesterone	receptors	and	exhibit	a	tissue	specific	
response	to	angiogenic	growth	factors.	Microcirculation,	1999.	6(2):	p.	127-40.	
10.	 Critchley,	H.O.,	et	al.,	Estrogen	receptor	beta,	but	not	estrogen	receptor	alpha,	is	present	
in	the	vascular	endothelium	of	the	human	and	nonhuman	primate	endometrium.	J	Clin	
Endocrinol	Metab,	2001.	86(3):	p.	1370-8.	
11.	 Kelly,	F.D.,	S.A.	Tawia,	and	P.A.	Rogers,	Immunohistochemical	characterization	of	human	
endometrial	microvascular	basement	membrane	components	during	the	normal	
menstrual	cycle.	Hum	Reprod,	1995.	10(2):	p.	268-76.	
12.	 Cao,	W.,	et	al.,	Progesterone	withdrawal	up-regulates	fibronectin	and	integrins	during	
menstruation	and	repair	in	the	rhesus	macaque	endometrium.	Hum	Reprod,	2007.	22(12):	
p.	3223-31.	
13.	 Henriet,	P.,	H.P.	Gaide	Chevronnay,	and	E.	Marbaix,	The	endocrine	and	paracrine	control	
of	menstruation.	Mol	Cell	Endocrinol,	2012.	358(2):	p.	197-207.	
14.	 Boonyaratanakornkit,	V.	and	D.P.	Edwards,	Receptor	mechanisms	mediating	non-genomic	
actions	of	sex	steroids.	Semin	Reprod	Med,	2007.	25(3):	p.	139-53.	
15.	 Detmar,	M.,	et	al.,	Hypoxia	regulates	the	expression	of	vascular	permeability	
factor/vascular	endothelial	growth	factor	(VPF/VEGF)	and	its	receptors	in	human	skin.	J	
Invest	Dermatol,	1997.	108(3):	p.	263-8.	
16.	 Neufeld,	G.,	et	al.,	Vascular	endothelial	growth	factor	(VEGF)	and	its	receptors.	Faseb	j,	
1999.	13(1):	p.	9-22.	
17.	 Smith,	W.L.,	D.L.	DeWitt,	and	R.M.	Garavito,	Cyclooxygenases:	structural,	cellular,	and	
molecular	biology.	Annu	Rev	Biochem,	2000.	69:	p.	145-82.	
18.	 Smyth,	E.M.,	et	al.,	Prostanoids	in	health	and	disease.	J	Lipid	Res,	2009.	50	Suppl:	p.	S423-
8.	
19.	 Narumiya,	S.,	Y.	Sugimoto,	and	F.	Ushikubi,	Prostanoid	receptors:	structures,	properties,	
and	functions.	Physiol	Rev,	1999.	79(4):	p.	1193-226.	
20.	 Forman,	B.M.,	et	al.,	15-Deoxy-delta	12,	14-prostaglandin	J2	is	a	ligand	for	the	adipocyte	
determination	factor	PPAR	gamma.	Cell,	1995.	83(5):	p.	803-12.	
21.	 Rossi,	A.,	et	al.,	Anti-inflammatory	cyclopentenone	prostaglandins	are	direct	inhibitors	of	
IkappaB	kinase.	Nature,	2000.	403(6765):	p.	103-8.	
247 
 
 
 
22.	 Bishop-Bailey,	D.	and	T.	Hla,	Endothelial	cell	apoptosis	induced	by	the	peroxisome	
proliferator-activated	receptor	(PPAR)	ligand	15-deoxy-Delta12,	14-prostaglandin	J2.	J	Biol	
Chem,	1999.	274(24):	p.	17042-8.	
23.	 Jones,	R.L.,	R.W.	Kelly,	and	H.O.	Critchley,	Chemokine	and	cyclooxygenase-2	expression	in	
human	endometrium	coincides	with	leukocyte	accumulation.	Hum	Reprod,	1997.	12(6):	p.	
1300-6.	
24.	 Critchley,	H.O.,	et	al.,	Role	of	inflammatory	mediators	in	human	endometrium	during	
progesterone	withdrawal	and	early	pregnancy.	J	Clin	Endocrinol	Metab,	1999.	84(1):	p.	
240-8.	
25.	 Smith,	O.P.,	H.N.	Jabbour,	and	H.O.	Critchley,	Cyclooxygenase	enzyme	expression	and	E	
series	prostaglandin	receptor	signalling	are	enhanced	in	heavy	menstruation.	Hum	
Reprod,	2007.	22(5):	p.	1450-6.	
26.	 Gargett,	C.E.,	et	al.,	Lack	of	correlation	between	vascular	endothelial	growth	factor	
production	and	endothelial	cell	proliferation	in	the	human	endometrium.	Hum	Reprod,	
1999.	14(8):	p.	2080-8.	
27.	 Gordon,	J.D.,	et	al.,	Angiogenesis	in	the	human	female	reproductive	tract.	Obstet	Gynecol	
Surv,	1995.	50(9):	p.	688-97.	
28.	 Uluer,	E.T.,	et	al.,	The	role	of	hypoxia	related	angiogenesis	in	uterine	smooth	muscle	
tumors.	Biotech	Histochem,	2015.	90(2):	p.	102-10.	
29.	 Triggle,	C.R.,	et	al.,	The	endothelium:	influencing	vascular	smooth	muscle	in	many	ways.	
Can	J	Physiol	Pharmacol,	2012.	90(6):	p.	713-38.	
30.	 Campbell,	J.H.	and	G.R.	Campbell,	Endothelial	cell	influences	on	vascular	smooth	muscle	
phenotype.	Annu	Rev	Physiol,	1986.	48:	p.	295-306.	
31.	 Jabbour,	H.N.,	et	al.,	Inflammatory	pathways	in	female	reproductive	health	and	disease.	
Reproduction,	2009.	138(6):	p.	903-19.	
32.	 Key,	T.J.	and	M.C.	Pike,	The	dose-effect	relationship	between	'unopposed'	oestrogens	and	
endometrial	mitotic	rate:	its	central	role	in	explaining	and	predicting	endometrial	cancer	
risk.	Br	J	Cancer,	1988.	57(2):	p.	205-12.	
33.	 Markee,	J.E.,	Menstruation	in	intraocular	endometrial	transplants	in	the	Rhesus	monkey.	
Am	J	Obstet	Gynecol,	1978.	131(5):	p.	558-9.	
34.	 Jabbour,	H.N.,	et	al.,	Endocrine	regulation	of	menstruation.	Endocr	Rev,	2006.	27(1):	p.	17-
46.	
35.	 Lumsden,	M.A.,	et	al.,	The	concentrations	of	prostaglandins	in	endometrium	during	the	
menstrual	cycle	in	women	with	measured	menstrual	blood	loss.	Prostaglandins	Leukot	
Med,	1986.	23(2-3):	p.	217-27.	
36.	 Szostek,	A.Z.,	et	al.,	Interleukins	affect	equine	endometrial	cell	function:	modulatory	action	
of	ovarian	steroids.	Mediators	Inflamm,	2014.	2014:	p.	208103.	
37.	 NICE,	Heavy	Menstrual	Bleeding.	March	2012.	Clinical	Guidline	44.	
38.	 Santer,	M.,	P.	Warner,	and	S.	Wyke,	A	Scottish	postal	survey	suggested	that	the	prevailing	
clinical	preoccupation	with	heavy	periods	does	not	reflect	the	epidemiology	of	reported	
symptoms	and	problems.	J	Clin	Epidemiol,	2005.	58(11):	p.	1206-10.	
39.	 Bhattacharya,	S.,	et	al.,	Hysterectomy,	endometrial	ablation	and	Mirena(R)	for	heavy	
menstrual	bleeding:	a	systematic	review	of	clinical	effectiveness	and	cost-effectiveness	
analysis.	Health	Technol	Assess,	2011.	15(19):	p.	iii-xvi,	1-252.	
40.	 Hallberg,	L.,	et	al.,	Menstrual	blood	loss	and	iron	deficiency.	Acta	Med	Scand,	1966.	
180(5):	p.	639-50.	
41.	 Fraser,	I.S.,	et	al.,	Efficacy	of	mefenamic	acid	in	patients	with	a	complaint	of	menorrhagia.	
Obstet	Gynecol,	1981.	58(5):	p.	543-51.	
42.	 RCOG,	National	Heavy	Menstrual	Bleeding	Auidt.	2012.	
43.	 Fraser,	I.S.,	et	al.,	Can	we	achieve	international	agreement	on	terminologies	and	
definitions	used	to	describe	abnormalities	of	menstrual	bleeding?	Hum	Reprod,	2007.	
22(3):	p.	635-43.	
248 
 
 
 
44.	 Diaz,	R.,	et	al.,	Hemostatic	abnormalities	in	young	females	with	heavy	menstrual	bleeding.	
J	Pediatr	Adolesc	Gynecol,	2014.	27(6):	p.	324-9.	
45.	 Schatz,	F.,	et	al.,	Implications	of	decidualization-associated	protease	expression	in	
implantation	and	menstruation.	Semin	Reprod	Endocrinol,	1999.	17(1):	p.	3-12.	
46.	 Wu,	Q.	and	Z.	Zhao,	Inhibition	of	PAI-1:	a	new	anti-thrombotic	approach.	Curr	Drug	
Targets	Cardiovasc	Haematol	Disord,	2002.	2(1):	p.	27-42.	
47.	 Rybo,	G.	and	L.	Hallberg,	Influence	of	heredity	and	environment	on	normal	menstrual	
blood	loss.	A	study	of	twins.	Acta	Obstet	Gynecol	Scand,	1966.	45(4):	p.	389-410.	
48.	 Clancy,	R.,	et	al.,	Nitric	oxide	synthase/COX	cross-talk:	nitric	oxide	activates	COX-1	but	
inhibits	COX-2-derived	prostaglandin	production.	J	Immunol,	2000.	165(3):	p.	1582-7.	
49.	 Chiarugi,	V.,	L.	Magnelli,	and	O.	Gallo,	Cox-2,	iNOS	and	p53	as	play-makers	of	tumor	
angiogenesis	(review).	Int	J	Mol	Med,	1998.	2(6):	p.	715-9.	
50.	 Fraser,	I.S.,	Prostaglandins,	prostaglandin	inhibitors	and	their	roles	in	gynaecological	
disorders.	Baillieres	Clin	Obstet	Gynaecol,	1992.	6(4):	p.	829-57.	
51.	 Cameron,	I.T.,	et	al.,	The	effects	of	mefenamic	acid	and	norethisterone	on	measured	
menstrual	blood	loss.	Obstet	Gynecol,	1990.	76(1):	p.	85-8.	
52.	 Kovachev,	S.M.,	S.D.	Nikolov,	and	A.P.	Mihova,	Uterine	leiomyoma	in	a	man	with	
persistent	Mullerian	duct	syndrome	and	seminoma.	Isr	Med	Assoc	J,	2014.	16(11):	p.	735-
7.	
53.	 Bozini,	N.	and	E.C.	Baracat,	The	history	of	myomectomy	at	the	Medical	School	of	
University	of	Sao	Paulo.	Clinics	(Sao	Paulo),	2007.	62(3):	p.	209-10.	
54.	 Siskin,	G.,	Thieme	Medical	Publishers	Inc.	
Interventional	Radiology	in	Women's	Health.	2009:	p.	27.	
55.	 Buttram,	V.C.,	Jr.	and	R.C.	Reiter,	Uterine	leiomyomata:	etiology,	symptomatology,	and	
management.	Fertil	Steril,	1981.	36(4):	p.	433-45.	
56.	 Baird,	D.D.,	et	al.,	High	cumulative	incidence	of	uterine	leiomyoma	in	black	and	white	
women:	ultrasound	evidence.	American	Journal	of	Obstetrics	and	Gynecology,	2003.	
188(1):	p.	100-7.	
57.	 Wise,	L.A.,	et	al.,	Reproductive	factors,	hormonal	contraception,	and	risk	of	uterine	
leiomyomata	in	African-American	women:	a	prospective	study.	Am	J	Epidemiol,	2004.	
159(2):	p.	113-23.	
58.	 Cardozo,	E.R.,	et	al.,	The	estimated	annual	cost	of	uterine	leiomyomata	in	the	United	
States.	Am	J	Obstet	Gynecol,	2012.	206(3):	p.	211.e1-9.	
59.	 2012-2013,	P.,	https://www.gov.uk/government/publications/payment-by-results-pbr-
operational-guidance-and-tariffs.	UK	Government	NHS	tariff.	
60.	 Ligon,	A.H.	and	C.C.	Morton,	Genetics	of	uterine	leiomyomata.	Genes	Chromosomes	
Cancer,	2000.	28(3):	p.	235-45.	
61.	 Moravek,	M.B.,	et	al.,	Ovarian	steroids,	stem	cells	and	uterine	leiomyoma:	therapeutic	
implications.	Hum	Reprod	Update,	2014.	
62.	 Vikhlyaeva,	E.M.,	Z.S.	Khodzhaeva,	and	N.D.	Fantschenko,	Familial	predisposition	to	
uterine	leiomyomas.	Int	J	Gynaecol	Obstet,	1995.	51(2):	p.	127-31.	
63.	 Ross,	R.K.,	et	al.,	Risk	factors	for	uterine	fibroids:	reduced	risk	associated	with	oral	
contraceptives.	Br	Med	J	(Clin	Res	Ed),	1986.	293(6543):	p.	359-62.	
64.	 Evans,	P.	and	S.	Brunsell,	Uterine	fibroid	tumors:	diagnosis	and	treatment.	Am	Fam	
Physician,	2007.	75(10):	p.	1503-8.	
65.	 D'Aloisio,	A.A.,	et	al.,	Association	of	intrauterine	and	early-life	exposures	with	diagnosis	of	
uterine	leiomyomata	by	35	years	of	age	in	the	Sister	Study.	Environ	Health	Perspect,	2010.	
118(3):	p.	375-81.	
66.	 Chen,	C.R.,	et	al.,	Risk	factors	for	uterine	fibroids	among	women	undergoing	tubal	
sterilization.	Am	J	Epidemiol,	2001.	153(1):	p.	20-6.	
67.	 Templeman,	C.,	et	al.,	Risk	factors	for	surgically	removed	fibroids	in	a	large	cohort	of	
teachers.	Fertil	Steril,	2009.	92(4):	p.	1436-46.	
249 
 
 
 
68.	 Terry,	K.L.,	et	al.,	Anthropometric	characteristics	and	risk	of	uterine	leiomyoma.	
Epidemiology,	2007.	18(6):	p.	758-63.	
69.	 Gupta,	S.,	J.	Jose,	and	I.	Manyonda,	Clinical	presentation	of	fibroids.	Best	Pract	Res	Clin	
Obstet	Gynaecol,	2008.	22(4):	p.	615-26.	
70.	 Myomas	and	reproductive	function.	Fertil	Steril,	2008.	90(5	Suppl):	p.	S125-30.	
71.	 Van	Voorhis,	B.,	A	41-year-old	woman	with	menorrhagia,	anemia,	and	fibroids:	review	of	
treatment	of	uterine	fibroids.	Jama,	2009.	301(1):	p.	82-93.	
72.	 Puri,	K.,	et	al.,	Submucosal	fibroids	and	the	relation	to	heavy	menstrual	bleeding	and	
anemia.	Am	J	Obstet	Gynecol,	2014.	210(1):	p.	38.e1-7.	
73.	 Sulaiman,	S.,	et	al.,	Uterine	fibroids--do	size	and	location	determine	menstrual	blood	loss?	
Eur	J	Obstet	Gynecol	Reprod	Biol,	2004.	115(1):	p.	85-9.	
74.	 Sinclair,	D.C.,	A.	Mastroyannis,	and	H.S.	Taylor,	Leiomyoma	simultaneously	impair	
endometrial	BMP-2-mediated	decidualization	and	anticoagulant	expression	through	
secretion	of	TGF-beta3.	J	Clin	Endocrinol	Metab,	2011.	96(2):	p.	412-21.	
75.	 Miller,	N.F.	and	P.P.	Ludovici,	On	the	origin	and	development	of	uterine	fibroids.	Am	J	
Obstet	Gynecol,	1955.	70(4):	p.	720-40.	
76.	 Farrer-Brown,	G.,	J.O.	Beilby,	and	M.H.	Tarbit,	Venous	changes	in	the	endometrium	of	
myomatous	uteri.	Obstet	Gynecol,	1971.	38(5):	p.	743-51.	
77.	 Chimbira,	T.H.,	A.B.	Anderson,	and	A.	Turnbull,	Relation	between	measured	menstrual	
blood	loss	and	patient's	subjective	assessment	of	loss,	duration	of	bleeding,	number	of	
sanitary	towels	used,	uterine	weight	and	endometrial	surface	area.	Br	J	Obstet	Gynaecol,	
1980.	87(7):	p.	603-9.	
78.	 Palmer,	S.S.,	et	al.,	Increased	expression	of	stromelysin	3	mRNA	in	leiomyomas	(uterine	
fibroids)	compared	with	myometrium.	J	Soc	Gynecol	Investig,	1998.	5(4):	p.	203-9.	
79.	 Stewart,	E.A.	and	R.A.	Nowak,	Leiomyoma-related	bleeding:	a	classic	hypothesis	updated	
for	the	molecular	era.	Hum	Reprod	Update,	1996.	2(4):	p.	295-306.	
80.	 Lai,	T.H.,	et	al.,	Expression	Patterns	of	VEGF	and	Flk-1	in	Human	Endometrium	during	the	
Menstrual	Cycle.	J	Reprod	Infertil,	2015.	16(1):	p.	3-9.	
81.	 Farquhar,	C.,	Do	uterine	fibroids	cause	infertility	and	should	they	be	removed	to	increase	
fertility?	Bmj,	2009.	338:	p.	b126.	
82.	 Templeton	A,	C.I.,	O'Brien	PMS,	Evidence	-based	Fertility	Treatment.	London	RCOG	Press,	
1998.	
83.	 Pritts,	E.A.,	W.H.	Parker,	and	D.L.	Olive,	Fibroids	and	infertility:	an	updated	systematic	
review	of	the	evidence.	Fertility	and	Sterility,	2009.	91(4):	p.	1215-23.	
84.	 Muram,	D.,	M.	Gillieson,	and	J.H.	Walters,	Myomas	of	the	uterus	in	pregnancy:	
ultrasonographic	follow-up.	Am	J	Obstet	Gynecol,	1980.	138(1):	p.	16-9.	
85.	 Barlow,	D.H.,	et	al.,	Individualized	vaginal	bleeding	experience	of	women	with	uterine	
fibroids	in	the	PEARL	I	randomized	controlled	trial	comparing	the	effects	of	ulipristal	
acetate	or	placebo.	Hum	Reprod,	2014.	29(3):	p.	480-9.	
86.	 Fedele,	L.,	et	al.,	Transvaginal	ultrasonography	versus	hysteroscopy	in	the	diagnosis	of	
uterine	submucous	myomas.	Obstet	Gynecol,	1991.	77(5):	p.	745-8.	
87.	 Vercellini,	P.,	et	al.,	The	role	of	transvaginal	ultrasonography	and	outpatient	diagnostic	
hysteroscopy	in	the	evaluation	of	patients	with	menorrhagia.	Hum	Reprod,	1997.	12(8):	p.	
1768-71.	
88.	 Wilde,	S.	and	S.	Scott-Barrett,	Radiological	appearances	of	uterine	fibroids.	Indian	J	Radiol	
Imaging,	2009.	19(3):	p.	222-31.	
89.	 Harlow,	B.L.,	N.S.	Weiss,	and	S.	Lofton,	The	Epidemiology	of	Sarcomas	of	the	Uterus.	
Journal	of	the	National	Cancer	Institute,	1986.	76(3):	p.	399-402.	
90.	 Quade,	B.J.,	et	al.,	Molecular	pathogenesis	of	uterine	smooth	muscle	tumors	from	
transcriptional	profiling.	Genes	Chromosomes	Cancer,	2004.	40(2):	p.	97-108.	
91.	 Leibsohn,	S.,	et	al.,	Leiomyosarcoma	in	a	series	of	hysterectomies	performed	for	presumed	
uterine	leiomyomas.	American	Journal	of	Obstetrics	and	Gynecology,	1990.	162(4):	p.	968-
74;	discussion	974-6.	
250 
 
 
 
92.	 Pritts,	E.A.,	et	al.,	The	prevalence	of	occult	leiomyosarcoma	at	surgery	for	presumed	
uterine	fibroids:	a	meta-analysis.	Gynecol	Surg,	2015.	12(3):	p.	165-177.	
93.	 Parker,	W.H.,	Etiology,	symptomatology,	and	diagnosis	of	uterine	myomas.	Fertil	Steril,	
2007.	87(4):	p.	725-36.	
94.	 Goto,	A.,	et	al.,	Usefulness	of	Gd-DTPA	contrast-enhanced	dynamic	MRI	and	serum	
determination	of	LDH	and	its	isozymes	in	the	differential	diagnosis	of	leiomyosarcoma	
from	degenerated	leiomyoma	of	the	uterus.	Int	J	Gynecol	Cancer,	2002.	12(4):	p.	354-61.	
95.	 Sato,	K.,	et	al.,	Clinical	application	of	diffusion-weighted	imaging	for	preoperative	
differentiation	between	uterine	leiomyoma	and	leiomyosarcoma.	American	Journal	of	
Obstetrics	and	Gynecology,	2014.	210(4):	p.	368	e1-8.	
96.	 Sutton,	C.,	Hysterectomy:	a	historical	perspective.	Baillieres	Clin	Obstet	Gynaecol,	1997.	
11(1):	p.	1-22.	
97.	 Philipp,	E.E.,	Victor	Bonney:	The	Gynaecological	Surgeon	of	the	Twentieth	Century.	Journal	
of	the	Royal	Society	of	Medicine,	2001.	94(6):	p.	311-312.	
98.	 Khan,	A.T.,	M.	Shehmar,	and	J.K.	Gupta,	Uterine	fibroids:	current	perspectives.	Int	J	
Womens	Health,	2014.	6:	p.	95-114.	
99.	 Eder,	S.,	et	al.,	Efficacy	and	safety	of	oral	tranexamic	acid	in	women	with	heavy	menstrual	
bleeding	and	fibroids.	Womens	Health	(Lond	Engl),	2013.	9(4):	p.	397-403.	
100.	 Lukes,	A.S.,	et	al.,	Tranexamic	acid	treatment	for	heavy	menstrual	bleeding:	a	randomized	
controlled	trial.	Obstet	Gynecol,	2010.	116(4):	p.	865-75.	
101.	 Peitsidis,	P.	and	A.	Koukoulomati,	Tranexamic	acid	for	the	management	of	uterine	fibroid	
tumors:	A	systematic	review	of	the	current	evidence.	World	J	Clin	Cases,	2014.	2(12):	p.	
893-8.	
102.	 Caglar,	G.S.,	et	al.,	Intravenous	tranexamic	acid	use	in	myomectomy:	a	prospective	
randomized	double-blind	placebo	controlled	study.	Eur	J	Obstet	Gynecol	Reprod	Biol,	
2008.	137(2):	p.	227-31.	
103.	 Sentilhes,	L.,	et	al.,	Tranexamic	acid	for	the	prevention	and	treatment	of	postpartum	
haemorrhage.	Br	J	Anaesth,	2015.	114(4):	p.	576-87.	
104.	 Lethaby,	A.,	K.	Duckitt,	and	C.	Farquhar,	Non-steroidal	anti-inflammatory	drugs	for	heavy	
menstrual	bleeding.	Cochrane	Database	Syst	Rev,	2013.	1:	p.	Cd000400.	
105.	 Edgren,	R.A.	and	F.Z.	Stanczyk,	Nomenclature	of	the	gonane	progestins.	Contraception,	
1999.	60(6):	p.	313.	
106.	 Nilsson,	C.G.,	E.D.	Johansson,	and	T.	Luukkainen,	A	D-norgestrel-releasing	IUD.	
Contraception,	1976.	13(4):	p.	503-14.	
107.	 Youm,	J.,	et	al.,	Factors	affecting	the	spontaneous	expulsion	of	the	levonorgestrel-
releasing	intrauterine	system.	Int	J	Gynaecol	Obstet,	2014.	126(2):	p.	165-9.	
108.	 Kriplani,	A.,	et	al.,	Efficacy	of	the	levonorgestrel-releasing	intrauterine	system	in	uterine	
leiomyoma.	Int	J	Gynaecol	Obstet,	2012.	116(1):	p.	35-8.	
109.	 Magalhaes,	J.,	J.M.	Aldrighi,	and	G.R.	de	Lima,	Uterine	volume	and	menstrual	patterns	in	
users	of	the	levonorgestrel-releasing	intrauterine	system	with	idiopathic	menorrhagia	or	
menorrhagia	due	to	leiomyomas.	Contraception,	2007.	75(3):	p.	193-8.	
110.	 Marshall,	J.C.	and	M.L.	Griffin,	The	role	of	changing	pulse	frequency	in	the	regulation	of	
ovulation.	Hum	Reprod,	1993.	8	Suppl	2:	p.	57-61.	
111.	 Jayes,	F.C.,	J.H.	Britt,	and	K.L.	Esbenshade,	Role	of	gonadotropin-releasing	hormone	pulse	
frequency	in	differential	regulation	of	gonadotropins	in	the	gilt.	Biol	Reprod,	1997.	56(4):	
p.	1012-9.	
112.	 Magon,	N.,	Gonadotropin	releasing	hormone	agonists:	Expanding	vistas.	Indian	J	
Endocrinol	Metab,	2011.	15(4):	p.	261-7.	
113.	 Bedaiwy,	M.A.,	N.A.	Mousa,	and	R.F.	Casper,	Aromatase	inhibitors	prevent	the	estrogen	
rise	associated	with	the	flare	effect	of	gonadotropins	in	patients	treated	with	GnRH	
agonists.	Fertil	Steril,	2009.	91(4	Suppl):	p.	1574-7.	
114.	 Agents	stimulating	gonadal	function	in	the	human.	Report	of	a	WHO	scientific	group.	
World	Health	Organ	Tech	Rep	Ser,	1973.	514:	p.	1-30.	
251 
 
 
 
115.	 Moroni,	R.,	et	al.,	Pharmacological	treatment	of	uterine	fibroids.	Ann	Med	Health	Sci	Res,	
2014.	4(Suppl	3):	p.	S185-92.	
116.	 De	Falco,	M.,	et	al.,	[GnRH	agonists	and	antagonists	in	the	preoperative	therapy	of	uterine	
fibroids:	literature	review].	Minerva	Ginecol,	2006.	58(6):	p.	553-60.	
117.	 Lethaby,	A.,	B.	Vollenhoven,	and	M.	Sowter,	Pre-operative	GnRH	analogue	therapy	before	
hysterectomy	or	myomectomy	for	uterine	fibroids.	Cochrane	Database	Syst	Rev,	2000(2):	
p.	CD000547.	
118.	 Sinai	Talaulikar,	V.,	A.M.	Belli,	and	I.	Manyonda,	GnRH	agonists:	do	they	have	a	place	in	
the	modern	management	of	fibroid	disease?	J	Obstet	Gynaecol	India,	2012.	62(5):	p.	506-
10.	
119.	 Mavrelos,	D.,	et	al.,	The	value	of	pre-operative	treatment	with	GnRH	analogues	in	women	
with	submucous	fibroids:	a	double-blind,	placebo-controlled	randomized	trial.	Hum	
Reprod,	2010.	25(9):	p.	2264-9.	
120.	 Freundl,	G.,	et	al.,	Steroidal	'add-back'	therapy	in	patients	treated	with	GnRH	agonists.	
Gynecol	Obstet	Invest,	1998.	45	Suppl	1:	p.	22-30;	discussion	35.	
121.	 Whitaker,	L.H.,	A.R.	Williams,	and	H.O.	Critchley,	Selective	progesterone	receptor	
modulators.	Curr	Opin	Obstet	Gynecol,	2014.	26(4):	p.	237-42.	
122.	 Carbonell,	J.L.,	et	al.,	Treatment	of	Uterine	Myoma	with	2.5	or	5	mg	Mifepristone	Daily	
during	3	Months	with	9	Months	Posttreatment	Followup:	Randomized	Clinical	Trial.	ISRN	
Obstet	Gynecol,	2013.	2013:	p.	649030.	
123.	 Talaulikar,	V.S.	and	I.T.	Manyonda,	Ulipristal	acetate:	a	novel	option	for	the	medical	
management	of	symptomatic	uterine	fibroids.	Adv	Ther,	2012.	29(8):	p.	655-63.	
124.	 Donnez,	J.,	et	al.,	Ulipristal	acetate	versus	placebo	for	fibroid	treatment	before	surgery.	N	
Engl	J	Med,	2012.	366(5):	p.	409-20.	
125.	 Donnez,	J.,	et	al.,	Long-term	treatment	of	uterine	fibroids	with	ulipristal	acetate.	Fertil	
Steril,	2014.	101(6):	p.	1565-73.e1-18.	
126.	 Donnez,	J.,	et	al.,	Efficacy	and	safety	of	repeated	use	of	ulipristal	acetate	in	uterine	
fibroids.	Fertil	Steril,	2015.	103(2):	p.	519-27.e3.	
127.	 Spitz,	I.M.,	Clinical	utility	of	progesterone	receptor	modulators	and	their	effect	on	the	
endometrium.	Curr	Opin	Obstet	Gynecol,	2009.	21(4):	p.	318-24.	
128.	 Williams,	A.R.,	et	al.,	Endometrial	morphology	after	treatment	of	uterine	fibroids	with	the	
selective	progesterone	receptor	modulator,	ulipristal	acetate.	Int	J	Gynecol	Pathol,	2012.	
31(6):	p.	556-69.	
129.	 Brazert,	M.,	M.P.	Korman,	and	L.A.	Pawelczyk,	[Applicability	of	selective	progesterone	
receptor	modulators	in	the	treatment	of	uterine	leiomyomata	and	their	future	role	in	the	
field	of	gynecology].	Ginekol	Pol,	2013.	84(9):	p.	794-800.	
130.	 Luyckx,	M.,	et	al.,	First	series	of	18	pregnancies	after	ulipristal	acetate	treatment	for	
uterine	fibroids.	Fertil	Steril,	2014.	102(5):	p.	1404-9.	
131.	 Varelas,	F.K.,	et	al.,	The	effect	of	anastrazole	on	symptomatic	uterine	leiomyomata.	Obstet	
Gynecol,	2007.	110(3):	p.	643-9.	
132.	 Ravina,	J.H.,	et	al.,	Arterial	embolisation	to	treat	uterine	myomata.	Lancet,	1995.	
346(8976):	p.	671-2.	
133.	 Gupta,	J.K.,	et	al.,	Uterine	artery	embolization	for	symptomatic	uterine	fibroids.	Cochrane	
Database	Systematic	Review,	2012.	5:	p.	Cd005073.	
134.	 Manyonda,	I.T.,	et	al.,	Uterine	artery	embolization	versus	myomectomy:	impact	on	quality	
of	life--results	of	the	FUME	(Fibroids	of	the	Uterus:	Myomectomy	versus	Embolization)	
Trial.	Cardiovasc	Intervent	Radiol,	2012.	35(3):	p.	530-6.	
135.	 Kaump,	G.R.	and	J.B.	Spies,	The	impact	of	uterine	artery	embolization	on	ovarian	function.	
J	Vasc	Interv	Radiol,	2013.	24(4):	p.	459-67.	
136.	 Stewart,	E.A.,	et	al.,	Focused	ultrasound	treatment	of	uterine	fibroid	tumors:	safety	and	
feasibility	of	a	noninvasive	thermoablative	technique.	Am	J	Obstet	Gynecol,	2003.	189(1):	
p.	48-54.	
252 
 
 
 
137.	 Hynynen,	K.,	et	al.,	A	clinical,	noninvasive,	MR	imaging-monitored	ultrasound	surgery	
method.	Radiographics,	1996.	16(1):	p.	185-95.	
138.	 Chung,	A.H.,	F.A.	Jolesz,	and	K.	Hynynen,	Thermal	dosimetry	of	a	focused	ultrasound	beam	
in	vivo	by	magnetic	resonance	imaging.	Med	Phys,	1999.	26(9):	p.	2017-26.	
139.	 Fan,	R.,	et	al.,	[Prospective	study	on	magnetic	resonance-guided	focused	ultrasound	
surgery	for	symptomatic	uterine	fibroid:	short-term	follow	up].	Zhonghua	Fu	Chan	Ke	Za	
Zhi,	2013.	48(3):	p.	183-7.	
140.	 Voogt,	M.J.,	et	al.,	Volumetric	feedback	ablation	of	uterine	fibroids	using	magnetic	
resonance-guided	high	intensity	focused	ultrasound	therapy.	Eur	Radiol,	2012.	22(2):	p.	
411-7.	
141.	 Froeling,	V.,	et	al.,	Midterm	results	after	uterine	artery	embolization	versus	MR-guided	
high-intensity	focused	ultrasound	treatment	for	symptomatic	uterine	fibroids.	Cardiovasc	
Intervent	Radiol,	2013.	36(6):	p.	1508-13.	
142.	 Gizzo,	S.,	et	al.,	Magnetic	resonance-guided	focused	ultrasound	myomectomy:	safety,	
efficacy,	subsequent	fertility	and	quality-of-life	improvements,	a	systematic	review.	
Reprod	Sci,	2014.	21(4):	p.	465-76.	
143.	 Garza	Leal,	J.G.,	et	al.,	Laparoscopic	ultrasound-guided	radiofrequency	volumetric	thermal	
ablation	of	symptomatic	uterine	leiomyomas:	feasibility	study	using	the	Halt	2000	
Ablation	System.	J	Minim	Invasive	Gynecol,	2011.	18(3):	p.	364-71.	
144.	 Berman,	J.M.,	et	al.,	Three-year	outcome	of	the	Halt	trial:	a	prospective	analysis	of	
radiofrequency	volumetric	thermal	ablation	of	myomas.	J	Minim	Invasive	Gynecol,	2014.	
21(5):	p.	767-74.	
145.	 Salama,	S.S.	and	G.S.	Kilic,	Uterine	fibroids	and	current	clinical	challenges.	J	Turk	Ger	
Gynecol	Assoc,	2013.	14(1):	p.	40-5.	
146.	 Hysterectomy-association.org.uk,	http://www.hysterectomy-
association.org.uk/research/latest-hysterectomy-statistics-in-uk-for-the-year-2011-to-
2012/.	2013.	
147.	 Okolo,	S.,	Incidence,	aetiology	and	epidemiology	of	uterine	fibroids.	Best	Pract	Res	Clin	
Obstet	Gynaecol,	2008.	22(4):	p.	571-88.	
148.	 Moss,	J.G.,	et	al.,	Randomised	comparison	of	uterine	artery	embolisation	(UAE)	with	
surgical	treatment	in	patients	with	symptomatic	uterine	fibroids	(REST	trial):	5-year	
results.	Bjog,	2011.	118(8):	p.	936-44.	
149.	 Bourdrez,	P.,	M.Y.	Bongers,	and	B.W.	Mol,	Treatment	of	dysfunctional	uterine	bleeding:	
patient	preferences	for	endometrial	ablation,	a	levonorgestrel-releasing	intrauterine	
device,	or	hysterectomy.	Fertil	Steril,	2004.	82(1):	p.	160-6,	quiz	265.	
150.	 Pitter,	M.C.	and	C.	Simmonds,	The	impact	of	different	surgical	modalities	for	hysterectomy	
on	satisfaction	and	patient	reported	outcomes.	2014.	3(3):	p.	e11.	
151.	 WL,	A.,	Removal	of	fibrous	tumour	of	the	uterus.	Am	J	Med	Sci,	1845.	11:	p.	309-35	
	
152.	 WA,	A.,	Myomectomy.	Med	Press	&	Circular,	1889.	14:	p.	47.	
153.	 Machupalli	S,	N.E.,	Mukherjee	TK,	Reilly	KD,	Abdominal	Myomectomy	Increases	Fertility	
Outcome.	Gynecol	Obste,	2013.	3:	p.	144.	
154.	 Metwally,	M.,	Y.C.	Cheong,	and	A.W.	Horne,	Surgical	treatment	of	fibroids	for	subfertility.	
Cochrane	Database	Syst	Rev,	2012.	11:	p.	Cd003857.	
155.	 van	der	Kooij,	S.M.,	W.M.	Ankum,	and	W.J.	Hehenkamp,	Review	of	nonsurgical/minimally	
invasive	treatments	for	uterine	fibroids.	Curr	Opin	Obstet	Gynecol,	2012.	24(6):	p.	368-75.	
156.	 Tinelli,	A.,	et	al.,	Laparoscopic	myomectomy	focusing	on	the	myoma	pseudocapsule:	
technical	and	outcome	reports.	Hum	Reprod,	2012.	27(2):	p.	427-35.	
157.	 Sizzi,	O.,	et	al.,	Italian	multicenter	study	on	complications	of	laparoscopic	myomectomy.	J	
Minim	Invasive	Gynecol,	2007.	14(4):	p.	453-62.	
158.	 Bernardi,	T.S.,	et	al.,	Laparoscopic	myomectomy:	a	6-year	follow-up	single-center	cohort	
analysis	of	fertility	and	obstetric	outcome	measures.	Arch	Gynecol	Obstet,	2014.	290(1):	p.	
87-91.	
253 
 
 
 
159.	 Parker,	W.H.,	et	al.,	Risk	factors	for	uterine	rupture	after	laparoscopic	myomectomy.	J	
Minim	Invasive	Gynecol,	2010.	17(5):	p.	551-4.	
160.	 Desai,	P.	and	P.	Patel,	Fibroids,	infertility	and	laparoscopic	myomectomy.	J	Gynecol	Endosc	
Surg,	2011.	2(1):	p.	36-42.	
161.	 Gambadauro,	P.,	J.	Gudmundsson,	and	R.	Torrejon,	Intrauterine	Adhesions	following	
Conservative	Treatment	of	Uterine	Fibroids.	Obstet	Gynecol	Int,	2012.	2012:	p.	853269.	
162.	 Bougie,	O.,	et	al.,	Treatment	of	Asherman's	Syndrome	in	an	Outpatient	Hysteroscopy	
Setting.	J	Minim	Invasive	Gynecol,	2014.	
163.	 Bosteels,	J.,	et	al.,	Hysteroscopy	for	treating	subfertility	associated	with	suspected	major	
uterine	cavity	abnormalities.	Cochrane	Database	Syst	Rev,	2013.	1:	p.	Cd009461.	
164.	 Sinha,	R.,	et	al.,	Robotic	surgery	in	gynecology.	J	Minim	Access	Surg,	2015.	11(1):	p.	50-9.	
165.	 Advincula,	A.P.	and	A.	Song,	Endoscopic	management	of	leiomyomata.	Semin	Reprod	
Med,	2004.	22(2):	p.	149-55.	
166.	 Nezhat,	C.,	et	al.,	Robotic-assisted	laparoscopic	myomectomy	compared	with	standard	
laparoscopic	myomectomy--a	retrospective	matched	control	study.	Fertil	Steril,	2009.	
91(2):	p.	556-9.	
167.	 Pitter,	M.C.,	et	al.,	Pregnancy	outcomes	following	robot-assisted	myomectomy.	Hum	
Reprod,	2013.	28(1):	p.	99-108.	
168.	 Higham,	J.M.,	P.M.	O'Brien,	and	R.W.	Shaw,	Assessment	of	menstrual	blood	loss	using	a	
pictorial	chart.	Br	J	Obstet	Gynaecol,	1990.	97(8):	p.	734-9.	
169.	 Noyes,	R.W.	and	J.O.	Haman,	Accuracy	of	endometrial	dating;	correlation	of	endometrial	
dating	with	basal	body	temperature	and	menses.	Fertil	Steril,	1953.	4(6):	p.	504-17.	
170.	 Critchley,	H.O.	and	P.T.	Saunders,	Hormone	receptor	dynamics	in	a	receptive	human	
endometrium.	Reprod	Sci,	2009.	16(2):	p.	191-9.	
171.	 Roongsitthichai,	A.,	et	al.,	Expression	of	cyclooxygenase-2	in	the	endometrium	of	gilts	with	
different	stages	of	endometritis.	J	Vet	Med	Sci,	2011.	73(11):	p.	1425-31.	
172.	 Fedchenko,	N.	and	J.	Reifenrath,	Different	approaches	for	interpretation	and	reporting	of	
immunohistochemistry	analysis	results	in	the	bone	tissue	-	a	review.	Diagn	Pathol,	2014.	9:	
p.	221.	
173.	 Obuchowski,	N.A.,	How	many	observers	are	needed	in	clinical	studies	of	medical	imaging?	
AJR	Am	J	Roentgenol,	2004.	182(4):	p.	867-9.	
174.	 Rupp,	G.M.	and	J.	Locker,	Purification	and	analysis	of	RNA	from	paraffin-embedded	
tissues.	Biotechniques,	1988.	6(1):	p.	56-60.	
175.	 Ribeiro-Silva,	A.,	H.	Zhang,	and	S.S.	Jeffrey,	RNA	extraction	from	ten	year	old	formalin-
fixed	paraffin-embedded	breast	cancer	samples:	a	comparison	of	column	purification	and	
magnetic	bead-based	technologies.	BMC	Mol	Biol,	2007.	8:	p.	118.	
176.	 Specht,	K.,	et	al.,	Quantitative	gene	expression	analysis	in	microdissected	archival	
formalin-fixed	and	paraffin-embedded	tumor	tissue.	Am	J	Pathol,	2001.	158(2):	p.	419-29.	
177.	 Broekmans,	F.J.,	et	al.,	Quantitative	MRI	of	uterine	leiomyomas	during	triptorelin	
treatment:	reproducibility	of	volume	assessment	and	predictability	of	treatment	response.	
Magn	Reson	Imaging,	1996.	14(10):	p.	1127-35.	
178.	 Koga,	K.,	et	al.,	Demonstration	of	angiogenin	in	human	endometrium	and	its	enhanced	
expression	in	endometrial	tissues	in	the	secretory	phase	and	the	decidua.	J	Clin	Endocrinol	
Metab,	2001.	86(11):	p.	5609-14.	
179.	 Ferrara,	N.,	Vascular	endothelial	growth	factor:	basic	science	and	clinical	progress.	Endocr	
Rev,	2004.	25(4):	p.	581-611.	
180.	 Furukawa,	Y.,	et	al.,	The	production	of	vascular	endothelial	growth	factor	and	
metalloproteinase	via	protease-activated	receptor	in	human	endometrial	stromal	cells.	
Fertil	Steril,	2009.	91(2):	p.	535-41.	
181.	 Fan,	X.,	et	al.,	VEGF	blockade	inhibits	angiogenesis	and	reepithelialization	of	
endometrium.	Faseb	j,	2008.	22(10):	p.	3571-80.	
182.	 Robinson,	C.J.	and	S.E.	Stringer,	The	splice	variants	of	vascular	endothelial	growth	factor	
(VEGF)	and	their	receptors.	J	Cell	Sci,	2001.	114(Pt	5):	p.	853-65.	
254 
 
 
 
183.	 Ferrara,	N.,	et	al.,	The	vascular	endothelial	growth	factor	family	of	polypeptides.	J	Cell	
Biochem,	1991.	47(3):	p.	211-8.	
184.	 Bakos,	O.,	O.	Lundkvist,	and	T.	Bergh,	Transvaginal	sonographic	evaluation	of	endometrial	
growth	and	texture	in	spontaneous	ovulatory	cycles--a	descriptive	study.	Hum	Reprod,	
1993.	8(6):	p.	799-806.	
185.	 Krikun,	G.,	F.	Schatz,	and	C.J.	Lockwood,	Endometrial	angiogenesis:	from	physiology	to	
pathology.	Ann	N	Y	Acad	Sci,	2004.	1034:	p.	27-35.	
186.	 Coudyzer,	P.,	et	al.,	Hypoxia	is	not	required	for	human	endometrial	breakdown	or	repair	in	
a	xenograft	model	of	menstruation.	Faseb	j,	2013.	27(9):	p.	3711-9.	
187.	 Lockwood,	C.J.,	Mechanisms	of	normal	and	abnormal	endometrial	bleeding.	Menopause,	
2011.	18(4):	p.	408-11.	
188.	 Khan,	K.N.,	et	al.,	Changes	in	tissue	inflammation,	angiogenesis	and	apoptosis	in	
endometriosis,	adenomyosis	and	uterine	myoma	after	GnRH	agonist	therapy.	Human	
Reproduction,	2010.	25(3):	p.	642-653.	
189.	 Vu,	K.,	et	al.,	Cellular	proliferation,	estrogen	receptor,	progesterone	receptor,	and	bcl-2	
expression	in	GnRH	agonist-treated	uterine	leiomyomas.	Human	Pathology,	1998.	29(4):	p.	
359-363.	
190.	 Di	Lieto,	A.,	et	al.,	Preoperative	administration	of	GnRH-a	plus	tibolone	to	premenopausal	
women	with	uterine	fibroids:	evaluation	of	the	clinical	response,	the	immunohistochemical	
expression	of	PDGF,	bFGF	and	VEGF	and	the	vascular	pattern.	Steroids,	2005.	70(2):	p.	95-
102.	
191.	 Smith,	S.K.,	et	al.,	Prostaglandin	synthesis	in	the	endometrium	of	women	with	ovular	
dysfunctional	uterine	bleeding.	Br	J	Obstet	Gynaecol,	1981.	88(4):	p.	434-42.	
192.	 Tong,	B.J.,	et	al.,	Heightened	expression	of	cyclooxygenase-2	and	peroxisome	proliferator-
activated	receptor-delta	in	human	endometrial	adenocarcinoma.	Neoplasia,	2000.	2(6):	p.	
483-90.	
193.	 Wu,	K.K.,	H.H.	Cheng,	and	T.C.	Chang,	5-methoxyindole	metabolites	of	L-tryptophan:	
control	of	COX-2	expression,	inflammation	and	tumorigenesis.	J	Biomed	Sci,	2014.	21:	p.	
17.	
194.	 Loftin,	C.D.,	H.F.	Tiano,	and	R.	Langenbach,	Phenotypes	of	the	COX-deficient	mice	indicate	
physiological	and	pathophysiological	roles	for	COX-1	and	COX-2.	Prostaglandins	Other	
Lipid	Mediat,	2002.	68-69:	p.	177-85.	
195.	 Lim,	H.	and	S.K.	Dey,	Prostaglandin	E2	receptor	subtype	EP2	gene	expression	in	the	mouse	
uterus	coincides	with	differentiation	of	the	luminal	epithelium	for	implantation.	
Endocrinology,	1997.	138(11):	p.	4599-606.	
196.	 Lim,	H.,	et	al.,	Multiple	female	reproductive	failures	in	cyclooxygenase	2-deficient	mice.	
Cell,	1997.	91(2):	p.	197-208.	
197.	 Davis,	B.J.,	et	al.,	Anovulation	in	cyclooxygenase-2-deficient	mice	is	restored	by	
prostaglandin	E2	and	interleukin-1beta.	Endocrinology,	1999.	140(6):	p.	2685-95.	
198.	 Jabbour,	H.N.,	et	al.,	Prostaglandin	receptors	are	mediators	of	vascular	function	in	
endometrial	pathologies.	Mol	Cell	Endocrinol,	2006.	252(1-2):	p.	191-200.	
199.	 Uotila,	P.J.,	R.U.	Erkkola,	and	P.J.	Klemi,	The	expression	of	cyclooxygenase-1	and	-2	in	
proliferative	endometrium	and	endometrial	adenocarcinoma.	Ann	Med,	2002.	34(6):	p.	
428-33.	
200.	 Sugino,	N.,	et	al.,	Withdrawal	of	ovarian	steroids	stimulates	prostaglandin	F2alpha	
production	through	nuclear	factor-kappaB	activation	via	oxygen	radicals	in	human	
endometrial	stromal	cells:	potential	relevance	to	menstruation.	J	Reprod	Dev,	2004.	50(2):	
p.	215-25.	
201.	 Milne,	S.A.,	et	al.,	Expression,	localization,	and	signaling	of	PGE(2)	and	EP2/EP4	receptors	
in	human	nonpregnant	endometrium	across	the	menstrual	cycle.	J	Clin	Endocrinol	Metab,	
2001.	86(9):	p.	4453-9.	
202.	 Giatromanolaki,	A.,	et	al.,	Differential	assessment	of	angiogenic	activity	and	of	vascular	
survival	ability	(VSA)	in	breast	cancer.	Clin	Exp	Metastasis,	2002.	19(8):	p.	673-9.	
255 
 
 
 
203.	 Han,	H.,	et	al.,	Vascular	endothelial	growth	factor	expression	in	stage	I	non-small	cell	lung	
cancer	correlates	with	neoangiogenesis	and	a	poor	prognosis.	Ann	Surg	Oncol,	2001.	8(1):	
p.	72-9.	
204.	 Goteri,	G.,	et	al.,	Expression	of	vascular	endothelial	growth	factor	(VEGF),	hypoxia	
inducible	factor-1alpha	(HIF-1alpha),	and	microvessel	density	in	endometrial	tissue	in	
women	with	adenomyosis.	Int	J	Gynecol	Pathol,	2009.	28(2):	p.	157-63.	
205.	 Hlatky,	L.,	P.	Hahnfeldt,	and	J.	Folkman,	Clinical	application	of	antiangiogenic	therapy:	
microvessel	density,	what	it	does	and	doesn't	tell	us.	J	Natl	Cancer	Inst,	2002.	94(12):	p.	
883-93.	
206.	 Hickey,	M.,	et	al.,	A	longitudinal	study	of	changes	in	endometrial	microvascular	density	in	
Norplant	implant	users.	Contraception,	1999.	59(2):	p.	123-9.	
207.	 Rogers,	P.A.,	C.L.	Au,	and	B.	Affandi,	Endometrial	microvascular	density	during	the	normal	
menstrual	cycle	and	following	exposure	to	long-term	levonorgestrel.	Hum	Reprod,	1993.	
8(9):	p.	1396-404.	
208.	 Czekierdowski,	A.,	et	al.,	Microvessel	density	assessment	in	benign	and	malignant	
endometrial	changes.	J	Physiol	Pharmacol,	2008.	59	Suppl	4:	p.	45-51.	
209.	 Tan,	G.,	et	al.,	Study	of	the	impact	of	uterine	artery	embolization	(UAE)	on	endometrial	
microvessel	density	(MVD)	and	angiogenesis.	Cardiovasc	Intervent	Radiol,	2013.	36(4):	p.	
1079-85.	
210.	 Scholzen,	T.	and	J.	Gerdes,	The	Ki-67	protein:	from	the	known	and	the	unknown.	J	Cell	
Physiol,	2000.	182(3):	p.	311-22.	
211.	 Gerdes,	J.,	et	al.,	Growth	fractions	in	malignant	non-Hodgkin's	lymphomas	(NHL)	as	
determined	in	situ	with	the	monoclonal	antibody	Ki-67.	Hematol	Oncol,	1984.	2(4):	p.	365-
71.	
212.	 Truskinovsky,	A.M.,	B.	Lifschitz-Mercer,	and	B.	Czernobilsky,	Hyperplasia	and	carcinoma	in	
secretory	endometrium:	a	diagnostic	challenge.	Int	J	Gynecol	Pathol,	2014.	33(2):	p.	107-
13.	
213.	 Konstantinos,	K.,	et	al.,	Expression	of	Ki-67	as	proliferation	biomarker	in	imprint	smears	of	
endometrial	carcinoma.	Diagn	Cytopathol,	2013.	41(3):	p.	212-7.	
214.	 Germeyer,	A.,	et	al.,	Changes	in	cell	proliferation,	but	not	in	vascularisation	are	
characteristic	for	human	endometrium	in	different	reproductive	failures--a	pilot	study.	
Reprod	Biol	Endocrinol,	2010.	8:	p.	67.	
215.	 Marusak,	R.A.,	Z.A.	Radi,	and	L.	Obert,	Expression	of	Ki-67	in	the	uterus	during	various	
stages	of	the	estrous	cycle	in	rats.	Exp	Toxicol	Pathol,	2007.	59(3-4):	p.	151-5.	
216.	 Khaund,	A.,	et	al.,	Evaluation	of	the	effect	of	uterine	artery	embolisation	on	menstrual	
blood	loss	and	uterine	volume.	Bjog,	2004.	111(7):	p.	700-5.	
217.	 T	Justin	Clark,	J.K.G.,	Endometrial	sampling	of	gynaecological	pathology.	The	Obstetrician	
and	Gynaecologist,	2002.	4:	p.	169-174.	
218.	 St-Louis,	I.,	et	al.,	Expression	of	COX-1	and	COX-2	in	the	endometrium	of	cyclic,	pregnant	
and	in	a	model	of	pseudopregnant	rats	and	their	regulation	by	sex	steroids.	Reprod	Biol	
Endocrinol,	2010.	8:	p.	103.	
219.	 Ma,	Y.,	et	al.,	[Targeted	interruption	of	COX-2	gene	by	siRNA	inhibits	the	expression	of	
VEGF,	MMP-9,	the	activity	of	COX-2	and	stimulates	the	apoptosis	in	eutopic,	ectopic	
endometrial	stromal	cells	of	women	with	endometriosis].	Zhonghua	Fu	Chan	Ke	Za	Zhi,	
2015.	50(10):	p.	770-6.	
220.	 Walker,	W.J.	and	J.P.	Pelage,	Uterine	artery	embolisation	for	symptomatic	fibroids:	clinical	
results	in	400	women	with	imaging	follow	up.	Bjog,	2002.	109(11):	p.	1262-72.	
221.	 JA,	S.,	The	blood	supply	of	uterine	myomata.	Surgical	Gynecology,	1912.	14:	p.	215-234.	
222.	 Gomez-Jorge,	J.,	et	al.,	Uterine	artery	anatomy	relevant	to	uterine	leiomyomata	
embolization.	Cardiovasc	Intervent	Radiol,	2003.	26(6):	p.	522-7.	
223.	 Pron,	G.,	et	al.,	The	Ontario	Uterine	Fibroid	Embolization	Trial.	Part	2.	Uterine	fibroid	
reduction	and	symptom	relief	after	uterine	artery	embolization	for	fibroids.	Fertil	Steril,	
2003.	79(1):	p.	120-7.	
256 
 
 
 
224.	 Murase,	E.,	et	al.,	Uterine	leiomyomas:	histopathologic	features,	MR	imaging	findings,	
differential	diagnosis,	and	treatment.	Radiographics,	1999.	19(5):	p.	1179-97.	
225.	 Hricak,	H.,	et	al.,	Uterine	leiomyomas:	correlation	of	MR,	histopathologic	findings,	and	
symptoms.	Radiology,	1986.	158(2):	p.	385-91.	
226.	 Pelage,	J.P.,	et	al.,	Uterine	fibroid	tumors:	long-term	MR	imaging	outcome	after	
embolization.	Radiology,	2004.	230(3):	p.	803-9.	
227.	 Firouznia,	K.,	et	al.,	Uterine	artery	embolization	in	101	cases	of	uterine	fibroids:	do	size,	
location,	and	number	of	fibroids	affect	therapeutic	success	and	complications?	Cardiovasc	
Intervent	Radiol,	2008.	31(3):	p.	521-6.	
228.	 Koesters,	C.,	et	al.,	Uterine	artery	embolization	in	single	symptomatic	leiomyoma:	do	
anatomical	imaging	criteria	predict	clinical	presentation	and	long-term	outcome?	Acta	
Radiol,	2014.	55(4):	p.	441-9.	
229.	 Parthipun,	A.A.,	et	al.,	Does	size	really	matter?	Analysis	of	the	effect	of	large	fibroids	and	
uterine	volumes	on	complication	rates	of	uterine	artery	embolisation.	Cardiovasc	Intervent	
Radiol,	2010.	33(5):	p.	955-9.	
230.	 Katsumori,	T.,	K.	Nakajima,	and	T.	Mihara,	Is	a	large	fibroid	a	high-risk	factor	for	uterine	
artery	embolization?	AJR	Am	J	Roentgenol,	2003.	181(5):	p.	1309-14.	
231.	 Berczi,	V.,	et	al.,	Safety	and	Effectiveness	of	UFE	in	Fibroids	Larger	than	10	cm.	Cardiovasc	
Intervent	Radiol,	2015.	
232.	 Smeets,	A.J.,	et	al.,	Uterine	artery	embolization	in	patients	with	a	large	fibroid	burden:	
long-term	clinical	and	MR	follow-up.	Cardiovasc	Intervent	Radiol,	2010.	33(5):	p.	943-8.	
233.	 Spielmann,	A.L.,	et	al.,	Comparison	of	MRI	and	sonography	in	the	preliminary	evaluation	
for	fibroid	embolization.	AJR	Am	J	Roentgenol,	2006.	187(6):	p.	1499-504.	
234.	 Naguib,	N.N.,	et	al.,	Leiomyoma	volume	changes	at	follow-up	after	uterine	artery	
embolization:	correlation	with	the	initial	leiomyoma	volume	and	location.	J	Vasc	Interv	
Radiol,	2010.	21(4):	p.	490-5.	
235.	 Zlotnik,	E.,	et	al.,	Predictive	factors	for	pelvic	magnetic	resonance	in	response	to	arterial	
embolization	of	a	uterine	leiomyoma.	Clinics	(Sao	Paulo),	2014.	69(3):	p.	185-9.	
236.	 Tropeano,	G.,	et	al.,	Incidence	and	predictive	factors	for	complications	after	uterine	
leiomyoma	embolization.	Hum	Reprod,	2014.	29(9):	p.	1918-24.	
237.	 Verma,	S.K.,	et	al.,	Submucosal	fibroids	becoming	endocavitary	following	uterine	artery	
embolization:	risk	assessment	by	MRI.	AJR	Am	J	Roentgenol,	2008.	190(5):	p.	1220-6.	
238.	 Redecha,	M.,	Jr.,	et	al.,	Myoma	expulsion	after	uterine	artery	embolization.	Arch	Gynecol	
Obstet,	2009.	280(6):	p.	1023-4.	
239.	 Hehenkamp,	W.J.,	et	al.,	Myoma	expulsion	after	uterine	artery	embolization:	complication	
or	cure?	Am	J	Obstet	Gynecol,	2004.	191(5):	p.	1713-5.	
240.	 Fleischer,	A.C.,	et	al.,	Three-dimensional	color	Doppler	sonography	before	and	after	fibroid	
embolization.	J	Ultrasound	Med,	2000.	19(10):	p.	701-5.	
241.	 deSouza,	N.M.	and	A.D.	Williams,	Uterine	arterial	embolization	for	leiomyomas:	perfusion	
and	volume	changes	at	MR	imaging	and	relation	to	clinical	outcome.	Radiology,	2002.	
222(2):	p.	367-74.	
242.	 Nikolaidis,	P.,	et	al.,	Incidence	of	nonviable	leiomyomas	on	contrast	material-enhanced	
pelvic	MR	imaging	in	patients	referred	for	uterine	artery	embolization.	J	Vasc	Interv	
Radiol,	2005.	16(11):	p.	1465-71.	
243.	 Katsumori,	T.,	et	al.,	Infarction	of	uterine	fibroids	after	embolization:	relationship	between	
postprocedural	enhanced	MRI	findings	and	long-term	clinical	outcomes.	Cardiovasc	
Intervent	Radiol,	2008.	31(1):	p.	66-72.	
244.	 Zimmermann,	A.,	et	al.,	Prevalence,	symptoms	and	management	of	uterine	fibroids:	an	
international	internet-based	survey	of	21,746	women.	BMC	Womens	Health,	2012.	12:	p.	
6.	
245.	 Wisot,	A.L.,	K.M.	Neimand,	and	A.H.	Rosenthal,	Symptomatic	myoma	in	a	13-year-old	girl.	
Am	J	Obstet	Gynecol,	1969.	105(4):	p.	639-41.	
257 
 
 
 
246.	 Tsili,	A.C.,	et	al.,	Fibromatous	uterus	in	a	16-year-old	girl:	a	case	report.	Case	Rep	Med,	
2010.	2010:	p.	932762.	
247.	 Tanweer	Karim,	K.P.,	Anuradha	Panchal,	Presentation	and	management	of	giant	fibroid	
uterus	in	an	adolescent	girl.	Open	Access	Surgery,	March	2010.	3.	
248.	 Fields,	K.R.	and	L.S.	Neinstein,	Uterine	myomas	in	adolescents:	case	reports	and	a	review	
of	the	literature.	J	Pediatr	Adolesc	Gynecol,	1996.	9(4):	p.	195-8.	
249.	 Van	Voorhis,	B.J.,	P.A.	Romitti,	and	M.P.	Jones,	Family	history	as	a	risk	factor	for	
development	of	uterine	leiomyomas.	Results	of	a	pilot	study.	J	Reprod	Med,	2002.	47(8):	p.	
663-9.	
250.	 Gabriel-Cox,	K.,	et	al.,	Predictors	of	hysterectomy	after	uterine	artery	embolization	for	
leiomyoma.	Am	J	Obstet	Gynecol,	2007.	196(6):	p.	588.e1-6.	
251.	 Sipola,	P.,	et	al.,	Preinterventional	quantitative	magnetic	resonance	imaging	predicts	
uterus	and	leiomyoma	size	reduction	after	uterine	artery	embolization.	J	Magn	Reson	
Imaging,	2010.	31(3):	p.	617-24.	
252.	 Jha,	R.C.,	et	al.,	Symptomatic	fibroleiomyomata:	MR	imaging	of	the	uterus	before	and	
after	uterine	arterial	embolization.	Radiology,	2000.	217(1):	p.	228-35.	
253.	 Tropeano,	G.,	et	al.,	Long-term	effects	of	uterine	fibroid	embolization	on	ovarian	reserve:	a	
prospective	cohort	study.	Fertil	Steril,	2010.	94(6):	p.	2296-300.	
254.	 Nalaboff,	K.M.,	J.S.	Pellerito,	and	E.	Ben-Levi,	Imaging	the	endometrium:	disease	and	
normal	variants.	Radiographics,	2001.	21(6):	p.	1409-24.	
255.	 Kitao,	K.,	et	al.,	The	development	of	placenta	increta	following	pelvic	transcatheter	artery	
embolization	for	postpartum	hemorrhage.	Clin	Exp	Obstet	Gynecol,	2009.	36(1):	p.	53-4.	
256.	 Tropeano,	G.,	et	al.,	Permanent	amenorrhea	associated	with	endometrial	atrophy	after	
uterine	artery	embolization	for	symptomatic	uterine	fibroids.	Fertil	Steril,	2003.	79(1):	p.	
132-5.	
257.	 Ochi,	J.,	et	al.,	Uterine	changes	during	tamoxifen,	toremifene,	and	other	therapy	for	breast	
cancer:	evaluation	with	magnetic	resonance	imaging.	Jpn	J	Radiol,	2010.	28(6):	p.	430-6.	
258.	 Hauth,	E.,	et	al.,	[MR	Imaging	of	the	pelvis	in	the	diagnosis	of	the	endometrium	in	breast	
cancer	patients	in	tamoxifen	therapy].	Rofo,	2006.	178(3):	p.	316-23.	
259.	 Scheurig-Muenkler,	C.,	et	al.,	Radiation	Exposure	During	Uterine	Artery	Embolization:	
Effective	Measures	to	Minimize	Dose	to	the	Patient.	Cardiovasc	Intervent	Radiol,	2014.	
260.	 Spies,	J.B.,	Uterine	artery	embolization	for	fibroids:	understanding	the	technical	causes	of	
failure.	J	Vasc	Interv	Radiol,	2003.	14(1):	p.	11-4.	
261.	 Razavi,	M.K.,	et	al.,	Angiographic	classification	of	ovarian	artery-to-uterine	artery	
anastomoses:	initial	observations	in	uterine	fibroid	embolization.	Radiology,	2002.	224(3):	
p.	707-12.	
262.	 Wolanske,	K.A.,	et	al.,	Coil	embolization	of	a	tuboovarian	anastomosis	before	uterine	
artery	embolization	to	prevent	nontarget	particle	embolization	of	the	ovary.	J	Vasc	Interv	
Radiol,	2003.	14(10):	p.	1333-8.	
263.	 Marx,	M.,	et	al.,	Ovarian	protection	by	occlusion	of	uteroovarian	collateral	vessels	before	
uterine	fibroid	embolization.	J	Vasc	Interv	Radiol,	2003.	14(10):	p.	1329-32.	
264.	 Stoelinga,	B.,	et	al.,	The	estimated	volume	of	the	fibroid	uterus:	a	comparison	of	
ultrasound	and	bimanual	examination	versus	volume	at	MRI	or	hysterectomy.	Eur	J	Obstet	
Gynecol	Reprod	Biol,	2015.	184:	p.	89-96.	
265.	 van	der	Kooij,	S.M.,	et	al.,	Uterine	artery	embolization	vs	hysterectomy	in	the	treatment	of	
symptomatic	uterine	fibroids:	5-year	outcome	from	the	randomized	EMMY	trial.	Am	J	
Obstet	Gynecol,	2010.	203(2):	p.	105.e1-13.	
266.	 Spies,	J.B.,	et	al.,	The	FIBROID	Registry:	symptom	and	quality-of-life	status	1	year	after	
therapy.	Obstet	Gynecol,	2005.	106(6):	p.	1309-18.	
267.	 Spies,	J.B.,	et	al.,	Complications	after	uterine	artery	embolization	for	leiomyomas.	Obstet	
Gynecol,	2002.	100(5	Pt	1):	p.	873-80.	
258 
 
 
 
268.	 Martin,	J.,	K.	Bhanot,	and	S.	Athreya,	Complications	and	reinterventions	in	uterine	artery	
embolization	for	symptomatic	uterine	fibroids:	a	literature	review	and	meta	analysis.	
Cardiovasc	Intervent	Radiol,	2013.	36(2):	p.	395-402.	
269.	 Leonhardt,	H.,	A.	Aziz,	and	L.	Lonn,	Post-embolization	syndrome	and	complete	expulsion	of	
a	leiomyoma	after	uterine	artery	embolization.	Acta	Obstet	Gynecol	Scand,	2005.	84(3):	p.	
303-5.	
270.	 Spies,	J.B.,	Recovery	after	uterine	artery	embolization:	understanding	and	managing	
short-term	outcomes.	J	Vasc	Interv	Radiol,	2003.	14(10):	p.	1219-22.	
271.	 Crea,	F.,	et	al.,	Role	of	adenosine	in	pathogenesis	of	anginal	pain.	Circulation,	1990.	81(1):	
p.	164-72.	
272.	 Hald,	K.,	et	al.,	Uterine	artery	embolization	versus	laparoscopic	occlusion	of	uterine	
arteries	for	leiomyomas:	long-term	results	of	a	randomized	comparative	trial.	J	Vasc	Interv	
Radiol,	2009.	20(10):	p.	1303-10;	quiz	1311.	
273.	 Mehta,	H.,	et	al.,	Review	of	readmissions	due	to	complications	from	uterine	fibroid	
embolization.	Clin	Radiol,	2002.	57(12):	p.	1122-4.	
274.	 Rajan,	D.K.,	et	al.,	Risk	of	intrauterine	infectious	complications	after	uterine	artery	
embolization.	J	Vasc	Interv	Radiol,	2004.	15(12):	p.	1415-21.	
275.	 Shlansky-Goldberg,	R.D.,	et	al.,	Outcomes	following	fibroid	expulsion	after	uterine	artery	
embolization.	J	Vasc	Interv	Radiol,	2011.	22(11):	p.	1586-93.	
276.	 Radeleff,	B.,	et	al.,	Expulsion	of	dominant	submucosal	fibroids	after	uterine	artery	
embolization.	Eur	J	Radiol,	2010.	75(1):	p.	e57-63.	
277.	 Laverge,	F.,	et	al.,	Spontaneous	expulsion	of	three	large	fibroids	after	uterine	artery	
embolization.	Fertil	Steril,	2003.	80(2):	p.	450-2.	
278.	 Preutthipan,	S.	and	Y.	Herabutya,	Vaginal	misoprostol	for	cervical	priming	before	
operative	hysteroscopy:	a	randomized	controlled	trial.	Obstet	Gynecol,	2000.	96(6):	p.	
890-4.	
279.	 Ahmad,	A.,	et	al.,	Uterine	artery	embolization	treatment	of	uterine	fibroids:	effect	on	
ovarian	function	in	younger	women.	J	Vasc	Interv	Radiol,	2002.	13(10):	p.	1017-20.	
280.	 Bergman,	R.,	An	anatomy	digital	library	-	Uterine	Artery.	Illustrated	Encyclopedia	of	
Human	Anatomic	Variation.	
281.	 Lai,	A.C.,	et	al.,	Sexual	dysfunction	after	uterine	artery	embolization.	J	Vasc	Interv	Radiol,	
2000.	11(6):	p.	755-8.	
282.	 Fatal	nontarget	embolization	via	an	intrafibroid	arterial	venous	fistula	during	uterine	
fibroid	embolization.	J	Vasc	Interv	Radiol,	2009.	20(3):	p.	419-20.	
283.	 Nikolic,	B.,	et	al.,	Changes	in	blood	coagulation	markers	associated	with	uterine	artery	
embolization	for	leiomyomata.	J	Vasc	Interv	Radiol,	2003.	14(9	Pt	1):	p.	1147-53.	
284.	 Lanocita,	R.,	A	fatal	complication	of	percutaneous	transcatheter	embolization	for	
treatment	of	uterine	fibroids.	paper	presented	at	:	Society	of	Minimally	Invasive	
Therapy/Centre	for	Innovative	Minimmally	Invasive	Therapy,	11th	international	
Conference,	September	16-18,	1999.	
285.	 Hamoda,	H.,	P.	Tait,	and	D.K.	Edmonds,	Fatal	pulmonary	embolus	after	uterine	artery	
fibroid	embolisation.	Cardiovasc	Intervent	Radiol,	2009.	32(5):	p.	1080-2.	
286.	 Czeyda-Pommersheim,	F.,	et	al.,	Venous	thromboembolism	after	uterine	fibroid	
embolization.	Cardiovasc	Intervent	Radiol,	2006.	29(6):	p.	1136-40.	
287.	 Freed,	M.M.	and	J.B.	Spies,	Uterine	artery	embolization	for	fibroids:	a	review	of	current	
outcomes.	Semin	Reprod	Med,	2010.	28(3):	p.	235-41.	
288.	 Tropeano,	G.,	S.	Amoroso,	and	G.	Scambia,	Non-surgical	management	of	uterine	fibroids.	
Hum	Reprod	Update,	2008.	14(3):	p.	259-74.	
289.	 Maresh,	M.J.,	et	al.,	The	VALUE	national	hysterectomy	study:	description	of	the	patients	
and	their	surgery.	Bjog,	2002.	109(3):	p.	302-12.	
290.	 Vashisht,	A.,	et	al.,	Fatal	septicaemia	after	fibroid	embolisation.	Lancet,	1999.	354(9175):	
p.	307-8.	
259 
 
 
 
291.	 de	Blok,	S.,	et	al.,	Fatal	sepsis	after	uterine	artery	embolization	with	microspheres.	J	Vasc	
Interv	Radiol,	2003.	14(6):	p.	779-83.	
292.	 Le	Bihan,	D.,	et	al.,	Diffusion	MR	imaging:	clinical	applications.	AJR	Am	J	Roentgenol,	
1992.	159(3):	p.	591-9.	
293.	 Mannelli,	L.,	et	al.,	Assessment	of	tumor	necrosis	of	hepatocellular	carcinoma	after	
chemoembolization:	diffusion-weighted	and	contrast-enhanced	MRI	with	histopathologic	
correlation	of	the	explanted	liver.	AJR	Am	J	Roentgenol,	2009.	193(4):	p.	1044-52.	
294.	 Tsien,	C.,	Y.	Cao,	and	T.	Chenevert,	Clinical	applications	for	diffusion	magnetic	resonance	
imaging	in	radiotherapy.	Semin	Radiat	Oncol,	2014.	24(3):	p.	218-26.	
295.	 Bammer,	R.,	Basic	principles	of	diffusion-weighted	imaging.	Eur	J	Radiol,	2003.	45(3):	p.	
169-84.	
296.	 Hein,	P.A.,	et	al.,	Diffusion-weighted	magnetic	resonance	imaging	for	monitoring	diffusion	
changes	in	rectal	carcinoma	during	combined,	preoperative	chemoradiation:	preliminary	
results	of	a	prospective	study.	Eur	J	Radiol,	2003.	45(3):	p.	214-22.	
297.	 Liapi,	E.,	et	al.,	Assessment	of	response	of	uterine	fibroids	and	myometrium	to	
embolization	using	diffusion-weighted	echoplanar	MR	imaging.	J	Comput	Assist	Tomogr,	
2005.	29(1):	p.	83-6.	
298.	 Hecht,	E.M.,	et	al.,	Diffusion-weighted	imaging	for	prediction	of	volumetric	response	of	
leiomyomas	following	uterine	artery	embolization:	a	preliminary	study.	J	Magn	Reson	
Imaging,	2011.	33(3):	p.	641-6.	
299.	 Faye,	N.,	et	al.,	Diffusion-weighted	imaging	for	evaluation	of	uterine	arterial	embolization	
of	fibroids.	Magn	Reson	Med,	2013.	70(6):	p.	1739-47.	
300.	 Stejskal	EO,	T.J.,	Spin	diffusion	measurements:	spinecho	
in	the	presence	of	a	time	dependent	field	gradient.	Journcal	of	Chemical	Physics,	1965(42):	p.	288-
92.	
301.	 Muir,	K.W.,	et	al.,	Imaging	of	acute	stroke.	Lancet	Neurol,	2006.	5(9):	p.	755-68.	
302.	 Whittaker,	C.S.,	et	al.,	Diffusion-weighted	MR	imaging	of	female	pelvic	tumors:	a	pictorial	
review.	Radiographics,	2009.	29(3):	p.	759-74;	discussion	774-8.	
303.	 Ananthakrishnan,	G.,	et	al.,	Diffusion-weighted	imaging	in	uterine	artery	embolisation:	do	
findings	correlate	with	contrast	enhancement	and	volume	reduction?	Br	J	Radiol,	2012.	
85(1019):	p.	e1046-50.	
304.	 Rees,	M.C.,	Role	of	menstrual	blood	loss	measurements	in	management	of	complaints	of	
excessive	menstrual	bleeding.	Br	J	Obstet	Gynaecol,	1991.	98(3):	p.	327-8.	
305.	 Higham,	J.M.	and	R.W.	Shaw,	Clinical	associations	with	objective	menstrual	blood	volume.	
Eur	J	Obstet	Gynecol	Reprod	Biol,	1999.	82(1):	p.	73-6.	
306.	 Hallberg,	L.,	et	al.,	Menstrual	blood	loss--a	population	study.	Variation	at	different	ages	
and	attempts	to	define	normality.	Acta	Obstet	Gynecol	Scand,	1966.	45(3):	p.	320-51.	
307.	 Edmonds,	D.K.,	Dewhurst's	Textbook	of	Obstetrics	and	Gynaecology.	2007(Chapter	42):	p.	
534.	
308.	 Coulter,	A.,	V.	Peto,	and	C.	Jenkinson,	Quality	of	life	and	patient	satisfaction	following	
treatment	for	menorrhagia.	Fam	Pract,	1994.	11(4):	p.	394-401.	
309.	 Wang,	W.,	et	al.,	Iron	deficiency	and	fatigue	in	adolescent	females	with	heavy	menstrual	
bleeding.	Haemophilia,	2013.	19(2):	p.	225-30.	
310.	 Olive,	D.L.	and	E.A.	Pritts,	Fibroids	and	reproduction.	Semin	Reprod	Med,	2010.	28(3):	p.	
218-27.	
311.	 Hallberg,	L.	and	L.	Nilsson,	DETERMINATION	OF	MENSTRUAL	BLOOD	LOSS.	Scand	J	Clin	
Lab	Invest,	1964.	16:	p.	244-8.	
312.	 van	Eijkeren,	M.A.,	et	al.,	The	alkaline	hematin	method	for	measuring	menstrual	blood	
loss--a	modification	and	its	clinical	use	in	menorrhagia.	Eur	J	Obstet	Gynecol	Reprod	Biol,	
1986.	22(5-6):	p.	345-51.	
313.	 Deeny,	M.	and	J.A.	Davis,	Assessment	of	menstrual	blood	loss	in	women	referred	for	
endometrial	ablation.	Eur	J	Obstet	Gynecol	Reprod	Biol,	1994.	57(3):	p.	179-80.	
260 
 
 
 
314.	 Zakherah,	M.S.,	et	al.,	Pictorial	blood	loss	assessment	chart	in	the	evaluation	of	heavy	
menstrual	bleeding:	diagnostic	accuracy	compared	to	alkaline	hematin.	Gynecol	Obstet	
Invest,	2011.	71(4):	p.	281-4.	
315.	 Larsen,	L.,	K.	Coyne,	and	K.	Chwalisz,	Validation	of	the	menstrual	pictogram	in	women	
with	leiomyomata	associated	with	heavy	menstrual	bleeding.	Reprod	Sci,	2013.	20(6):	p.	
680-7.	
316.	 Hald,	K.	and	M.	Lieng,	Assessment	of	periodic	blood	loss:	interindividual	and	
intraindividual	variations	of	pictorial	blood	loss	assessment	chart	registrations.	J	Minim	
Invasive	Gynecol,	2014.	21(4):	p.	662-8.	
317.	 Schumacher,	U.,	et	al.,	Estimation	of	menstrual	blood	loss	volume	based	on	menstrual	
diary	and	laboratory	data.	BMC	Womens	Health,	2012.	12:	p.	24.	
318.	 Wyatt,	K.M.,	et	al.,	Determination	of	total	menstrual	blood	loss.	Fertil	Steril,	2001.	76(1):	
p.	125-31.	
319.	 Dasharathy,	S.S.,	et	al.,	Menstrual	bleeding	patterns	among	regularly	menstruating	
women.	Am	J	Epidemiol,	2012.	175(6):	p.	536-45.	
320.	 Gudmundsdottir,	B.R.,	et	al.,	Quantification	of	menstrual	flow	by	weighing	protective	pads	
in	women	with	normal,	decreased	or	increased	menstruation.	Acta	Obstet	Gynecol	Scand,	
2009.	88(3):	p.	275-9.	
321.	 Higham,	J.M.,	P.M.	O'Brien,	and	R.W.	Shaw,	Assessment	of	menstrual	blood	loss	using	a	
pictorial	chart.	Br.J.Obstet.Gynaecol.,	1990.	97(8):	p.	734-739.	
322.	 McPherson,	K.,	et	al.,	A	randomised	trial	of	treating	fibroids	with	either	embolisation	or	
myomectomy	to	measure	the	effect	on	quality	of	life	among	women	wishing	to	avoid	
hysterectomy	(the	FEMME	study):	study	protocol	for	a	randomised	controlled	trial.	Trials,	
2014.	15:	p.	468.	
323.	 Redecha,	M.,	Jr.,	et	al.,	Pregnancy	after	uterine	artery	embolization	for	the	treatment	of	
myomas:	a	case	series.	Arch	Gynecol	Obstet,	2013.	287(1):	p.	71-6.	
324.	 Yong	Li,	Z.G.,	Expressions	of	MVD,	VEGF,	Ki67	in	residual	prostate	cancer	after	
cryoablation.	Clinical	Oncology	and	Cancer	Research,	2011.	8(1):	p.	27-32.	
325.	 RCOG/RCR,	Clinical	recommendations	on	th	euse	of	uterine	artery	embolisation	(UAE)	in	
the	management	of	fibroids.	2013.	
326.	 Czuczwar,	P.,	et	al.,	Predicting	the	results	of	uterine	artery	embolization:	correlation	
between	initial	intramural	fibroid	volume	and	percentage	volume	decrease.	Prz	
Menopauzalny,	2014.	13(4):	p.	247-52.	
327.	 Tamai,	K.,	et	al.,	Diffusion-weighted	MR	imaging	of	uterine	endometrial	cancer.	J	Magn	
Reson	Imaging,	2007.	26(3):	p.	682-7.	
328.	 Chua,	G.C.,	et	al.,	Comparison	of	particle	penetration	with	non-spherical	polyvinyl	alcohol	
versus	trisacryl	gelatin	microspheres	in	women	undergoing	premyomectomy	uterine	artery	
embolization.	Clin	Radiol,	2005.	60(1):	p.	116-22.	
329.	 Kovacs,	P.,	et	al.,	The	effect	of	endometrial	thickness	on	IVF/ICSI	outcome.	Hum	Reprod,	
2003.	18(11):	p.	2337-41.	
 
  
261 
 
 
 
  
262 
 
 
 
 
 
 
 
 
